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The E3 Ligase TRIM32 is an Effector 
of the RAS family GTPase RAP2 
Classical RAS oncogenes are mutated in approximately 30% of human tumours and 
RAP proteins are closely related to classical RAS proteins. RAP1 has an identical 
effector domain to RAS whereas RAP2 differs by one amino acid. RAP2 not only 
shares effectors with other classical RAS family members, but it also has its own 
specific effectors that do not bind to RAP1 or classical RAS family proteins. Thus, 
although closely related, RAP2 performs distinct functions, although these have 
been poorly characterised. 
Using RAP2 as bait in Tandem Affinity Purifications, we have identified several RAP2 
interacting proteins including TRIM32; a protein implicated in diverse pathological 
processes such as Limb-Girdle Muscular Dystrophy (LGMD2H), and Bardet-Biedl 
syndrome (BBS). 
TRIM32 was shown to interact specifically with RAP2 in an activation- and effector 
domain-dependent manner; demonstrating stronger interaction with the RAP2 V12 
mutant than the wild-type RAP2 and defective binding to the effector mutant RAP2 
V12A38. 
The interaction was mapped to the C-terminus of TRIM32 (containing the NHL 
domains) while mutations found in LGMD2H (R394H, D487N, ∆588) were found to 
disrupt binding to RAP2. The TRIM32 P130S mutant linked to BBS did not affect 
binding to RAP2, suggesting that the RAP2-TRIM32 interaction may be functionally 
involved in LGMD2H. 
Because TRIM32 is an E3 ubiquitin ligase, the possible ubiquitination of interacting 
proteins by TRIM32 was assessed along with the potential for modulation by RAP2. 
RAP2 stimulates the ubiquitin ligase activity of TRIM32 against some substrates but 
not others. We propose that RAP2 uses TRIM32 to regulate the signalling properties 
of other RAP2 effectors. 
Furthermore, our data also shows that the overexpression of TRIM32 may increase 
C2C12 mouse myoblast cell differentiation whereas the inhibition of RAP2 
expression decreases differentiation in C2C12 cells. Further study could lead to a 
potential link to Limb-Girdle Muscular Dystrophy that remains to be elucidated. 
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CHAPTER 1: RAS Proteins form 
Interesting Targets for Research 
RAS proteins 
RAS proteins are signal transducers that possess an activating mutation in around 
30% of human cancers, although they could be indirectly involved in many more via 
aberrant signalling of their activators (Malumbres and Barbacid 2003; Repasky, 
Chenette et al. 2004).  
Significance of RAS proteins for study 
The RAS genes were first identified as transforming oncogenes, responsible for the 
carcinogenic activities of the Harvey and Kirsten sarcoma viruses, discovered by 
Jennifer Harvey and Werner Kirsten, respectively (Harvey 1964; Kirsten and Mayer 
1967). In 1982, activated and transforming human homologues of H- and KRAS 
genes were discovered in human cancer cells and subsequent studies in human 
neuroblastoma cells identified a third human RAS gene, designated as NRAS (Shih, 
Padhy et al. 1981). 
H-, K- and NRAS (referred to as the classical RAS family members) are mutated to a 
varying degree in specific cancers (e.g., KRAS in lung, colon and pancreatic tumours, 
NRAS in melanomas and haematopoietic malignancies). These differences cannot 
be attributed to differential expression, but suggest tissue-specific signalling 
properties for the three RAS proteins. 
The RAS superfamily, also referred to as the RAS family GTPases (RFG), consists of 
over 150 identified members (Wennerberg, Rossman et al. 2005) (Figure 1). Other 
members of the RFG share many of the biochemical properties of the classical RAS 
proteins, including the ability to behave as oncogene products and interact with a 
selection of known RAS effectors, though they have important functions of their 
own; e.g. R-RAS in adhesion, Ral in endocytosis, and Rheb in the regulation of cell 
growth (role in the TOR/S6K signalling pathway) (Long, Lin et al. 2005). 
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A)  
 
Figure 1: RAS family 
GTPase members. A) 
The RAS superfamily 
consists of over 150 
members, including 
the Rho/Rac family 
and the Rab family. 
Circled is the RAS 
family sub-group, 
also shown below. B) 
There are multiple 
members of the RAS 
family with 
overlapping as well 
as distinct functions. 
Highlighted are the 
classical RAS family 
and RAP proteins. 
Figure from 
(Karnoub and 
Weinberg 2008). B) 
 
 
The function of many RAS family members has not been elucidated. Some, such as 
Rerg and the DIRAS subgroup, have even demonstrated tumour suppressor 
properties (Yu, Xu et al. 1999; Luo, Fang et al. 2003; Key, Andres et al. 2006). How 
signalling specificity among the closely related RAS family members is achieved and 
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their role in tumourigenesis is poorly understood and still remains to be 
investigated. 
RAS superfamily biochemistry and regulation 
The RFG switch between active GTP and inactive GDP-bound states (see Figure 2), 
which enables them to function as hubs in signalling cascades (Herrmann 2003). A 
small number of GTPases can respond to multiple signals and also activate multiple 
downstream pathways. This results in diverse and specific cellular responses such as 
proliferation, differentiation, survival and migration (Aoki, Niihori et al. 2008).  
 
Figure 2: RAS functions as a molecular switch. Guanine nucleotide exchange factors (GEFs) 
stimulate the GDP to GTP exchange whereas GTPase activating proteins (GAPs) stimulate the 
intrinsic GTPase activity that hydrolyses GTP to GDP. Figure adapted from (Malumbres and 
Barbacid 2003). 
 
The exchange in activation state is enhanced by guanine nucleotide exchange 
factors (GEFs, which stimulate the release of GDP) and GTPase activating proteins 
(GAPs) which enhance the intrinsic GTPase activity that hydrolyses GTP to GDP (see 
Figure 2). Most upstream signals induce GEFs to act on specific GTPases and 
therefore GEFs serve to link activated receptors to downstream signalling cascades 
and provide signalling specificity (Raaijmakers and Bos 2009). As the “switch-on” 
and “switch-off” reactions in the cycle of RFG are intrinsically very low, the 
regulatory input by GEFs and GAPs determines the lifetime of the two states 
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(Bourne, Sanders et al. 1990; Bourne, Sanders et al. 1991; Vetter and Wittinghofer 
2001). Although it is not well defined, there is some overlap in the way in which at 
least some of the RFGs are regulated, with both GEFs and GAPs having overlapping 
specificities and activating several RAS family members (Ehrhardt, Ehrhardt et al. 
2002; Quilliam, Rebhun et al. 2002). 
A)  B)  
 
Inactive RAS Active RAS Inactive RAS Active RAS 
 
Figure 3: The structure of RAS. The nucleotide-sensitive switch I and II regions depicted in red and 
green, respectively. The GDP and GTP nucleotides are shown as balls. A) The RAS three-dimensional 
fold is shown to consist of six -sheets and five -helices interconnected by a series of ten loops. 
Crystallographic structures of inactive RASGDP99 (2.0 Å resolution; Protein Data Bank code 4q21) 
and active RASGppNHp97 (1.35 Å resolution; PDB code 5p21) are shown, with. B) Nucleotide-
dependent structural rearrangements. Figure from (Karnoub and Weinberg 2008). 
 
The exchange of GDP for GTP induces a conformational change in RFG that allows 
them to interact with their downstream effectors (introduced below) and carry out 
their multiple biological functions (Lowy and Willumsen 1993; Repasky, Chenette et 
al. 2004). Only two small regions of the protein change conformation on GTP 
binding: the core effector domain or switch I region (amino acids 30-40) and the 
switch II region (amino acids 60-76) (Figure 3). The conformational changes that 
result from GTP binding allow RFG to interact with its effectors via the effector 
domain or the RAS/RAP-binding domain (RBD); mutations in this region can disrupt 
this interaction. Oncogenic RFG harbour single amino-acid missense mutations in 
their effector domain (equivalent to residues G12V, G13V or Q61K in the classical 
RAS proteins) which render them insensitive to regulation by GAP. They thus remain 
in a constitutively active GTP bound state (Herrmann 2003). 
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The RAS effectors are defined as proteins with strong preferential binding to the 
GTP-bound form of RFG. The best characterised RAS effectors are the RAF kinases, 
through which RAS activates the mitogen-activated protein kinase (MAPK) cascade, 
the p110 catalytic subunit of class I phophoinositide 3-kinases (PI3Ks), and a family 
of Ral exchange factors (RalGEFs) (Kodaki, Woscholski et al. 1994; Rodriguez-
Viciana, Warne et al. 1994; Wan, Garnett et al. 2004; Wong 2009; Neel, Martin et al. 
2011). The RBDs of RAF, PI3Ks, and RalGEFs have considerable structural similarities 
despite having little sequence homology, leading to distinct domains that are found 
in other proteins; e.g. RAF-type RBD, RA (RalGDS/AF6, RAS association) domains 
(Nassar, Horn et al. 1995). 
Lipid modification and membrane targeting 
Posttranslational modification is a common cellular process by which proteins are 
modulated by intrinsic or extrinsic factors in order to potentiate or initiate a specific 
function. This is achieved in a variety of ways, e.g., the addition of other 
biochemical functional groups (such as acetate, phosphate, lipids and 
carbohydrates), alteration of the chemical nature of an amino acid (e.g. 
citrullination), or the introduction of structural changes (e.g. formation of disulfide 
bridges). In addition, enzymes may remove amino acids from the N-terminal end of 
the protein or cleave the peptide chain at specific sites. A typical example is the 
peptide hormone preproinsulin which is cleaved twice after disulfide bonds are 
formed, eventually resulting in the formation of insulin, which consists of two 
polypeptide chains connected by disulfide bonds. Methionine, which is present at 
the -N-terminus of most nascent polypeptides, is also commonly removed during 
post-translational modification. Other modifications, like phosphorylation, are part 
of common mechanisms for controlling the behaviour of a protein, for instance 
activating or inactivating an enzyme. 
Proteins can be covalently modified by a variety of lipids such as octanoic acid, 
myristic acid, palmitic acid, palmitoleic acid, stearic acid, a farnesyl or 
geranylgeranyl group and cholesterol. Most of these modifications take place in the 
cytoplasm or in the cytoplasmic face of membranes. The processing of RAS family 
proteins is essential for effector activation and membrane localisation (Takai, Sasaki 
et al. 2001). RAS proteins are located on the inner layer of the plasma membrane 
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and are switched on in response to the activation of cell surface receptors. Active 
RFGs function as adaptor proteins which recruit effectors to the membrane and 
allow their interaction with other proteins or lipids in order to generate intracellular 
signals. 
RAS family proteins undergo two types of C-terminal post-translational processing 
(Takai, Sasaki et al. 2001; Rocks, Peyker et al. 2006) primarily associated with the 
CAAX motif (“C”, cysteine; “A”, aliphatic; “X”, any residue). Proteins synthesised in 
the cytosol are prenylated at the CAAX cysteine (farnesylated or 
gernaylgeranylated, depending on “X” (Takai, Sasaki et al. 2001)), whereupon the 
prenylcysteine targets the proteins to the endoplasmic reticulum (ER). Here, 
proteolytic removal of “AAX”, and carboxyl-methylation of the prenylcysteine takes 
place. Following CAAX-processing, some RAS family proteins undergo a second type 
of processing either in the ER or the Golgi, where cysteine(s) upstream of the 
prenycysteine is/are palmitoylated. For instance, all RAS proteins are farnesylated 
during the CAAX-processing. Subsequently, NRAS and HRAS are palmitoylated at 
one and two sites, respectively (Takai, Sasaki et al. 2001). 
RAF proteins interact with RAS proteins at two sites: the RBD and the cysteine-rich 
domain (CRD) (Hu, Kariya et al. 1995; Morrison and Cutler 1997; Takai, Sasaki et al. 
2001). The RBD-RAS interaction is involved in initial complex formation and the 
CRD-RAS interactions are involved in activation. Unprocessed RAS proteins interact 
with but do not activate RAF1 and BRAF because the processing is a prerequisite for 
the CRD-RAS interaction (Hu, Kariya et al. 1995; Morrison and Cutler 1997; Takai, 
Sasaki et al. 2001). Therefore, a fully processed HRAS cannot activate RAF1 properly 
if the CRD-binding interface is mutated (Tamada, Hu et al. 1997). Mutations in 
palmitoylation sites impair the HRAS-induced transformation of NIH-3T3 cells 
(Hancock, Paterson et al. 1990), demonstrating the significance of these 
posttranslational modifications. 
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Figure 4: RAS proteins are post-translationally modified. RAS proteins differ in their trafficking to 
and association with the plasma membrane. RAS proteins are synthesised initially as cytosolic 
proteins in which the C-terminal CAAX motif is the target of post-translational modification that 
involves the addition of a farnesyl isoprenoid lipid, catalysed by the enzyme farnesyl transferase. 
Endoplasmic reticulum-associated enzymes then catalyse the proteolytic cleavage of the AAX 
residues and carboxyl methylation of the now C-terminal farnesylated cysteine residue by 
isoprenylcycsteine carboxymethyltransferase-1 enzyme. Different targeting mechanisms might result 
in their localisation to functionally distinct microdomains of the plasma membrane. Figure from 
(Shields, Pruitt et al. 2000) 
 
Prenylation 
Prenylation involves the covalent addition of either farnesyl (15-carbon) or more 
commonly geranylgeranyl (20-carbon) isoprenoids via thioether linkages to cysteine 
residues at or near the C-terminus of intracellular proteins. The attached lipid is 
required for proper function of the modified protein, either as a mediator of 
membrane association or a determinant for specific protein-protein interactions 
(Novelli and D'Apice 2012). 
There are three enzymes that carry out prenylation in the cell, farnesyl transferase 
(Maltese 1990; Clarke 1992), geranylgeranyl transferase I and Rab 
geranylgeranyltransferase/protein geranylgeranyltransferase type II (Casey and 
Seabra 1996). Farnesyl transferase and geranylgeranyl transferase I are designated 
CAAX prenyltransferases since they recognise the CAAX box at the C-terminus of the 
target protein (Clarke 1992; Zhang and Casey 1996). Substrates for farnesyl 
transferase include RAS GTPases, lamin B and several proteins involved in visual 
signal transduction (Clarke 1992; Omer and Gibbs 1994; Caldwell, Naider et al. 
1995). Known targets of geranylgeranyl transferase I include most subunits of 
heterotrimeric G proteins and RAS-related GTPases such as members of the RAS 
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and Rac/Rho families (Clarke 1992; Glomset and Farnsworth 1994). 
Geranylgeranyltransferase type II attaches geranylgeranyl groups to two C-terminal 
cysteines in the Rab family that terminates in CC or CXC motifs (Seabra, Goldstein et 
al. 1992; Glomset and Farnsworth 1994). 
Palmitoylation 
Palmitoylation is the covalent attachment of fatty acids, such as palmitic acid, to 
cysteine and less frequently to serine and threonine residues of proteins. The exact 
function of palmitoylation depends on the particular protein being considered. For 
example, it can enhance the hydrophobicity of proteins and contribute to their 
membrane association, can also play a role in the subcellular trafficking of proteins 
between membrane compartments (Rocks, Peyker et al. 2005), or modulate 
protein-protein interactions. Some of these proteins are modified sequentially with 
different lipids but others are exclusively S-palmitoylated. As the bond between 
palmitic acid and the protein is often a thioester bond, palmitoylation is usually 
reversible and the reverse reaction is catalysed by palmitoyl protein thioesterases.  
Other common posttranslational modifications 
Myristoylation 
Myristoylation is an irreversible, co-translational protein modification found in 
animals, plants, fungi, protozoans and viruses. Myristoylation is crucial for the 
cellular proliferation process and is required for the growth and development in a 
number of organisms including many human pathogens and viruses. 
In this protein modification, a myristoyl group (derived from myristic acid) is 
covalently attached via an amide bond to the alpha-amino group of an N-terminal 
amino acid of a nascent polypeptide. It is more common on glycine residues 
exposed during co-translational N-terminal methionine removal but also occurs on 
other amino acids (Farazi, Waksman et al. 2001). This protein modification is 
catalysed by the enzyme N-Myristoyl Transferase (NMT) that uses myristoyl-CoA 
and the peptide N-terminus as co-substrates after recognition of a GXXX(S/T/C) N-
terminal consensus sequence (Maurer-Stroh, Eisenhaber et al. 2002; Maurer-Stroh, 
Eisenhaber et al. 2002). 
27 
 
It has been estimated that approximately 0.5% of eukaryotic proteins are 
myristoylated (Maurer-Stroh and Eisenhaber 2004). In many cases, protein N-
myristoylation is required (though not sufficient) for stable and permanent 
membrane anchoring; (Peitzsch and McLaughlin 1993; Shahinian and Silvius 1995; 
Navarro-Lerida, Alvarez-Barrientos et al. 2002) it often occurs together with S-
acylation of proximal cysteine residues or a polybasic amino acid domain next to the 
N-terminus. N-myristoylation can also occur post-translationally when an internal 
glycine becomes exposed by caspase-mediated proteolytic cleavage (Zha, Weiler et 
al. 2000). 
Glycosylation 
Glycosylation is a form of posttranslational modification which consists of the 
enzymatic addition of a glycosyl group to either arginine, asparagine, cysteine, 
hydroxylysine, serine, threonine, tyrosine, or tryptophan resulting in a glycoprotein 
(Freeze and Sharma 2010; Reis, Osorio et al. 2010). Glycosylation mostly occurs in 
the ER or Golgi apparatus and can affect protein folding and stability, influence 
protein trafficking and interfere with protein function (Reis, Osorio et al. 2010; 
Roth, Zuber et al. 2010; Pinho, Seruca et al. 2011). 
Phosphorylation 
Phosphorylation is the addition of a phosphate group, usually to serine, threonine, 
and tyrosine (O-linked), or histidine (N-linked). Posttranslational modification 
through phosphorylation acts as a major regulatory pathway in normal protein life 
cycles and can be further affected in pathological states by the upregulation of 
kinase pathways. These pathways regulate protein functions through addition of a 
phosphate group by kinases, which may lead to alterations in the hydrophobicity, 
charge and potentially structural organization of proteins, either promoting or 
inhibiting normal functions (Huttlin, Jedrychowski et al. 2010; Davis 2011; Nishi, 
Hashimoto et al. 2011). 
S-nitrosylation 
Posttranslational modification can also occur through S-nitrosylation, in which nitric 
oxide can bind to a reactive cysteine thiol, producing an S-nitrosothiol (Stamler, 
Simon et al. 1992). While proteins often contain multiple cysteine residues, the 
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majority of the observed biological effects imparted by nitric oxide occur on single 
or only a few cysteine residues within a protein. In addition to direct modification of 
proteins by S-nitrosylation, this posttranslational modification can indirectly 
regulate other protein modifications including acetylation, phosphorylation and 
ubiquitination (Park, Yu et al. 2004; Yasukawa, Tokunaga et al. 2005; Whalen, Foster 
et al. 2007; Hess and Stamler 2012). 
Others 
Other existing posttranslational modifications are either introduced elsewhere, or 
not discussed as they are beyond the scope of this project. These include acylation, 
alkylation, amide bond formation, butyrylation, Vitamin K-dependent gamma-
carboxylation, malonylation, hydroxylation, iodination, nucleotide addition (such as 
ADP-ribosylation), oxidation, propionylation, pyroglutamate formation, S-
glutathionylation, succinylation, sulfation, and selenoylation.  
Posttranslational modifications involving the addition of cofactors which enhance 
enzymatic activity include lipoylation, attachment of a lipoate (C8) functional group, 
flavin moiety (FMN or FAD) covalent attachment, heme C attachment via thioether 
bonds with cysteins, phosphopantetheinylation, the addition of a 4'-
phosphopantetheinyl moiety fromcoenzyme A, polyketide, non-ribosomal peptide 
and leucine biosynthesis, and retinylidene Schiff base formation. 
Posttranslational modifications involving unique modifications of translation factors 
consist of diphthamide formation (on a histidine found in eEF2), ethanolamine 
phosphoglycerol attachment (on glutamte found in eEF1α), and hypusine formation 
(on conserved lysine of eIF5A (eukaryotic) and aIF5A (archeal)).  
Posttranslational modifications involving non-enzymatic additions in vivo and in 
vitro include glycation, the addition of a sugar molecule to a protein without the 
controlling action of an enzyme, biotinylation, acylation of conserved lysine residues 
with a biotin appendage, and pegylation.  
Posttranslational modifications involving changing the chemical nature of amino 
acids are citrullination, or deimination, the conversion of arginine to citrulline, 
deamidation, the conversion of glutamine to glutamic acid or asparagine to aspartic 
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acid, eliminylation, the conversion to an alkene by beta-elimination of 
phosphothreonine and phosphoserine, or dehydration of threonine and serine, as 
well as by decarboxylation of cysteine, and carbamylation, the conversion of lysine 
to homocitrulline.  
Finally, the posttranslational modifications involving structural changes are the 
formation of disulfide bridges, the covalent linkage of two cysteine amino acids, 
proteolytic cleavage, cleavage of a protein at a peptide bond, and racemisation of 
proline by prolyl isomerase (Wang, Pattison et al. 2013). 
RAP proteins 
The RAP proteins are members of the RFG, and contain similar effector binding 
domains as RAS. Effector proteins for RAP also typically contain an RBD or an RA 
domain (Taira, Umikawa et al. 2004; Kukimoto-Niino, Takagi et al. 2006). Mammals 
express two RAP1 (RAP1A and RAP1B) and three RAP2 (RAP2A, RAP2B, RAP2C) 
proteins. RAP1 and RAP2 differ in their effector domain by one amino acid and 
share 60% sequence homology. 
Localisation 
As with RAS proteins, RAP membrane anchoring is mediated by lipid modifications 
within the C-terminal (CAAX) tail which results in their differential modification due 
to tail sequence variations. RAP proteins were previously predicted to localise to the 
Golgi apparatus (Pizon, Desjardins et al. 1994), although they have since been 
shown to localise at recycling endosomes (Uechi, Bayarjargal et al. 2009). 
Several signalling pathways modulate RAP by altering its cellular distribution by 
post-translational modifications; RAP1 is phosphorylated in its C-terminus by the 
cAMP-effector protein Protein Kinase-A (PKA), which has been proposed to alter 
substrate binding as well as its localisation (Rundell, Repellin et al. 2004; Edreira, Li 
et al. 2009). Two enzymes, NEDD4-1 and Cullin-5, have been shown to ubiquitinate 
RAP2 and thereby control its membrane targeting and effector binding respectively 
(Lee, Iioka et al. 2007; Kawabe, Neeb et al. 2010). 
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Activation 
The diverse functions of RAP are partially cell type-specific. The existence of distinct 
cellular pools of RAP as well as an exclusive sub-set of activator and effector 
proteins might further explain the multiple biological responses triggered by RAP, 
even in a single cell. 
 
 
Figure 5: Domain architecture of mammalian RAPGEFs and RAPGAPs. GEFs and GAPs for which a 
direct effect on nucleotide binding of RAP has been demonstrated in vitro are shown. Binding of 
GEFs modulates the nucleotide-binding site, resulting in the release and subsequent replacement of 
the bound nucleotide by the cellularly abundant GTP. Broken lines indicate the putative extra CNB-L 
domain in PDZ-GEF1 and a putative RA domain in Epac1. 
Abbreviations: BTK, Bruton's tyrosine kinase motif; CDC25-HD, CDC25 homology domain; CNB, cyclic 
nucleotide binding; CNB-L, cyclic nucleotide binding-like; DEP, dishevelled; Egl-10, pleckstrin; EF, EF-
hands; GAP, GTPase-activating protein; PH, pleckstrin homology; PLC, phospholipase C catalytic 
domain; RA, RAS/RAP association; REM, RAS exchange motif; PDZ, PSD95, DlgA, Zo-1. Figure from 
(Gloerich and Bos 2011). 
 
GEFs and GAPs which have a direct effect on RAP are referred to as RAPGEFs and 
RAPGAPs respectively. These individual RAPGEFs and RAPGAPs are regulated by 
distinct upstream signals that affect their activity, cellular distribution or stability 
(for review see (Spilker and Kreutz 2010; Vigil, Cherfils et al. 2010; Gloerich and Bos 
2011)). Numerous mammalian RAPGEFs have been identified (Figure 5) that act 
primarily on both RAP1 and RAP2. Some show preference for distinct RAP family 
members; for example, RASGEF1 selectively activates RAP2 (Yaman, Gasper et al. 
2009), whereas C3G displays higher exchange activity towards RAP1 (van den 
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Berghe, Cool et al. 1997). Moreover, some of the RAPGEFs also act on other 
members of the RAS family, which provides overlap between these signalling 
pathways. Additionally, several mammalian RAPGAPs that either act selectively on 
RAP or display broader specificity have been described (Gloerich and Bos 2011). 
Although closely related to RAS, the RAP proteins are implicated in a variety of 
distinct biological processes. 
RAP1 
RAP1 has a role in the regulation of integrin-mediated adhesion, cell-cell junction 
formation, exocytosis, cell proliferation, and establishment of cell polarity (Bos, de 
Bruyn et al. 2003; Rangarajan, Enserink et al. 2003; Fukuhara, Sakurai et al. 2005; 
Frische and Zwartkruis 2010). 
RAP1 also regulates cadherins, adhesion molecules that are components of 
adherens junctions. These form calcium-dependent, homotypic interactions which 
stabilise cell-cell contacts. The cytoplasmic tails of cadherins bind to several 
proteins, including β-catenin and p120ctn, to form a connection with the actin 
cytoskeleton (Aberle, Butz et al. 1994; Davis, Ireton et al. 2003).  
RAP1 activity has also been shown to promote metastasis in human breast and 
prostate cancer cells (Itoh, Nelson et al. 2007; Bailey, Kelly et al. 2009) and is 
required for RET/PTC1-induced BRAF activation, mitogenesis and cytoskeletal 
reorganisation in thyroid cells (De Falco, Castellone et al. 2007). 
RAP2 
Structure 
The three RAP2 isoforms, RAP2A, RAP2B, and RAP2C are differentially post-
translationally modified at the C-terminus due to variations in their C-terminal 
membrane targeting (CAAX) region (Figure 4, Figure 6). After farnesylation during 
the CAAX-processing, RAP2A and RAP2B are farnesylated and gernaylgeranylated, 
respectively (Farrell, Yamamoto et al. 1993), and RAP2C is assumed to be 
farnesylated, as its “X” is identical to that in RAP2A (Paganini, Guidetti et al. 2006).  
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The two cysteines (C176 and C177) upstream of the CAAX cysteine (C180) are the 
sites of palmitoylation in RAP2 proteins. Once fully processed, these are targeted to 
the recycling endosomes in a palmitoylation-dependent manner. As palmitoylation 
is necessary for membrane-association of RAP2A and RAP2C but not RAP2B, this has 
possible implications for differential localisation, e.g. different membrane 
compartments (Uechi, Bayarjargal et al. 2009). 
 
 
 
Figure 6: High degree of homology in the C-termini between RAP2 isoforms. 
Variations in the CAAX domain lead to specific post-translational modifications 
(Uechi, Bayarjargal et al. 2009). RAP2A is farnesylated, RAP2B 
geranygeranylated, and RAP2C is predicted to be farnesylated (Takai, Sasaki et 
al. 2001; Paganini, Guidetti et al. 2006). Figure from (Uechi, Bayarjargal et al. 
2009) 
  
Biological functions of RAP2: Neural function 
In hippocampal pyramidal neurons RAP2 opposes RAS-ERK signalling by inhibiting 
dendritic spine development/maintenance; shortening of dendrites and axons, loss 
of dendritic spines and spiny synapses in neurons, as well as an increase in 
filopodia-like protrusion and shaft synapses. These RAP2 morphological effects are 
absent in interneurons, or when RAP1 is overexpressed (Fu, Lee et al. 2007). 
RAP2 impairs learning and promotes synaptic depression rather than long-term 
potentiation (LTP) (Ryu, Futai et al. 2008), whereas RAP1 has been shown to be 
critical for long-term depression (LTD) of synaptic transmission in hippocampal 
synapses (Zhu, Qin et al. 2002; Huang, You et al. 2004). The findings also implicate 
RAP2 signalling in fear extinction mechanisms, which are thought to be aberrant in 
anxiety disorders and posttraumatic stress disorder (Fischer, Radulovic et al. 2007; 
Myers and Davis 2007; Ryu, Futai et al. 2008). 
Nedd-4-1 is a “neuronal precursor cell expressed and developmentally down-
regulated protein” and among the most abundant E3 ubiquitin ligases in 
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mammalian neurons, playing a critical role in dendrite formation. Nedd4-1, TNIK 
and RAP2A form a complex that controls Nedd4-1-mediated ubiquitination of 
RAP2A. Mono- or di-ubiquitination of RAP2 has been shown to inhibit its function. 
By perturbing the RAP2 interaction with the RAP2 effector TNIK, activity of the TNIK 
kinases in inhibited, leading to promoted dendrite growth and branching (Kawabe, 
Neeb et al. 2010). 
Biological functions of RAP2: Receptor trafficking 
RAP2 is a key player in the regulation of receptor trafficking that might affect cell 
responsiveness to extracellular ligands and signalling duration (Choi, Kim et al. 
2008). RAP2 is required to remove α-amino-3-hydroxy-5-methylisoxazole-4-
propionate (AMPA) receptors during synaptic depotentiation (Zhu, Qin et al. 2002; 
Zhu, Pak et al. 2005). RAP2 also positively regulates the trafficking of Activin/Nodal 
receptors to modulate signalling activity by sorting internalised Activin/Nodal 
receptors into a recycling pathway in the absence of ligand activation and thus 
maintaining their proper levels at the cell surface (Fu, Lee et al. 2007; Choi, Kim et 
al. 2008). 
RAP2A is required for intestinal epithelial brush border formation, whereas 
overexpression of RAP2C inhibits brush border formation. RAP2A requires its 
effector TNIK, but not MINK or NIK, to mediate brush border formation. RAP2A 
directly links polarisation of intestinal epithelial cells to the formation of an apical 
brush border (Gloerich, ten Klooster et al. 2012).  
RAP effectors 
Ste20 kinases – TNIK, MINK and MAP4K4/NIK 
TRAF2- and Nck-Interacting Kinase (TNIK) (Taira, Umikawa et al. 2004) and Mitogen-
activated protein kinases (MAPK) kinase kinase kinase 4 (MAP4K4)/Nck-Interacting 
Kinase (NIK) (Machida, Umikawa et al. 2004) and the Misshapen/NIK-related Kinase 
(MINK) (Nonaka, Takei et al. 2008) are a subgroup of MAPKs that have been 
identified as specific downstream effectors of RAP2, but not RAS or RAP1 (Fu, Shen 
et al. 1999; Dan, Watanabe et al. 2000; Dan, Watanabe et al. 2001; Machida, 
Umikawa et al. 2004; Taira, Umikawa et al. 2004; Bos 2005; Nonaka, Takei et al. 
2008). 
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Background 
MAPK are a family of conserved serine/threonine protein kinases that transmit 
extracellular signals into the cytoplasm. They are commonly activated through 
phosphorylation cascades, such as by the Ste20 kinases (Sells and Chernoff 1997; 
Bagrodia and Cerione 1999; Kyriakis 1999), and subsequently phosphorylate a 
number of effectors that contribute to the regulation of diverse cellular events, 
including differentiation (Eriksson and Leppa 2002; Aouadi, Bost et al. 2006), 
proliferation (Barr and Bogoyevitch 2001; Roux and Blenis 2004), survival (Lee, 
Sartor et al. 2004), migration (Su, Lu et al. 2009), and invasion (Ip and Davis 1998; 
Widmann, Gibson et al. 1999; Wendt and Schiemann 2009). 
Phylogenic grouping 
 
 
Figure 7: Phylogenetic tree, domain structure, and multiple sequence alignments of the GCK and 
PAK subfamilies of STE20-type kinases from humans and C. elegans. p21-activated kinases (PAKs) 
fall into two structurally similar subfamilies, PAK-I and PAK-II, whereas germinal center kinases 
(GCKs) fall into eight subfamilies, one of which (GCK-VII) is not represented in C. elegans. The human 
kinases are designated in the phylogram with their common names. STE20-related kinases grouped 
by ClustalW protein alignment, and distance matrices and trees were subsequently calculated using 
Phylip.  
The C. elegans kinases are shown as cosmid open reading frames for predicted genes or official gene 
names where designated. Y38F1A.10 does not fall into any of the subfamilies, but it is most closely 
related to the PAKs. For reference, yeast kinase Ste20p, the founding member of this family, is also 
shown. Representative domain structures are shown for each subfamily. Protein kinase domains 
(IPR000719) are indicated by blue boxes. Citron-like domains (IPR001180, green box) may be 
involved in macromolecular interactions, particularly with small GTPases. The SARAH domain 
(IPR0011524, orange box) facilitates dimerisation and is unique to the GCK-II family. PAK domains 
(IPR000095, brown box) allow the PAK family kinases to bind to members of the p21 and Rho 
families. Finally, the DUF334 domain (IPR005602, purple box) is of unknown function. Motifs that 
are functionally conserved generally show up in multiple sequence alignments. In the alignments for 
each subfamily shown immediately below the domain structures, red indicates 100%, orange >50%, 
and blue <50% identity. Figure from (Strange, Denton et al. 2006). 
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The Ste20 group of protein kinases are a large group of protein kinases comprising 
approximately 30 members (www.UniProt.org) (see Figure 7). They are further 
divided into the p21-Activated Kinase (PAK) and Germinal Centre Kinase (GCK) 
families, which have various intracellular regulatory effects including the regulation 
of apoptosis, rearrangement of the cytoskeleton leading to cell-shape change and 
cell motility (Sells and Chernoff 1997; Bagrodia and Cerione 1999; Kyriakis 1999). 
TNIK, MINK and NIK belong to the GCK IV subgroup (also referred to as the NIK-
related kinases or the NIK subfamily kinases) of the Ste20 family of protein kinases 
(Figure 7) and show overlapping as well as distinct functions. 
Structure 
Their structure (see Figure 8) is characterised by an N-terminal kinase domain and a 
non-catalytic C-terminal citron homology (CNH)/GCK homology (GCKH) domain. 
NIK-related kinases share around 90% amino acid identity in the CNH/GCKH region 
(Su, Han et al. 1997; Su, Treisman et al. 1998; Fu, Shen et al. 1999; Kanai-Azuma, 
Kanai et al. 1999), which is also the RAP2 binding site for TNIK, MINK and NIK (Taira, 
Umikawa et al. 2004; Nonaka, Takei et al. 2008). In the intermediate region the 
sequence homology is less striking and MINK displays less than 45% amino acid 
identity with other NIK-related kinases (Fu, Shen et al. 1999; Dan, Watanabe et al. 
2001), leading to activation of diverse signalling pathways. 
TNIK, MINK and NIK contain eight proline-rich motifs (PXXP) that are the Src 
homology 3 (SH3) domain binding regions, where they interact with Nck (Su, Han et 
al. 1997; Fu, Shen et al. 1999). Nck is implicated in the regulation of the actin 
cytoskeleton by receptor or non-receptor tyrosine kinases (McCarty 1998; Buday, 
Wunderlich et al. 2002; Rivera, Briceno et al. 2004). Although regions of high 
homology lead to overlapping functions, sequence deviation of MINK in its 
intermediate region suggests that it may also be involved in different signalling 
cascades (Dan, Watanabe et al. 2000). 
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Figure 8: Homologies of 
MINK to other NIK 
subfamily kinases and 
GCK. The kinase domain is 
represented by gray 
boxes, the intermediate 
region by horizontal lines, 
and the GCKH region by 
white boxes. Locations of 
proline-rich motifs (PXXP) 
are indicated by vertical 
bars and glutamine-rich 
motifs are shown by 
vertical arrowheads. 
Amino acid identities 
relative to muMINK 
within each domain and 
in the whole molecule (on 
the right) are shown. The 
huMINK sequence was 
predicted from a genomic 
sequence. Figure from 
(Dan, Watanabe et al. 
2000). 
 
Expression 
MINK is ubiquitously expressed; however it is most abundant in the brain (Dan, 
Watanabe et al. 2000) and moderately expressed in kidney and spleen, whereas NIK 
and TNIK are expressed at low levels. NIK and TNIK are abundant in adult skeletal 
muscle and the heart while MINK is not (Dan, Watanabe et al. 2000). 
Function 
TNIK, MINK and NIK activate c-Jun N-terminal kinase (JNK), a stress-activated MAPK 
(Dan, Watanabe et al. 2000), via different mechanisms. TNIK and MINK have also 
been shown to differentially impinge upon RAP2 signalling in hippocampal 
dendrites/neuronal cells as MINK, but not TNIK, overexpression is sufficient to 
disrupt RAP2-mediated removal of AMPA-Rs (Zhu, Pak et al. 2005; Fu, Lee et al. 
2007; Hussain, Hsin et al. 2010). 
TNIK 
TNIK was originally identified as “TRAF2- and Nck-interacting kinase” (Fu, Shen et al. 
1999). TRAF2 belongs to a family of adaptor proteins that shares a common 
structural domain (the TRAF domain) and is implicated in the regulation of JNK and 
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the transcription factor NF-κB by the tumour necrosis factor (TNF) receptor or 
related receptors (Bradley and Pober 2001).  
TNIK functions as an essential activator of Wnt target genes (Mahmoudi, Li et al. 
2009; Gui, Yang et al. 2011) by interacting directly with β-catenin and TCF4 (a key 
transcription factor of Wnt signalling) in a kinase dependent manner (Shitashige, 
Satow et al. 2008; Mahmoudi, Li et al. 2009). TNIK phosphorylates TCF4 at S154 and 
activates the transcriptional activity of the β-catenin-TCF4 complex which is 
indispensable for colon cancer cell growth. Colorectal cancer cells have been shown 
to be highly dependent on the expression levels and kinase activity of TNIK for 
proliferation (Mahmoudi, Li et al. 2009; Shitashige, Satow et al. 2010). 
In the brain, TNIK functions as a susceptibility gene for schizophrenia and related 
diseases (Glatt, Everall et al. 2005; Matigian, Windus et al. 2007; Potkin, Turner et 
al. 2009; Shi, Levinson et al. 2009). TNIK mRNA is upregulated in the dorsolateral 
prefrontal cortex of schizophrenia patients (Glatt, Everall et al. 2005) and in 
lymphoblastoid cell lines from bipolar disorder patients (Matigian, Windus et al. 
2007). TNIK is a regulatory kinase at the postsynaptic density (PSD) (Peng, Kim et al. 
2004; Collins, Yu et al. 2005) and is inhibited by a physical interaction with Disrupted 
in schizophrenia 1 (DISC1) (Wang, Charych et al. 2011), a strong candidate gene for 
schizophrenia and other psychiatric disorders (Chubb, Bradshaw et al. 2008; 
Brandon, Millar et al. 2009). 
TNIK also regulates the actin cytoskeleton by inducing actin fibre disassembly 
through its kinase domain (Fu, Shen et al. 1999; Taira, Umikawa et al. 2004). 
Therefore, with the expression of TNIK, adherent cells round up and lose 
attachment to culture dishes, but remain viable and do not undergo apoptosis (Fu, 
Shen et al. 1999). GTP-bound RAP2 interacts with TNIK in an effector domain 
dependent manner (Taira, Umikawa et al. 2004) and enhances the inhibitory 
function of TNIK against cell spreading by promoting auto-phosphorylation and 
translocation of TNIK to the cytoskeleton. This suggests that TNIK is a specific 
effector of RAP2 and regulates the actin cytoskeleton (Fu, Shen et al. 1999; Taira, 
Umikawa et al. 2004). In HEK-293T cells RAP2 proteins localise and recruit TNIK to 
the recycling endosomes (Uechi, Bayarjargal et al. 2009). 
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MINK 
MINK is involved in the p38 pathway, interacts with Nck and activates the JNK 
pathway independently of its kinase activity. MINK is also involved in the regulation 
of the actin cytoskeleton, cell-matrix adhesion and cell-cell adhesion, leading to 
changes in cell morphology, migration and invasion (Hu, Leo et al. 2004). 
MINK is a distal target of RAS signalling in the induction of a growth-arrested, 
senescent-like phenotype that may act to oppose oncogenic transformation in 
human ovarian surface epithelial (HOSE) cells (Nicke, Bastien et al. 2005). 
The expression of MINK has been found to be up-regulated during the postnatal 
development of the mouse brain (Dan, Watanabe et al. 2000). As with RAP2, 
expression of MINK (and TNIK) in neurons is required for normal dendritic 
arborisation and surface expression of AMPA receptors. This overlapping function 
suggests a potential role of the RAP2 interaction with MINK and TNIK in neuronal 
development and cellular differentiation (Zhu, Pak et al. 2005; Fu, Lee et al. 2007).  
MAP4K4/NIK 
MAP4K4 consists of multiple isoforms resulting from alternative splicing, (Wright, 
Wang et al. 2003) and is known in humans and mice as hematopoietic progenitor 
kinase (HPK)/GCK-like kinase (HGK) (Yao, Zhou et al. 1999) and NIK (Su, Han et al. 
1997) respectively. 
NIK activates the JNK/SAPK pathway (Machida, Umikawa et al. 2004; Collins, Hong 
et al. 2006) and RAP2 interacts with the CNH domain of NIK (Machida, Umikawa et 
al. 2004), enhancing the JNK activation by NIK (Machida, Umikawa et al. 2004). 
Conversely, expression of TNIK alone substantially activates JNK whilst co-
expression of RAP2 does not enhance this activation (Fu, Shen et al. 1999).  
NIK is overexpressed in many types of human cancer (Collins, Hong et al. 2006; 
Liang, Wang et al. 2008). NIK over-expression is prognostically significant in patients 
with stage II pancreatic ductal adenocarcinoma (Liang, Wang et al. 2008). NIK is also 
frequently overexpressed in human hepatocellular carcinoma (HCC) tissues as well 
as several HCC cells lines including HepG2 and Hep3B, again associated with worse 
prognosis of HCC patients (Liu, Cai et al. 2011). Experimentally, silencing of NIK 
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causes reduced tumour cell motility in SKOV-3 ovarian carcinoma-derived cell lines 
(Collins, Hong et al. 2006) and in HepG2 and Hep3B liver cells (Liu, Cai et al. 2011). 
RIN 
The RAS and Rab interactor (RIN) family consists of three members, RIN1, RIN2 and 
RIN3. These function as GEFs for Rab5 (Bliss, Venkatesh et al. 2006) and are 
associated with endosomal trafficking (Saito, Murai et al. 2002; Grosshans, Ortiz et 
al. 2006).  
Rab proteins constitute a subfamily of over 40 small GTPases that localise to distinct 
intracellular compartments and regulate the transport between specific organelles 
(Olkkonen and Stenmark 1997; Zerial and McBride 2001). Rab5 is primarily localised 
to early endosomes (Gorvel, Chavrier et al. 1991) and plays a role in membrane 
budding and trafficking in the early endocytic pathways (Kajiho, Saito et al. 2003; 
Saito, Kajiho et al. 2005; Kajiho, Sakurai et al. 2011; Woller, Luiskandl et al. 2011). 
RIN1, RIN2 and RIN3 contain an N-terminal SH2 domain, intermediate proline-rich, 
RH and Vps9 domains and a C-terminal RA domain (Han, Wong et al. 1997) (Colicelli, 
Nicolette et al. 1991; Saito, Murai et al. 2002). RIN2 and RIN3 preferentially interact 
with the GTP-bound form of Rab5, while RIN1 preferentially interacts with GDP-
bound Rab5 (Tall, Barbieri et al. 2001; Saito, Murai et al. 2002). 
The RIN1 RA domain was initially identified as a region interacting with HRAS (Hofer, 
Fields et al. 1994; Ponting and Benjamin 1996), suggesting that RINs are capable of 
binding not only to Rab5 but also to the RAS-family GTPases. The GEF activity of 
RIN1 for Rab5 is enhanced by its interaction with HRAS (Han and Colicelli 1995; Tall, 
Barbieri et al. 2001). However, HRAS does not interact with RIN3 or RIN2 to 
stimulate their GEF activities in conditions under which it certainly binds to RIN1 
(Rodriguez-Viciana, Sabatier et al. 2004; Wohlgemuth, Kiel et al. 2005). 
RIN1, RIN2 and RIN3 mRNA distribution is different; RIN1 is highly expressed in 
neuronal tissues in the mature forebrain neurons and moderately expressed in 
epithelial and hematopoietic cells (Hu, Bliss et al. 2005; Deininger, Eder et al. 2008), 
RIN2 is abundant in the heart, kidney and lung (Saito, Murai et al. 2002), and RIN3 in 
peripheral blood cells. 
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The intracellular localisations of the three RIN members are not identical. In HeLa 
cells RIN3 and RIN2 localise with Rab5 to endocytic vesicles, whereas RIN1 exhibits a 
cytoplasmic distribution. RIN1 partially co-localises with Rab5-positive vesicles upon 
co-expression, and stimulates epidermal-growth-factor-receptor (EGFR)-mediated 
endocytosis (Tall, Barbieri et al. 2001). 
RIN1 was originally identified as a RAS effector that interferes with RAS-induced 
phenotypes in yeast Saccharomyces cerevisiae (Colicelli, Nicolette et al. 1991; Han, 
Wong et al. 1997; Bliss, Venkatesh et al. 2006). RIN1 has also been shown to 
positively regulate endocytosis and cytoskeletal remodelling, epithelial-cell 
adhesion and migration (Hu, Bliss et al. 2005; Cao, Tanis et al. 2008; Ziegler, Eiseler 
et al. 2011) by activating downstream Rab5 GTPases and the Abl tyrosine kinase 
(Han, Wong et al. 1997; Tall, Barbieri et al. 2001; Barbieri, Kong et al. 2003; Hu, Bliss 
et al. 2005). 
RIN1 was also reported to be involved in regulating insulin receptor and IL3 
receptor signal transduction pathways (Hunker, Galvis et al. 2006; Hunker, Giambini 
et al. 2006). It directly interacts with activated EGFR through its SH2 domain (Afar, 
Han et al. 1997; Han, Wong et al. 1997; Barbieri, Kong et al. 2003; Hu, Bliss et al. 
2005; Cao, Tanis et al. 2008) playing an important role in mediating EGFR trafficking 
and degradation (Tall, Barbieri et al. 2001; Barbieri, Fernandez-Pol et al. 2004; Chen, 
Kong et al. 2009; Tomshine, Severson et al. 2009). 
RIN1 gene expression is closely associated with mitosis, neoplastic transformation 
(Samant, Debies et al. 2002; Bliss, Venkatesh et al. 2006; Fujioka, Goi et al. 2009; 
Bliss, Gray et al. 2010; Chetcuti, Aktas et al. 2011; Thai, Ting et al. 2011) and, 
through duplications or aberrant expression, with several types of cancers including 
squamous cell, cervical, colorectal, gastric, breast and non-small cell lung cancer, 
Wilms’ tumour and acute myeloid leukaemia (Shuster, Han et al. 2000; Zainabadi, 
Benyamini et al. 2005; Milstein, Mooser et al. 2007; Senda, Goi et al. 2007; Fujioka, 
Goi et al. 2009; Tomshine, Severson et al. 2009; Wang, Gao et al. 2012). RIN1 
knockout mice demonstrated a major physiological role for RIN1 in mature neurons 
(Dhaka, Costa et al. 2003). 
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RIN2 has also been shown to regulate E-cadherin internalisation (Kimura, Sakisaka 
et al. 2006) in hepatocyte growth factor (HGF)-induced endocytosis of E-cadherins 
in rat liver cells. It is a direct target of RAS and transduces signal activation from 
activated RAS to Rab5 (Kimura, Sakisaka et al. 2006). 
RalGEF family 
RalGDS is a known RAS effector protein. It is a guanine exchange factor (GEF) that 
contains a RAS-GEF domain in its N-terminal domain. RalGDS is one of the GEFs, 
along with Rlf, Rgl, Rgl3, that are downstream effectors of RAS proteins. They aid 
the dissociation of GDP for the small GTPase proteins RalA and RalB, thus allowing 
GTP binding and subsequent activation. In addition to binding to and activating the 
Ral G-proteins, it also enables PDK1 to interact with Akt thus allowing its 
phosphorylation on T308 (Hao, Wong et al. 2008); this contributes to the activation 
of Akt by growth factors. 
RGL/Rlf 
Ral guanine nucleotide dissociation stimulator-like 2 is encoded by RGL2 in humans 
(Isomura, Okui et al. 1996) and has been shown to interact with HRAS (Peterson, 
Trabalzini et al. 1996; Mitin, Ramocki et al. 2004). 
RGL2 is phosphorylated both in vitro and in mammalian cells by PKA at S737 located 
at the C-terminus of its RBD. Phosphorylation significantly reduces the ability of 
RGL2 to bind HRAS and RAP1B (Ferro, Magrini et al. 2008). This phosphorylation site 
is conserved in the RGL2 murine ortholog RLF but not in RalGDS, RGL and RGL3. 
Thus, while all RalGDS proteins are able to bind RAS proteins, only in the case of 
RGL2/RLF, this interaction may be regulated by PKA phosphorylation. This suggests 
that RAS proteins may distinguish between the different RalGDS family members 
through their phosphorylation by PKA and pointing towards a general mechanism 
used by RAS to distinguish the different effectors (Ferro, Magrini et al. 2008). 
AF6/Afadin 
AF6 is a multidomain F-actin-binding protein that is expressed in almost all 
epithelial tissues, and in a variety of other cell types including neurons, fibroblasts 
and endothelial cells (Mandai, Nakanishi et al. 1997; Takai, Ikeda et al. 2008). 
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AF6 is an adaptor protein that localises to cell-cell junctions. AF6 is described as a 
regulator of integrin-mediated cell adhesion (Su, Hattori et al. 2003) and cell 
migration (Lorger and Moelling 2006; Miyata, Ogita et al. 2009; Severson, Lee et al. 
2009). AF6 has been implicated in RAS-induced junction breakdown (Yamamoto, 
Harada et al. 1997), and in binding p120 catenin in a RAP-dependent manner to 
prevent internalisation of E-cadherin (Hoshino, Sakisaka et al. 2005). 
The long isoform of AF6 comprises (from the N- to C-terminus) two RA domains 
(RAS/RAP1 association); the N-terminal RA domain binds both RAS and RAP1 with 
high affinity, a Forkhead, a dilute domain, a PDZ domain and an actin-binding 
domain (Hofmann and Bucher 1995; Ponting 1995; Mandai, Nakanishi et al. 1997; 
Yamamoto, Harada et al. 1997; Linnemann, Geyer et al. 1999). The longer isoform 
of AF6 regulates E-cadherin in a RAP-independent manner (Lorger and Moelling 
2006) whereas the short isoform lacks the actin-binding domain (Saito, Matsushima 
et al. 1998). 
In T-cells, AF6 is a negative regulator of RAP-induced integrin mediated cell 
adhesion (Zhang, Rehmann et al. 2005). Additionally, the role of AF6 in oncogenesis 
has been documented in some acute lymphoid and myeloid leukaemias. The MLLT4 
gene is a fusion partner of the mixed lineage leukaemia gene MLL (Prasad, Gu et al. 
1993). Self-association of AF6 activates the oncogenic potential of MLL-AF6 fusion 
protein (Liedtke, Ayton et al. 2010). 
In mice, AF6 knockout results in embryonic lethality with defects starting at 
gastrulation. This includes disorganisation of the ectoderm, impaired migration of 
the mesoderm and loss of somites (Ikeda, Nakanishi et al. 1999; Zhadanov, 
Provance et al. 1999). 
Potential RAP2 Interactors 
VPS35/VPS29 
The retromer complex is a key mediator of trafficking from endosomes to the Golgi 
complex (Bonifacino and Hurley 2008; McGough and Cullen 2011; Temkin, Lauffer 
et al. 2011). These complexes are involved in the recycling of endosomal SNAREs 
(soluble N-ethylmaleimide-sensitive factor attachment protein receptor), trafficking 
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of Wnt receptors, retrograde transport of shiga toxins, the delivery of polymeric 
immunoglobulin receptor (pIgR) and the regulation of amyloid β (Aβ)-peptide 
processing by its sorting receptor, the sortillin-related receptor with A-type repeats 
(sorLA) (Hettema, Lewis et al. 2003; Verges, Luton et al. 2004; Andersen, Reiche et 
al. 2005; Bujny, Popoff et al. 2007; Belenkaya, Wu et al. 2008). 
The retromer complex can be functionally dissected into two subcomplexes; the 
cargo-selective subcomplex is a trimer of the VPS26, VPS29 and VPS35 proteins, 
whilst the SNX-BAR dimer of the VPS5 and VPS17 proteins acts to form membrane 
tubules at the endosome (Seaman, McCaffery et al. 1998). 
VPS29 is a rigid scaffold that interacts with various proteins that function with 
retromer in endosomal protein sorting (Swarbrick, Shaw et al. 2011). VPS29 links 
the two subcomplexes together with a conserved hydrophobic patch on the surface 
of VPS29 that is critical for the assembly of the heteropentamer. 
VPS35 selects cargo proteins for retrieval (Nothwehr, Ha et al. 2000; Collins, 
Norwood et al. 2008) and can be mutated in autosomal dominant late-onset 
Parkinson disease (Vilarino-Guell, Wider et al. 2011; Zimprich, Benet-Pages et al. 
2011) at D620N, P316S and R524W. 
Although the RAP2-VPS35/VPS29 interaction was validated by overexpressing 
tagged proteins (see later), we were not able to validate the endogenous 
interaction with our antibodies and it was not pursued further as not many tools or 
reagents were available at the time. 
TBC1D10B 
TBC1D10B functions as a GAP for several proteins of the Rab family and is involved 
in exocytosis (Ishibashi, Kanno et al. 2009; Hsu, Morohashi et al. 2010). The TBC 
(Tre2, Bub2, and Cdc16) domain regulates the activity of small Rab GTPases via a 
dual-finger mechanism (Pan, Eathiraj et al. 2006). Rab GAPs are essentially 
implicated in the spatial and temporal dynamics of the cellular endomembrane 
system (Barr and Lambright 2010). 
Using tagged constructs in co-transfection experiments we were not able to 
reproducibly validate this interaction. Furthermore, because there are no 
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commercial antibodies available against TBC1D10B, this interaction was not further 
pursued and remains to be validated. 
TRIM32 
The TRIM32 interaction is the main focus of this project and is part of the tripartite 
motif (TRIM) family of proteins. 
TRIM 
TRIM family proteins are involved in a broad range of biological processes and their 
mutations are associated with diverse pathological conditions, such as 
neurodegenerative diseases, developmental disorders, viral infections and cancer 
(Meroni and Diez-Roux 2005; Ozato, Shin et al. 2008). Most of the TRIM proteins 
function as E3 ubiquitin ligases; proteins that carry out post-translational 
modification of targets via a cascade of ubiquitin-modifying reactions (Pickart and 
Eddins 2004) (described in more detail later).  
There are more than 70 known TRIM proteins in humans and mice, which are 
encoded by approximately 71 genes in humans, several of which are clustered 
together. TRIM proteins are classified into subfamilies I to XI on the bases of their 
domain structure (Figure 9) (Short and Cox 2006; Ozato, Shin et al. 2008; McNab, 
Rajsbaum et al. 2011). They contain three linked motifs namely a RING finger, 1-2 
zinc binding B-box domains, and a coiled coil domain, together with a variable C-
terminal region (Reymond, Meroni et al. 2001). They are often defined as E3 
ubiquitin ligases due to the presence of a RING-finger domain, although not all 
proteins contacting a RING-finger domain function as E3 ubiquitin ligases 
(Reymond, Meroni et al. 2001). 
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Figure 9: The structural classification of TRIM subfamily (C-I to C-XI). Almost all TRIM proteins have 
a RING-finger domain (R), one or two B-box domains (B) and a coiled-coil domain (CC). Some 
members of the subfamily lack one or more amino-terminal domains (shown as dashed outline 
domains). ACID, acid-rich region; ARF, ADP-ribosylation factor family domain; BROMO, 
bromodomain; COS, cos-box; FIL, filamin-type I G domain; FN3, fibronection type III repeat; MATH, 
meprin and TRAF-homology domain; NHL, NCL1, HT2A and LIN41 domain; PHD, PHD domain; PRY, 
PRY domain; SPRY, SPRY domain; TM, transmembrane region; Ub, ubiquitin. Figure from 
(Hatakeyama 2011). 
 
TRIM32 
TRIM32 is classified as a member of the C-VII sub-family, and its variable region 
consists of 6 NHL motifs; [NHL repeats are conserved domains defined by amino 
acid sequence homologies among Ncl-1, HT2A and Lin-41 proteins (InterPro 
database)], likely to mediate protein-protein interactions (Figure 10)(Slack and 
Ruvkun 1998). 
 
Figure 10: Structure of Trim32. RING finger, one or two B-Box zinc binding domains, a coiled coil 
domain and six NHL repeats. Figure adapted from (Saccone, Palmieri et al. 2008). 
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RING-type zinc finger domains are 40 to 60 residues long, bind two atoms of zinc 
and are involved in mediating protein-protein interactions (Freemont 1993). The 
RING domain of TRIM32 has E3 ubiquitin ligase activity (Kudryashova, Kudryashov 
et al. 2005; Albor, El-Hizawi et al. 2006; Kano, Miyajima et al. 2008). 
B-box-type zinc finger domains are around 40 residues in length. B-box zinc fingers 
can be divided into two groups, where types 1 and 2 B-box domains differ in their 
consensus sequence and in the spacing of the 7-8 zinc-binding residues. TRIM 
proteins contain a type 2 B-box domain, and may also contain a type 1 B-box 
(Reymond, Meroni et al. 2001). 
The NHL repeat of TRIM32 folds into a six-bladed β-propeller structure, with the 
blades arrayed in a radial fashion around a central axis, and each blade composed of 
a highly twisted four stranded antiparallel beta-sheet (Edwards, Wilkinson et al. 
2003). These mediate protein–protein interactions (Slack and Ruvkun 1998) 
(Gentry, Worby et al. 2005). 
TRIM32 (OMIM 602290) has been implicated in diverse pathological processes such 
as head and neck cancer (Horn, Albor et al. 2004; Kano, Miyajima et al. 2008), 
squamous cell carcinogenesis (Albor, El-Hizawi et al. 2006; Kano, Miyajima et al. 
2008), Bardet-Biedl syndrome (BBS) (Chiang, Beck et al. 2006), Alzheimer’s disease 
(Yokota, Mishra et al. 2006), psoriasis lesions (Liu, Lagowski et al. 2010) and Limb-
Girdle Muscular Dystrophy (LGMD2H) (Frosk, Weiler et al. 2002; Schoser, Frosk et 
al. 2005; Saccone, Palmieri et al. 2008) which is discussed in more detail below. 
Several muscle-specific substrates and interacting partners of TRIM32 have been 
identified, including myosin, actin (Kudryashova, Kudryashov et al. 2005), and 
dysbindin (Locke, Tinsley et al. 2009), yet the biological role of these interactions is 
not understood. 
Role in Cancer 
It has been reported that the expression of TRIM32 is increased in transformed 
keratinocytes, ultraviolet (UV) irradiation-induced squamous cell carcinoma (SCC), 
chemically induced papillomas, and head and neck SCCs (Horn, Albor et al. 2004). In 
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addition, TRIM32 overexpression protects keratinocytes from TNF and UV 
irradiation-induced apoptosis, suggesting that TRIM32 can function as an oncogene 
(Horn, Albor et al. 2004). 
In NIH-3T3 and Hep-2 (epithelial) cells, TRIM32 binds to and ubiquitinates Abl-
interactor 2 (ABI2), resulting in its degradation (Kano, Miyajima et al. 2008); ABI2 is 
a tumour suppressor gene that inhibits cell migration and overexpression of 
TRIM32-promoted cell proliferation, motility and transformation. This suggests that 
TRIM32 can promote tumour growth and metastasis through degradation of ABI2 
(Kano, Miyajima et al. 2008). 
Conversely, in HEK-293T cells TRIM32 induces tumour necrosis factor (TNF)-
mediated apoptosis through its direct interaction and ubiquitnation of X-linked 
inhibitor of apoptosis (XIAP). The degradation of XIAP prevents its inhibition of pro-
apoptotic caspases (Ryu, Lee et al. 2011). These findings suggest that TRIM32 could 
function as a tumour suppressor. TRIM32 suppresses apoptosis induced by cis-
diamminedichloroplatinum (II)(cDDP) in Hep2 cell lines (Kano, Miyajima et al. 2008). 
The Drosophila melanogaster homologues of TRIM32; Brat and mei-26, cause 
tumour formation when mutated in flies (Neumuller, Betschinger et al. 2008; 
Schwamborn, Berezikov et al. 2009) suggesting they may have tumour suppressor 
properties. 
Role in Bardet-Biedl Syndrome (BBS) 
BBS (OMIM 209900) is a pleiotropic autosomal recessive human genetic disorder 
that affects many body systems and has variable expressivity and a wide range of 
clinical variability observed both within and between families. Symptoms include 
polydacyly, truncal obesity and learning difficulties (Beales, Elcioglu et al. 1999; 
Abd-El-Barr, Sykoudis et al. 2007)i.  
Many of the gene products encoded by these BBS genes are assembled into a 
multiple protein complex, called the “BBSome” that is proposed to be responsible 
for transporting intracellular vesicles to the base of the cilia and to play an 
important role in ciliary function. Since abnormalities of cilia are known to be 
related to a wide range of disease symptoms including those commonly seen in BBS 
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patients, it is now widely accepted that mutated BBS genes affect normal cilia 
functions. Fourteen different genetic mutations have been currently identified in 
BBS (OMIM 209900), one of which consists of a homozygous P130S mutation in the 
B-box domain of TRIM32 (BBS11) (Chiang, Beck et al. 2006). 
TRIM32 is required for neuronal differentiation 
The Drosophila orthologues of TRIM32, Brat and Brat-like protein Mei-P26, control 
stem cell proliferation in the Drosophila nervous system and ovaries respectively 
(Bello, Reichert et al. 2006; Betschinger, Mechtler et al. 2006; Lee, Robinson et al. 
2006; Neumuller, Betschinger et al. 2008; Harris, Pargett et al. 2011). Thus, 
deregulation of muscle stem cell activity upon loss of TRIM32 could contribute to 
the formation of LGMD2H. TRIM32 has been shown to be necessary for the 
regulation of differentiation and self-renewal in neural progenitor cells during 
mouse embryonic brain development. In cultured cortical progenitors TRIM32 
regulates protein degradation and microRNA (miRNA) activity to control the balance 
of two daughter cell types in neural progenitor cells. PKCζ binds TRIM32 and by 
mediating its localisation in the cytoplasm inhibits the poly-ubiquitination of nuclear 
c-Myc. PKCζ and probably TRIM32 itself are targets for TRIM32-dependent 
ubiquitination. Upon neuronal differentiation, PKCζ levels decrease, allowing 
TRIM32 to become polarised and concentrated in one of the daughter cells, where 
it ubiquitinates and degrades c-Myc inducing neuronal differentiation 
(Schwamborn, Berezikov et al. 2009; Hillje, Worlitzer et al. 2011). Additionally, in 
two different lines of TRIM32 null mice, loss of TRIM32 function caused a LGMD2H-
like phenotype which is associated with dysfunctional muscle satellite cells. 
Moreover, skeletal muscle regeneration is greatly impaired in these mice, indicating 
an important role for TRIM32 in the regulation of skeletal muscle stem cells. 
TRIM32 functions as one of the co-activators for RARα-mediated transcription; 
overexpression of TRIM32 in mouse neuroblastoma cells and embryonal carcinoma 
cells promotes the stability of RARα, resulting in increased neural differentiation 
(Sato, Okumura et al. 2011). These findings suggest that TRIM32 is a potential 
therapeutic target for developmental disorders and RARα-dependent leukaemias. 
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Role in Muscular Dystrophy 
The Muscular Dystrophies (MD) are an inherited group of genetic muscle disorders 
characterised by progressive muscle wasting and weakness. They share common 
histological features of “dystrophic” muscle biopsy changes (including variation in 
muscle fibre size, muscle fibre degeneration and regeneration) and replacement of 
muscle by connective tissue and fat (Motlagh, MacDonald et al. 2005). More than 
30 genetically distinct types of muscular dystrophy have been identified. The 
prognosis for people with muscular dystrophy varies according to the type and 
progression of the disorder. Some have prenatal onset, while others affect only 
adults; some are rapidly progressive, while others are associated with prolonged 
periods of stability. Many are associated with multisystem involvement including 
the heart, eyes and, central nervous, gastrointestinal, and endocrine systems 
(Emery 2002; Bushby, Lochmuller et al. 2009; Kaplan 2009)ii. 
The major variants of MD are Duchenne (DMD), Becker (BMD), Limb-Girdle (LGMD), 
congenital, facioscapulohumeral, myotonic, oculopharyngeal, distal, and Emery-
Dreifuss muscular dystrophy (EDMD)ii. These diseases predominately affect males, 
although females may be carriers.  
Although a curative treatment is not yet available, many individuals can now survive 
into adulthood. 
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MD OMIM GENE ONSET SYMPTOMS PROGNOSIS 
Duchenne 
Muscular 
Dystrophy  
310200 dystrophin at 
Xp21 
(Muntoni, 
Torelli et al. 
2003). 
2-5 years Abnormal gait, scoliosis, respiratory 
insufficiency, cardiomyopathy, calf 
hypertrophy and difficulty in rising 
from the floor. Speech delay in 
minority of cases
iii
 (Essex and Roper 
2001). Feeding difficulties and weight 
loss common in the late stages of 
disease. 
Poor; death 
in late teens 
or early 
twenties 
Becker 
muscular 
dystrophy 
300376 truncated, but 
partially 
functional 
form 
of dystrophin 
 Cognitive and behavioural deficits, 
autistic spectrum disorders (Young, 
Barton et al. 2008); typical 
hypertrophic, proximal weakness, 
quadriceps myopathy, myoglobinuria 
(Bushby, Cleghorn et al. 1991) and 
isolated cardiomyopathy in up to 72% 
of patients (Piccolo, Azan et al. 1994). 
Variable; 
most 
patients 
survive past 
40. 
Limb-
girdle 
muscular 
dystrophy 
Multiple Multiple childhoo
d- or 
adult-
onset 
Skeletal muscle typically affected. 
Proximal weakness and wasting with 
features of muscle 
degeneration/regeneration. 
Variable 
Congenital 
muscular 
dystrophy  
Multiple Multiple At birth Mild or severe muscle degeneration; 
Severe brain malformations (e.g. 
lissencephaly, hydrocephalus). 
Generalised muscle weakness and 
joint deformities; slow progresseion. 
Variable but 
generally 
poor 
Distal 
muscular 
dystrophy 
254130 DYSF 20 to 60 
years 
Weakness and wasting of muscles of 
the hands, forearms, and lower legs; 
slow progression 
Good 
prognosis. 
Miyoshi myopathy 
(sub-type of Distal 
muscular dystrophy) 
    
Emery-
Dreifuss 
muscular 
dystrophy 
310300, 
181350 
EMD, LMNA childhoo
d and the 
early 
teenage 
years 
Distal limb muscle weakness and 
wasting, progressing to limb-girdle 
muscles. Cardiac conduction defects 
and arrhythmias in most patients. 
Increased 
risk of 
stroke and 
sudden 
death. 
Facioscapu
lohumeral 
muscular 
dystrophy 
158900 DUX4 teenage 
years 
Muscles of the face, shoulders, and 
upper arms affected (progressive 
weakness.). 
Severe 
disability 
Myotonic 
muscular 
dystrophy 
160900, 
602668 
DMPK, ZNF9 adult Myotonia (delayed relaxation of 
muscles), muscle wasting and 
weakness. Other body systems can be 
affected including the heart, 
endocrine organs, eyes, and 
gastrointestinal tract. 
 
Variable 
 
Table 1: Clinical overview of muscular dystrophy disorders 
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Limb-Gridle Muscular Dystrophy 
Limb-girdle muscular dystrophy (LGMD) refers to childhood- or adult-onset 
muscular dystrophies that are distinct from the much more common X-linked 
dystrophinopathies, DMD and BMD. LGMDs are much rarer than DMD and BMD, 
and in addition there is a significant genetic and clinical heterogeneity. Individuals 
with LGMD generally show weakness and wasting restricted to the limb 
musculature, as well as muscle degeneration/regeneration on muscle biopsy. Onset, 
progression, and distribution of the weakness and wasting vary considerably among 
individuals and genetic subtypes. 
LGMD affects both males and females, affecting the upper arms and legs. Many 
forms of LGMD have been identified, showing different patterns of inheritance; (e.g. 
autosomal dominant vs autosomal recessive classified as LGMD1 and LGMD2 
respectively). Dominant LGMDs are less frequent than the recessive forms and 
usually show adult onset whilst recessive LGMDs usually have childhood or teenage 
onset. Though a person normally leads a normal life with assistance, death can 
occur from cardiac complications. 
Mutations at more than 50 loci have been shown to cause LGMD. The overall 
frequency of LGMD is one in 15 000 (Emery 1991). LGMD2I is the commonest 
muscular dystrophy in certain northern European countries, whereas a higher 
incidence of sarcoglycanopathy is detected in northern Africa. LGMD2B and 
LGMD2A predominate in an Australian cohort (Lo, Cooper et al. 2008). 
An overview of the clinical features of muscular dystrophies presenting with limb-
girdle muscle weakness are summarised in Table 2, including information of the 
predominance of certain subtypes in certain populations. 
 
Disease Name 
(Synonym) 
Gene 
Symbol 
Locus Symptoms Onset 
(Average) 
Wheelchair 
Bound 
Populations 
with 
Mutations 
LGMD1A 
(Myotilinopathy) 
MYOT 5q31.2 Proximal weakness, 
progressive distal weakness. 
Tight Achilles tendons; nasal, 
dysarthric speech (50%), 
respiratory insufficiency and 
dysphagia 
18-40 years  German, 
Argentinian, 
Turkish, 
Japanese 
LGMD1B LMNA 1q22 Proximal lower limb 
weakness 
Mild contractures of elbows, 
Birth to 
adulthood 
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Arrhythmia and other 
cardiac complications (25-45 
years), Sudden death 
LGMD1C 
(Caveolinopathy) 
CAV3 3p25.3 Mild-moderate proximal 
weakness 
Cramping, Rippling muscle 
disease, Calf hypertrophy 
~5 years  Italian 
LGMD1D DES 2q35 Proximal muscle weakness 
Cardiac conduction defects, 
dilated cardiomyopathy 
<25 yrs All 
individuals 
remain 
ambulatory 
 
LGMD1E DNAJB6 7q36.3 Proximal or distal weakness 
in the lower limbs. 
18-40 years Wheelchair 
bound at 
age 45-62 
years 
 
LGMD1F Unknown 7q32.1-
q32.2 
Proximal lower and upper 
limb weakness, later distal 
weakness. 
1-58 years 
(juvenile-
onset and 
adult-onset 
form) 
 Spanish 
LGMD1G Unknown 4q21 Proximal lower limb 
weakness; proximal upper 
limb weakness in later stages 
Progressive limitation of 
finger and toe flexion. 
30-47 years  Brazilian-
European 
LGMD1H Unknown 3p25.1-
p23 
Proximal lower limb 
weakness 
Muscle hypotrophy of limb 
girdle muscles with calf 
hypertrophy. 
16-50 years 
(39) 
 Italian 
       
Calpainopathy 
(LGMD2A) 
CAPN3 15q15.1 Proximal (normal hip 
extensors and adductors). 
Difficulty to run, walk, toe 
walk; calf muscle atrophy. 
2-40 yrs (8-15 
yrs) 
11-28 yrs 
after onset 
Amish, La 
Reunion 
Island, 
Basque 
(Spain), 
Turkish 
Dysferlinopathy 
(LGMD2B) 
DYSF 2p13.2 Distal and/or pelvic-femoral 
Difficulty to tip-toe; difficulty 
run, walk; transient calf 
muscle hypertrophy (rare). 
17-23 yrs  Libyan 
Jewish 
Australian 
Gamma- 
sarcoglycanopathy 
(formerly 
SCARMD) 
(LGMD2C) 
SGCG 13q12.12 Proximal weakness. 
difficulty to run and walk; 
calf muscle hypertrophy. 
3-15 yrs (8.5 
yrs) 
~15 yrs North 
Africans; 
Gypsies 
Alpha- 
sarcoglycanopathy 
(LGMD2D) 
SGCA 17q21.33  Childhood -
adulthood 
 None 
Beta- 
sarcoglycanopathy 
(LGMD2E) 
SGCB 4q12 Cramps, exercise intolerance Adolescent - 
young 
adulthood 
 Amish 
Delta- 
sarcoglycanopathy 
(LGMD2F) 
SGCD 5q33.3  Childhood -
adulthood 
 Brazilian 
LGMD2G TCAP 17q12 Lower limb and proximal 
upper limb weakness 
Difficulty to run, walk; foot 
drop 
9-15 yrs ~18 yrs 
after onset 
Brazilian, 
Italian 
LGMD2H TRIM32 9q33.1 Proximal lower limb, neck 
and facial weakness. 
Waddling gait, difficulty with 
stairs, calf muscle wasting. 
1-9 yrs Late in life Manitoba 
Hutterites 
LGMD2I FKRP 19q13.32 Proximal weakness; upper > 1.5-27 yrs 23-26 yrs Northern 
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(MDDGC5) lower limb 
Difficulty to run, walk; calf 
muscle hypertrophy, 
rare/late 
contractures/scoliosis 
(11.5 yrs) after onset European 
LGMD2J TTN 2q31.2 Proximal weakness 5-25 yrs Average 20 
yrs after 
onset 
Finland, 
Moroccan, 
Sudanese 
LGMD2K 
(MDDGC1) 
POMT1 9q34.13 Mild weakness; proximal > 
distal 
Fatigability, difficulty 
climbing stairs and running; 
cognitive delay with limited 
language development, 
hypertrophy of calves and 
thighs 
1-3 yrs varies Turkish 
LGMD2L ANO5 11p14.3 Proximal weakness, pelvic-
femoral or distal in the lower 
limbs. 
Difficulties standing on toes, 
Contractures (wrist, finger, 
TA) 
Late teens-
50s 
 Northern 
European 
LGMD2M 
(MDDGC4) 
FKTN 9q31.2 Proximal weakness; lower > 
upper limb 
Difficulties climbing stairs, 
severe weakness after 
illness; steroid responsive 
4 mo - 4 yrs Not 
reported 
Japanese 
LGMD2N 
(MDDGC2) 
POMT2 14q24.3 Slowness in running and 
getting up, scapular winging 
and mild lordosis; intellectual 
disability 
18 mo; 
asymptomatic 
at 5 yrs 
 Unknown 
LGMD2O 
(MDDGC3) 
POMGNT1 1p34.1 Proximal weakness > distal. 
Difficulty standing from the 
sitting position and climbing 
stairs; severe myopia, ankle 
contractures 
12 yrs  Unknown 
LGMD2Q PLEC 8q24.3 Proximal weakness. 
Delayed achievement of 
motor milestones, difficulties 
climbing stairs. 
2-3 yrs  Turkish 
 
Table 2: Clinical Features of LGMD. 
 
LGMD2H 
Mutations in TRIM32 are responsible for LGMD2H. The first TRIM32 mutation 
described, p.Asp487Asn, is a founder mutation in the Hutterite population of North 
America with one sibling pair identified in a non-Hutterite family in Germany 
(country of Hutterite origin). Sarcotubular myopathy (STM), also found in the 
Hutterite population, is caused by the same mutation in TRIM32 (Schoser, Frosk et 
al. 2005; Borg, Stucka et al. 2009). 
54 
 
 
Figure 11: TRIM32 mutations fall within the BBox and NHL domain. Mutations in the BBox domain 
demonstrate a role in Bardet-Biedl syndrome whereas those located in the NHL repeats are linked 
to Limb-Girdle Muscular Dystrophy Type 2H (indicated by the blue arrows). 
 
Subsequently, additional mutations in TRIM32 were identified in patients with 
LGMD (Figure 11); c.1180G>A (p.R394H) (Saccone, Palmieri et al. 2008)], one codon 
deletion [c.1761–1763delGAT (p.D588 del) (Saccone, Palmieri et al. 2008)], three 
frameshift mutations [c.1559delC (p.T520TfsX13) (Saccone, Palmieri et al. 2008), 
c.1753–1766dup (p.I590LfsX38) (Cossee, Lagier-Tourenne et al. 2009), c.1560delC 
(p.C521VfsX13) (Borg, Stucka et al. 2009)] and one intragenic deletion that removes 
the entire open reading frame [del 30 586 bp + insert 2 bp (Borg, Stucka et al. 
2009)]. Similar to the previously identified D487N mutation, all these new 
mutations occurred in the C-terminal NHL domains of TRIM32. 
Disease severity ranges from asymptomatic to severe proximal weakness. Facial 
weakness and a "flat smile" are common (Weiler, Greenberg et al. 1998; Saccone, 
Palmieri et al. 2008). Affected individuals can maintain their ability to walk well into 
adulthood with some reports of patients remaining capable of walking (with 
difficulty) into their sixties (Weiler, Greenberg et al. 1998; Saccone, Palmieri et al. 
2008). Irreversible loss of motility has been reported after prolonged immobilization 
(Saccone, Palmieri et al. 2008). 
LGMD2H biopsies show myopathic features of central nucleation, fiber splitting, Z-
line streaming, and a dilated sarcotubular system with vacuoles (Jerusalem, Engel et 
al. 1973; Shokeir and Kobrinsky 1976; Shokeir and Rozdilsky 1985; Muller-Felber, 
Schlotter et al. 1999; Frosk, Weiler et al. 2002; Schoser, Frosk et al. 2005; Saccone, 
Palmieri et al. 2008).  
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Drosophila studies demonstrate that the TRIM32 ortholog Thin (tn) is a key 
structural protein maintaining myofibrillar stability. Myofibrils in tn mutants 
unbundle during development, leading to muscle wastage over time. The gaps in 
the myofibrils of tn mutants appear analogous to the gaps in the myofibrils of 
diseased muscle tissue from individuals with muscle. The muscle defects observed 
in Drosophila are more pronounced than those seen in TRIM32 deficient mammals. 
it is likely that Thin plays a greater functional role in Drosophila while it is likely that 
multiple mechanisms contribute to the muscle breakdown that occurs in humans 
suffering from LGMD2H myopathies (LaBeau-DiMenna, Clark, et al. 2012). 
A TRIM32 knock-out mouse model recapitulates human muscular dystrophy 
phenotypes see in LGMD2H and sarcotubular myopathy, demonstrating similar 
muscle morphology as patient muscle biopsies. Moreover, it allowed for the 
uncovering of a neurogenic component caused by disruption of the TRIM32 gene, 
suggesting a novel role for TRIM32 in the nervous system (Kudryashova, Struyk et 
al. 2011; Kudryashova, Wu et al. 2009). Additionally, it has been shown that TRIM32 
deficiency plays a role premature senescence of myogenic cells, leading to a lack of 
adequate muscle regrowth after atrophy. This premature senescence contributes to 
cell differentiation and proliferation defects in myogenic cultures, leading to 
impaired myotube formation (Kudryashova, Struyk et al. 2011; Kudryashova, 
Kramerova et al. 2012). During fasting-induced atrophy, Trim32 catalyses the loss of 
thin filament and Z-band components through effects on the key cytoskeletal 
protein – desmin (Cohen, Zhai et al. 2012). In muscle, desmin forms intermediate 
filaments that are localised in the sarcolemma, mitochondria, and nuclear 
membrane and between adjacent myofibrils linking them laterally to the Z-lines 
(Lazarides and Hubbard 1976; Lazarides 1978). Mice lacking desmin exhibit 
misaligned sarcomeres and disorganised myofibrils in skeletal and cardiac muscle 
(Milner, Weitzer et al. 1996). 
Neurodevelopmental Phenotypes 
Recent studies conducted by Lionel et al. have demonstrated that rare copy number 
variants that dirupt TRIM32 have been reported. Although their work focuses 
mainly on the identification of ASTN1 and ASTN2 variants, they have shown that 
exonic deletions affecting multiple isoforms of TRIM32 are enriched in 
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neurodevelopmental disorders with patient phenotypes ranging from language 
delay and anxiety to gross motor delay and fine motor delay (Lionel, et al. 2014). 
TRIM32 expression levels have also been linked to autism spectrum disorder, 
attention deficit disorder, obsessive compulsive disorder, and stress-related 
anxiety- and depression-like behaviours when exposed to mild stress (Ruan, Wang, 
et al. 2014; Lionel, et al. 2011, 2014). 
Combined with findings that TRIM32 expression levels in the mouse neocortex have 
been shown to determine the post-differentiation fates of neuronal stem cells and 
that TRIM32 is a key regulator of neural differentiation, it would be of interest to 
replicate some of our findings in neural cell lines to assess whether the TRIM32-
RAP2 interaction also plays a role and to try and understand the implications on the 
above conditions (Schwamborn, Berezikov et al. 2009; Sato, Okumura et al. 2011). 
NOEY2/DIRAS/ARHI 
The DIRAS family 
The Distinct subgroup of the RAS family (DIRAS) was identified as a member of the 
RAS family by Kontani et al (Kontani, Tada et al. 2002). They are 26kDa GTPases 
comprised of 229 amino acids. Similarly to other members of the RAS family; they 
are localised to the plasma membrane/vacuole membrane, in a CAAX dependent 
manner. 
NOEY2/DIRAS3/ARHI 
The tumour suppressor NOEY2, also designated DIRAS3 and Aplysia RAS Homology 
member I (ARHI), was identified as a deletion occuring on chromosome 1p31 in 28–
50% of breast cancers and 40% of ovarian cancers (Hoggard, Brintnell et al. 1995; 
Loupart, Armour et al. 1995; Nagai, Negrini et al. 1995; Yu, Xu et al. 1999; Peng, Xu 
et al. 2000). Aberrant NOEY2 signalling is also found in other cancers, showing 
decreased expression in uterine serous papillary carcinoma and squamous NSCLC. 
Decreased expression of NOEY2 also occurs in follicular thyroid carcinoma (FTC), but 
not in classic papillary thyroid carcinoma (PTC) or follicular adenoma (FA). FTCs 
show strong allelic imbalance with reduction in copy number/loss of heterozygosity 
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in 69% of cases, compared with less than 10% for FAs (Weber, Aldred et al. 2005). 
However, studies are predominantly carried out in breast and ovarian cancers. 
NOEY2 spans approximately 8 kb and contains one promoter, two exons and one 
intron. Exon 1 contains 83 non-translated nucleotides and is connected to exon 2 
with a 3.2-kb intron. The entire protein-coding region of 687 bp is located within 
exon 2 of 1401 bp and encodes a 26-kDa protein. Although NOEY2 and DIRAS family 
members share 50–60% amino acid homology with RAS and RAP family members 
(Table 3), and have the similar highly conserved GTP-binding domains with high 
GTPase activity, the function differs from that of the RAS and RAP, e.g. DIRAS 
proteins do not bind RAF or PI3K (Yu, Xu et al. 1999). NOEY2 also differs from HRAS 
in residues critical for GTPase activity and for putative effector function. The 
substitutions within the GTP binding domain of NOEY2 are consistent with the 
mutations of RAS responsible for its constitutive activation. Correspondingly, NOEY2 
has been found predominantly in its active GTP-bound state in cells (Luo, Fang et al. 
2003). 
 
NOEY2:  Homology   Table 3: Homology of 
DIRAS3 compared 
with various RAS 
family members. 
RAP1A  56%   
RAP1B  58%   
RAP2A  62%   
RAP2B  59%   
KRAS  59%   
HRAS  54%   
NRAS  51%   
 
NOEY2 has a distinctive 34aa N-terminal extension that is critical for the 
suppression of tumour growth. Cleavage of this N-terminal region abrogates its 
tumour suppressor activity (Luo, Fang et al. 2003). Additionally, NOEY2 is 
constitutively expressed in normal breast and ovarian epithelial cells, but is lost or 
dramatically down-regulated in 40% of ductal carcinomas in situ, 70% of invasive 
breast cancers and 80% of ovarian cancers (Yu, Xu et al. 1999; Hisatomi, Nagao et al. 
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2002; Wang, Hoque et al. 2003). Studies by Wang et al have shown an inverse 
correlation between NOEY2 expression levels and tumour invasiveness (Wang, 
Hoque et al. 2003). 
Re-expression of NOEY2 in breast and ovarian cancers, but not in lung cancer cell 
lines, suppressed clonogenic growth of tumour cells and induced apoptosis (Bao, Le 
et al. 2002; Luo, Fang et al. 2003; Rosen, Wang et al. 2004; Nishimoto, Yu et al. 
2005), while in SKOV3 ovarian cancer cells autophagy was also induced. 
Overexpression of NOEY2 causes down regulation of cyclin D1 promoter activity and 
induces p21WAF1/CIP1 causing cell cycle arrest and growth inhibition in cell cultures 
(Xu, Xia et al. 2000). 
NOEY2 mutations have rarely been reported (Yu, Xu et al. 1999). However, NOEY2 
promoter hypermethylation and transcriptional silencing have been identified in the 
breast hyperplastic cell line (MCF10A cell line), pre-malignant cell line (MCF10AT), 
invasive breast cancer line (MCF10CA1a, MCF10CA1d, MCF10CA1h) and primary 
breast cancer (Yang, Klinkebiel et al. 2005).  
NOEY2 is an imprinted tumour suppressor 
Genomic imprinting is an epigenetic process that involves DNA methylation and 
histone modifications in order to achieve monoallelic gene expression without 
altering the genetic sequence. Imprinted alleles are silenced such that the genes are 
either expressed only from the non-imprinted allele inherited from the mother (e.g. 
H19 or CDKN1C), or in other instances from the non-imprinted allele inherited from 
the father (e.g. IGF-2). These epigenetic marks are established in the germline and 
are maintained throughout all somatic cells of an organism (Reik, Dean et al. 2001).  
Appropriate expression of imprinted genes is important for normal development, 
with numerous genetic diseases associated with imprinting defects including 
Beckwith–Wiedemann syndrome, Silver–Russell syndrome, Angelman syndrome 
and Prader–Willi syndrome (Eggermann, Eggermann et al. 2008; Williams, Driscoll 
et al. 2010). Forms of aberrant genomic imprinting have been implicated in 
oncogenesis through loss of tumour suppressor gene regulation, e.g. the WT1 gene, 
in particular, is part of an imprinted cluster with INS, IGF2, H19, and p57KIP2 on 
chromosome 11p (Zhang, Shields et al. 1993). 
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Genomic imprinting and monoallelic gene expression play an important role in 
tumourigenesis (Barlow 1995). Sapienz was the first to incorporate genetic 
imprinting into Knudson's two “hit” tumourigenesis model. If an imprinted gene is 
involved, the first hit can be explained by the non-expression of one of the alleles 
because of the imprinting process, only preserving the function of monoallelic 
expression. The second hit may be mutational or may result from a loss of all or part 
of the chromosome carrying the remaining functional suppressor allele, resulting in 
total loss of the function of tumour suppressor (Sapienza 1991).  
NOEY2 has been identified as a maternally imprinted gene and was the first 
imprinted tumour suppressor gene identified in adult tumours (Luo, Fang et al. 
2003). In normal cells, the maternal copy is silenced by methylation early in 
embryonic development and NOEY2 is expressed in all normal cells only from the 
paternal allele (Yu, Xu et al. 1999). Thus, the change of the allelic gene inherited 
from the father (such as loss of heterozygosity, mutation and DNA methylation) 
would directly affect the expression of protein and its function as tumour 
suppressor, resulting in malignant transformation. 
Three potential CpG islands, of approximately 300bp (base pairs) each, were found 
within the promoter and exons of the NOEY2 gene. CpG island I is located about 1 
kb upstream of the transcription initiation site; CpG island II is near the transcription 
initiation region; and CpG island III is located in the protein encoding region of exon 
2. CpG island II is particularly important because it spans the 5’-upstream region of 
NOEY2, including the transcription initiation site and a portion of exon 1 (Yu, Fujii et 
al. 2003). 
NOEY2 CpG islands are partially methylated (one allele) in normal breast epithelial 
cells and although many cancer cell lines completely lack NOEY2 expression, the 
extent to which the CpG islands are methylated differs (Yuan, Luo et al. 2003). 
Treatment with CpG demethylating agents and/or histone deacetylase inhibitors 
can reactivate both the silenced and imprinted alleles of NOEY2 (Fujii, Luo et al. 
2003). Reactivation of NOEY2 expression by these reagents is related to the 
methylation status of the CpG islands in the NOEY2 promoter. Histone H3 lysine-
9/18 acetylation levels associated with NOEY2 in normal cells are significantly 
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higher than those in breast cancer cell lines that lack NOEY2 expression. Treatment 
with a CpG demethylating agent and/or histone deacetylase inhibitor increases 
NOEY2 expression in breast cancer cells, with a corresponding increase in histone 
H3 lysine-9/18 acetylation and decrease in histone H3 lysine-9 methylation (Fujii, 
Luo et al. 2003). 
NOEY2 mouse model 
Mouse homologues exist for DIRAS1 and 2, however no mouse homologue for 
DIRAS3/NOEY2 has been found. NOEY2 transgenic mice were therefore generated 
with NOEY2 overexpression driven by the cytomegalovirus (CMV) promoter. 
Transgenic mouse models overexpressing NOEY2 have shown impaired organ 
development and 10-40% lower body weight than the wild-type mouse, as seen in 
Figure 12. Morphological alterations are seen in neurons of the hippocampus and in 
Purkinje cells of the cerebellum. The severity of the phenotype has been shown to 
correlate with the level of transgene expression (Xu, Xia et al. 2000).  
A) B) 
  
Figure 12: Over-expression of NOEY2 reduces weight. A) Picture of WT (left) and NOEY2 transgenic 
(right) mice. B) Body weight of WT and NOEY2 transgenic mice. Figure from (Xu, Xia et al. 2000). 
 
The NOEY2 transgenic mouse model shows impaired mammary gland development 
and lactation with 8/22 mice unable to lactate and 4/22 showing a reduced ability 
to lactate. The failure of ovarian folliculogenesis in females mice results in 
decreased fertility/sterility while inability of Sertoli cells to mature in male mice 
leads to sterility (Xu, Xia et al. 2000).  
Transgenic mice also show lower levels of progesterone and oestrogen receptor in 
mammary glands and ovaries with decreased prolactin and progesterone levels, 
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leading to a decrease in mammary tissue proliferation. NOEY2 inhibits prolactin 
(PRL) secretion and acts as a negative regulator in murine growth and development. 
These data suggest that NOEY2 is a negative regulator of growth and development 
of the breast and reproductive systems in mice (Xu, Xia et al. 2000). Interestingly, 
PRL knockout mice share many similarities with NOEY2 transgenic mice; they also 
show deficiency in lactation and are infertile. However, there is no overall change 
seen in body size (Figure 13)(Xu, Xia et al. 2000). 
 
Figure 13: 
Downstream effects 
of NOEY2 (ARHI) 
overexpression. 
Many inhibitory 
effects were seen in 
the transgenic mice, 
affecting multiple 
systems. Major 
abnormalities 
include failure to 
lactate, reduced 
fertility and small 
body size (Xu, Xia et 
al. 2000). 
 
DIRAS1 
Other members of the DIRAS family have also been shown to have tumour 
suppressor function. DIRAS1/Rig has also shown loss of expression in primary neural 
tumours, suggesting a role as a tumour suppressor and perhaps indicating a 
subgroup specific function (Ellis, Vos et al. 2002). 
Protein Kinases 
Protein kinases are part of a large family of proteins that regulate a plethora of 
biological processes and their aberrant signalling is associated with many diseases. 
Protein kinase A/cyclic adenosine monophosphate (cAMP/3'-5'-cyclic adenosine 
monophosphate)-dependent protein kinase (PKA) serves in many ways as a 
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prototype for the entire superfamily of eukaryotic protein kinases, having played a 
central role in the unravelling of the mechanisms that regulates protein 
phosphorylation (for review see (Taylor, Ilouz et al. 2012; Scott, Dessauer et al. 
2013). 
cAMP signalling 
G-protein coupled receptors (GPCRs) are seven-transmembrane proteins which are 
activated by exchanging bound GDP for GTP upon ligand binding (Svoboda, 
Teisinger et al. 2004). Activation causes dissociation of the trimer into Gα and Gβγ 
subunits. The Gα subunit inhibits adenylyl cyclase, a membrane bound-enzyme, 
which then converts adenosine triphosphate (ATP) to the second messenger cAMP 
(Figure 14) (Sunahara, Dessauer et al. 1996). cAMP is a second messenger important 
in many biological processes and is used for intracellular signal transduction in many 
different organisms, conveying the cAMP-dependent pathway. Many different 
physiological responses are mediated by cAMP including increase in heart rate, 
cortisol secretion and breakdown of glycogen and fat. 
 
Figure 14: PKA signalling. Upstream signalling 
from GPCR leads to adenylyl cyclise 
converting ATP to cAMP. This then activates 
PKA. Figure from (Murray 2008). 
 
PKA 
In eukaryotes, cAMP activates PKA, a ubiquitous serine/threonine protein kinase 
that is regulated by intracellular cAMP levels by altering the interaction between 
the catalytic and regulatory subunits of PKA (Bossis and Stratakis 2004). 
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Figure 15: Structures of the regulatory and catalytic subunits. The structure of the PKA regulatory 
subunit consists of an N-terminal dimerisation domain, an inhibitory domain (pseudosubstrate for RI 
and substrate site for RII) and two cAMP binding domains. The catalytic subunit (PKA-cat) has an ATP 
binding domain, substrate binding domain and a regulatory substrate binding domain at the C-
terminus. Figure adapted from (Taylor, Kim et al. 2005). 
 
The regulatory subunits each have two isoforms (α and β), which have been shown 
through knockout mouse studies to be functionally non-redundant (Kim, Cheng et 
al. 2007; Wu, Brown et al. 2007; Brown, Wu et al. 2009). Both R1α and R2α are 
ubiquitously distributed whereas R1β and R2β are detected primarily in the brain 
(Gamm, Baude et al. 1996). Within the cell, R1 is localised in the cytoplasm whereas 
R2 subunits are localised by anchoring to subcellular structures and compartments 
by A kinase anchoring proteins (AKAPs). 
Under low levels of cAMP PKA remains an intact and inactive holoenzyme, PKA 
catalytic subunits (PKA-cat) are normally sequestered as an inactive tetrameric 
complex, consisting of two catalytic and two regulatory units, with the regulatory 
units blocking the catalytic centres of the catalytic units (Kim, Cheng et al. 2007; 
Wu, Brown et al. 2007; Brown, Wu et al. 2009). The regulatory subunits are the 
receptors for cAMP, and the inactive holoenzyme is activated when the 
concentration of cAMP rises (e.g. activation of adenylate cyclases by G protein-
coupled receptors coupled to Gs, inhibition of phosphodiesterases that degrade 
cAMP) and cAMP binds to the two binding sites on the regulatory subunits of the 
protein kinase. This causes dissociation between the regulatory and catalytic 
subunits into a dimer of regulatory subunits and two free monomeric catalytic 
subunits, thus liberating the catalytic sites, activating the catalytic units and 
enabling them to phosphorylate substrate proteins. For maximal function, each 
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catalytic subunit must also be phosphorylated, which occurs on T197, and helps 
orientate catalytic residues in the active site. The free catalytic subunits can then 
enter the nucleus and catalyse the transfer of ATP terminal phosphates to protein 
substrates at serine, or threonine residues. Since PKAs are present in a variety of 
cells and act on different substrates, PKA and cAMP regulation are involved in many 
different pathways and targets many different proteins such as CREB, CREM, ATF1. 
PKA Inhibition 
Down-regulation of protein kinase A occurs by a feedback mechanism: One of the 
substrates that are activated by the kinase is a Phosphodiesterase (PDE), which 
hydrolyses cAMP to AMP, thus reducing the amount of cAMP that can activate PKA. 
Also, the catalytic subunit itself can be down-regulated by phosphorylation. Protein 
Kinase Inhibitors (PKI) act as a chaperone for the nuclear export of the PKA catalytic 
subunits and downregulate PKA activity.  
A Kinase Anchoring Proteins (AKAPs) 
Targeting of PKA to specific sites within the cell is largely achieved by AKAPs (Wong 
and Scott 2004; Pidoux and Tasken 2010). AKAPs are scaffolding proteins that 
sequester signalling enzymes to specific subcellular environment. They prevent 
indiscriminate phosphorylation and form multi-protein complexes that enable the 
integration of cAMP signalling with other signalling events. 
The regulatory subunit dimer of PKA is important for localising the kinase inside the 
cell. The dimerisation and docking (D/D) domain of the dimer binds to the A-kinase 
binding (AKB) domain of AKAPs. The AKAPs localise PKA to various locations (e.g. 
plasma membrane, mitochondria) within the cell. For example, an AKAP located 
near the nucleus of a heart muscle cell would bind both PKA and PDE which allows 
the cell to limit the productivity of PKA since the catalytic subunit is activated once 
cAMP binds to the regulatory subunits. AKAPs also introduce an additional level of 
regulation as PKA activity is inhibited when bound to AKAP. 
PKA – Role in Cancer 
PRKAR1A, the gene coding for the 1α regulatory (R1α) subunit of PKA, has already 
been shown to have a role in cancer, with mutations detected in multiple endocrine 
neoplasias as well as in Primary pigmented micronodular adrenal disease (PPNAD) 
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and the Carney complex. Decreased expression of PRKAR1A leads to an increase in 
the level of ‘free’ PKA-cat, thus leading to higher activity. 
PRKAR1A; Carney Complex 
Carney complex (CNC) is a multiple neoplasia tumour predisposition syndrome that 
is inherited in an autosomal dominant manner. It is characterised by schwannomas, 
endocrine neoplasms, breast ductal carcinomas and several types of skin, liver, 
cardiac, and neural myxomatous tumours (Carney, Gordon et al. 1985; Stratakis, 
Kirschner et al. 2001). 
While it is an autosomal dominant disease, CNC can occur as sporadic germline 
mutations. Two distinct loci have been identified for CNC that show no phenotypic 
differences when mutated, CNC1 & CNC2. While the gene coded for by CNC2 (2p16) 
is unknown, PRKAR1A has been shown to map to CNC1 (17q23-24) and is often 
mutated/inactivated in CNC patients, confirming its role (Kirschner, Carney et al. 
2000; Kirschner, Sandrini et al. 2000). In this study by Kirschner et al (Kirschner, 
Carney et al. 2000), 22 out of 54 patients (40.7%) presented with PRKAR1A 
mutations. 
There are many mutations identified in PRKAR1α in this disease, the majority of 
which lead to a premature stop codon due to non-sense mediated mRNA decay 
(Kirschner, Sandrini et al. 2000; Robinson-White, Hundley et al. 2003). Altered 
PRKAR1A activity, or haploinsufficiency, are each sufficient to increase PKA activity, 
which predisposes to tumourigenesis (Kirschner, Carney et al. 2000; Kirschner, 
Kusewitt et al. 2005). 
Involvement of PDE mutations 
Some cases with similar adrenal phenotype to CNC show PDE mutations, although 
these are not associated with non-adrenal features of CNC. A PDE mutation 
(decrease/ablation) would lead to increase cAMP levels, thereby increasing PKA 
pathway activity. This reinforces the involvement of the PKA pathway in this disease 
(Almeida and Stratakis 2010). 
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Other PRKAR1A linked diseases 
McCune-Albright syndrome 
McCune-Albright syndrome (MAS) is a sporadic condition resulting from GNAS 
(guanine nucleotide binding protein alpha stimulating) activating mutations and 
involving multiple endocrine and non-endocrine tumours. It shares skin 
abnormalities and some non-endocrine tumours with the lentiginoses of CNC. 
Although this in not PKA itself, GNAS1 is the gene coding for Gα subunit which is 
upstream of the PKA pathway. GNAS activating mutations lead to constitutive 
stimulation of adenylate cyclase and PKA activationand a variety of manifestations, 
including the classic triad of polyostotic fibrous dysplasia, café au lait skin 
pigmentation, and autonomous endocrine hyperfunction (Weinstein, Shenker et al. 
1991). The most frequent affected endocrine tissues are pituitary, ovarian and 
thyroid, but bilateral macronodular adrenocortical hyperplasia can also be found in 
the context of MAS (Lee, Van Dop et al. 1986; Stratakis and Kirschner 1998).  
Genetic defects in cAMP-binding PDEs have been described in isolated 
micronodular adrenocortical hyperplasia (MAH) (Stratakis 2009), significantly 
affecting the ability of PDEs to degrade cAMP in vitro (Horvath, Boikos et al. 2006; 
Horvath, Giatzakis et al. 2006; Horvath, Mericq et al. 2008). 
Papillary thyroid carcinoma 
Papillary thyroid carcinoma is a relatively common thyroid cancer with evidence 
that it is caused by a number of genetic changes (OMIM 188550). Chimeric 
oncogenes form due to the fusion of the tyrosine kinase domain of the RET proto-
oncogene to the 5-prime terminal region of PKA-R1α. This has been seen in both 
familial and sporadic cases (Salabe 2001). 
Acute promyelocytic leukemia (APL) 
APL is a malignancy of the blood and bone marrow characterised by a translocation 
involving the retinoic acid receptor (RARA). The PRKAR1A/RARA fusion gene is 
formed by the insertion of RARA distal to PRKAR1A and the deletion of 3-prime 
PRKAR1A, 5-prime RARA and any intervening sequences. Specifically the fusion of 
the R1-alpha dimerization domain to RARA may be involved in deregulation of PKA 
(Catalano, Dawson et al. 2007). 
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Systemic lupus erythematosus 
Systemic lupus erythematosus (SLE) is an autoimmune disorder characterised by 
diverse dysfunctions of immune effector cells, including proliferation and 
cytotoxicity. PKA activity in T cells is dramatically reduced because of decreased 
expression of the α and β Reg subunits. Transcript mutations (deletions, transitions, 
and transversions) are found in PRKAR1A at a frequency 7.5 times higher in SLE 
patients than in control T cells. No genomic mutations were identified 
(Laxminarayana, Khan et al. 2002). 
GPCR and G-proteins 
GPCR and G-proteins have also been shown to have a role in cancer (e.g. MAS, the 
first GPCR identified as having oncogenic potential (Young, Waitches et al. 1986)), 
with activating mutations leading to ovarian, adrenal, pituitary and thyroid 
adenomas and carcinomas, once again highlighting the importance of this pathway. 
PRKAR1A Mouse model 
PRKAR1A haploinsufficient mice, carrying a floxed copy of exon 2 of the 
murine PRKAR1A gene, led to the development of tumours arising in cAMP-
responsive tissues, such as the bone, Schwann and thyroid follicular 
cells. PRKAR1A+/-mice developed non-pigmented schwannomas and fibro-osseous 
bone lesions beginning around 6 months of age. Benign and malignant thyroid 
neoplasias were observed in 10% of older mice (Kirschner, Kusewitt et al. 2005). 
Although the spectrum of tumours overlapped with what is seen in CNC patients, 
this mouse model did not present some of the most frequent CNC tumours, such as 
skin and heart myxomas and pituitary adenomas (Kirschner, Kusewitt et al. 2005). 
An alternative mouse model carrying an antisense transgene for PRKAR1A showed 
approximately 50% decrease in PKA-R1α protein levels similar to haploinsufficiency 
and consequently increased cAMP signalling. It also developed similar phenotype to 
CNC patients, further supporting the role of PRKAR1A in this disease (Griffin, 
Kirschner et al. 2004; Griffin, Kirschner et al. 2004). Mice developed thyroid 
follicular hyperplasia and adenomas, adrenocortical hyperplasia, 
hypercorticosterolemia, late-onset weight gain, visceral adiposity, lymphomas, 
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sarcomas and mesenchymal tumours. The thyroid and adrenocortical tumours 
showed loss of heterozygosity at the PRKAR1A locus (Griffin, Kirschner et al. 2004). 
Adrenal-cortex specific PRKAR1A knockout mice developed autonomous adrenal 
hyper-activity and bilateral hyperplasia which are both observed in human PPNAD 
which is caused by proliferation of cortisol-producing foetal adrenocortical cells 
induced by PKA dysregulation (Sahut-Barnola, de Joussineau et al. 2010). 
Ubiquitination 
Ubiquitination is one of the most utilised posttranslational modifications in 
eukaryotes and is involved in a wide range of cellular processes. Ubiquitin (Ub) 
alters the longevity, localisation, and/or activity of proteins via one or more 
covalent bonds between the C-terminal carboxyl group of ubiquitin and a 
nucleophilic moiety on the substrate/target protein, but is mostly known as a signal 
for proteasomal degradation. The ubiquitin-proteasome pathway is the principal 
pathway for intracellular protein degradation (Goldberg, Stein et al. 1995; Coux, 
Tanaka et al. 1996; King, Deshaies et al. 1996). Protein substrates are ‘marked‘ with 
a poly-ubiquitin chain (Chau, Tobias et al. 1989) and then degraded to peptides and 
free ubiquitin by a large multimeric protease, the proteasome, which exists within 
all eukaryotic cells (Goldberg, Stein et al. 1995; Coux, Tanaka et al. 1996; King, 
Deshaies et al. 1996). 
The covalent conjugation of Ub molecules onto target proteins (ubiquitination) is 
mediated by the action of the three enzymes E1 ubiquitin-activating enzymes, E2 
ubiquitin-conjugating enzymes and E3 ubiquitin ligases that together mediate the 
transfer of the 76-amino acid protein ubiquitin to specific lysine (K) residues on 
target proteins (Hershko and Ciechanover 1998; Leithe and Rivedal 2007; Willis, 
Townley-Tilson et al. 2010).  
E1 and E2 function sequentially, E1 activating enzyme creates a thioester bond 
between its conserved cysteine residue and the C-terminal carboxyl group of 
monomeric Ub in an ATP-dependent manner (Figure 16A) (Haas and Rose 1982). 
The activated Ub is passed to a reactive cysteine residue of a specific E2 conjugating 
enzyme (E2~Ub), recruited by the C-terminal ubiquitin-fold domain of E1 (Ye and 
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Rape 2009). Together with an E3 ligation enzyme, E2 conjugates Ubs to either the 
N-terminus or internal lysine residues of targeted proteins. The E3 ligase catalyses 
the transfer of one Ub molecule at a time or a Ub chain to a protein target 
(Hochstrasser 2006). There are three types of E3 ligases; HECT (homologous to the 
E6-AP carboxyl terminus)-type of E3 ligases transfer activated Ub to the E3 cysteine 
residue and form a transient thioester intermediate between Ub and the E3, before 
this is ligated onto targeted proteins (Fang and Weissman 2004). RING (Really 
Interesting New Gene) and U-box E3 ligases do not seem to possess catalytic 
function and act as scaffolds for the conjugation reaction by bridging the E2~Ub and 
its substrate. 
 
 
Figure 16: Ubiquitination Schematic model of sequential action of E1, E2, and E3 enzymes to create 
various ubiquitin tags onto their targets. (A) In an ATP-dependent manner E1 activates a ubiquitin 
molecule which is then passed onto the reactive cysteine residue of an E2 conjugating enzyme. E2 
either passes the ubiquitin to the reactive cysteine on a HECT or U-box-type E3 enzyme to be ligated 
onto the target, or it cooperates with a RING-box E3 enzyme for substrate selectivity and directly 
adds the ubiquitin to the target itself. (B) A schematic representation of proteins that contain either 
mono-, multi-, or polyubiquitin tags, all resulting in different fates. Figure from (Nagy and Dikic 
2010). 
 
Ubiquitin has seven lysine residues that may serve as points of ubiquitination: K48, 
K63, K6, K11, K27, K29 and K33 resulting in different tertiary structures (Peng, 
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Schwartz et al. 2003; Pickart and Fushman 2004; Xu and Peng 2008), in addition 
chains can assemble on the N-terminus of a ubiquitin molecule ("linear chains") 
(Kirisako, Kamei et al. 2006). Following the addition of a single ubiquitin moiety to a 
protein substrate (mono-ubiquitination), further ubiquitin molecules can be added 
to the first yielding a poly-ubiquitin chain. In addition, some substrates are modified 
by addition of ubiquitin molecules to multiple lysine residues in a process termed 
multi-ubiquitination. Mono-, multi-, or poly-ubiquitination of substrate proteins are 
molecular signatures recognised and sorted by a diverse set of proteins containing 
ubiquitin binding domains (Figure 16B; (Dikic, Wakatsuki et al. 2009)). Addition of a 
single Ub molecule to one (mono-ubiquitination) or several (multi-ubiqutination) 
acceptor lysine residues of proteins causes subcellular localisation, activity, tertiary 
structure formation or interaction with other proteins respectively (Figure 16B). Ub 
binding domain-containing effector molecules discriminate poly-ubiquitin chains 
primarily by their tertiary structures (Komander, Reyes-Turcu et al. 2009; Xu, Duong 
et al. 2009). 
One example is the K63 linkage, which is known to be involved in DNA damage 
recognition of DNA double-strand breaks. The K63 linkage is placed on the H2AX 
histone by the E2/E3 ligase pair, Ubc13-Mms2/RNF168. This K63 chain recruits 
RAP80, which contains a UIM, and RAP80 then helps localise BRCA1. This pathway 
will eventually recruit the necessary proteins for Homologous Recombination 
Repair. 
Ubiquitin polymerisation occurs as its K residues serve as acceptor sites for 
additional ubiquitin molecules. Multiple ubiquitins can be covalently linked via K48 
to form poly-ubiquitin chains, which target the ubiquitinated protein for 
degradation by the multi-subunit 26S proteasome (Voges, Zwickl et al. 1999; Leithe 
and Rivedal 2007; Willis, Townley-Tilson et al. 2010). Role of K63 chains in DNA 
repair and kinase activation in mammalian cells (Peng, Schwartz et al. 2003). K63 
chains are also implicated in vacuolar targeting (Lauwers, Erpapazoglou et al. 2010). 
Poly-ubiquitination via K48 ubiquitin chains typically leads to proteasome-
dependent degradation of cytosolic proteins. Endoplasmic reticulum (ER)-retained 
proteins are degraded in a proteasome-dependent fashion via ER associated 
degradation. Plasma membrane-resident receptors and transporters tend to be 
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vacuolar protease substrates following internalisation and sorting into multi-
vesicular bodies. Multi-vesicular bodies assembly and maturation depend on the 
endosomal sorting complex required for transport assemblies (Katzmann, Babst et 
al. 2001; Babst, Katzmann et al. 2002), which are complexes that recognise proteins 
destined for the vacuole by binding ubiquitin (Shields, Oestreich et al. 2009). While 
mono-ubiquitination is usually sufficient for internalisation, multi-ubiquitination 
and K63 poly-ubiquitination enhance endocytic rates. Several plasma membrane-
resident transmembrane proteins have been shown to require K63 poly-
ubiquitination for endosomal sorting complex required for transport -dependent 
sorting into multi-vesicular bodies (Lauwers, Erpapazoglou et al. 2010). 
In addition to families of E2 and E3 enzymes, eukaryotes express proteins with 
ubiquitin-deconjugating and ubiquitin-binding abilities. The former are 
deubiquitylating proteases that that uniquely recognise and cleave the bond linking 
the two moieties, removing ubiquitin (D'Andrea and Pellman 1998), while the latter 
interact with different types of ubiquitinated proteins (Andersen, Hofmann et al. 
2005). Ubiquitin-binding proteins can mediate interaction between ubiquitin-
modified targets and the proteasome (Fu, Lin et al. 2010), shuttle ubiquitinated 
proteins from one compartment to another, or serve to modulate the activities of 
others in the same complex (Hicke and Dunn 2003). Alternative fates of 
ubiquitinated targets include proteolysis in the lytic compartment of the vacuole or 
the central cavity of the proteasome, nonproteolytic inhibition, and even protein 
activation. 
The presence of membrane-localised E2 and E3 enzymes suggests that 
ubiquitination occurs near membrane surfaces. 
A wide variety of E3 ligases have been identified and many of those are associated 
with diseases (Jiang and Beaudet 2004). Furthermore, muscle-specific E3 ligases 
have been shown to participate in muscle atrophy (Attaix, Ventadour et al. 2005). 
Ubiquitin-like modifiers 
There are several ubiquitin-like proteins that modify cellular targets in a similar, but 
distinct, pathway to ubiquitin. Known Ub-like proteins include RUB (related to 
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ubiquitin), SUMO (small ubiquitin-like modifier), ATG8 and ATG12 (autophagy 8 and 
12 respectively), MUB (membrane-anchored ubiquitin-fold protein), UFM1 
(ubiquitin-fold modifier1), URM1 (ubiquitin-related modifier 1), HUB1 (homology to 
ubiquitin1), amongst others (Miura, Jin et al. 2007; Hochstrasser 2009; Vierstra 
2009; Li and Vierstra 2012). 
Ub and most Ub-like modifiers enter the same E1→E2→E3 reaction cascade that 
involves a signature high-energy thioester intermediate. Like Ub, conjugation of 
most Ub-like modifiers is transient and can be reversed by unique proteases that 
release the isopeptide-linked UBL moiety (Kerscher, Felberbaum et al. 2006). These 
“deconjugases” are highly specific for the corresponding tag and fail to recognise or 
poorly recognise even closely related members (e.g. Ub and RUB). 
SUMOylation 
SUMOylation is the covalent linkage to the small ubiquitin-like modifier (SUMO) 
family of proteins. SUMOylation acts in most cellular compartments to adapt 
proteins in multiple processes including transcription, translation, cellular transport, 
protein interactions, cell growth and programmed cell death (Geiss-Friedlander and 
Melchior 2007). 
Three SUMO isoforms have been identified, SUMO1, 2, and 3. SUMO is distantly 
related to ubiquitin (20% identity) and differs from other Ub-like modifiers by a long 
N-terminal extension that appears unstructured in solution. Desumoylating 
proteases not only disassemble SUMO conjugates but are needed to generate 
mature SUMO by trimming extra amino acids beyond the C-terminal di-Gly. 
Whereas most targets bear a single SUMO moiety, some can be modified with 
multiple SUMOs or poly-SUMO chains via iterative cycles of conjugation analogous 
to ubiquitylation (Miller, Barrett-Wilt et al. 2010; Wilkinson and Henley 2010). 
Based on alignments of known SUMO attachment sites, sumoylation appears to 
employ several loose consensus motifs; one prevalent in plants, yeast, and 
mammals encompasses a ΨKXE motif (where Ψ is a large hydrophobic residue and 
K is the Lys where SUMO is linked) and two others identified thus far in mammals 
contain extended motifs rich in phosphorylated or negatively charged residues 
(Miller, Barrett-Wilt et al. 2010; Wilkinson and Henley 2010). 
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The functions of sumoylation are diverse and mostly nonproteolytic and include 
controls on localisation, interaction, and activity of the modified protein (Miura, Jin 
et al. 2007; Wilkinson and Henley 2010). One unique situation has also been 
reported in mammalian cells, where SUMO addition protects the IκBα protein from 
Ub addition by blocking accessible Lys residues (Desterro, Rodriguez et al. 1998). 
Some of these effects are mediated by a collection of binding partners bearing 
SUMO-interacting motifs. 
Research principle 
The aim of this project has been to identify and validate novel effectors of RAP2, in 
the first instance, and NOEY2, in the second instance, in order to elucidate its 
function, both under normal circumstances and in disease. 
Tandem Affinity Purification 
Tandem affinity purification (TAP) is an unbiased procedure for protein purification 
and proteome exploration in order to detect novel protein-protein interactions. 
After two sequential affinity column purifications using mild washing and eluting 
conditions, proteins co-purifying with the tagged-bait are identified by mass 
spectrometry. An advantage of this method is the detection of novel protein 
partners in vivo without prior knowledge of complex composition. 
 
 
Figure 17: Tandem Affinity Purification was used to pull down potential targets of RAS family 
members. Using overexpressed TAP-tagged proteins, two rounds of purification, using His and 
Strep beads, were used in order to identify potential interactions. 
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Established by a research team working in the European Molecular Biology 
Laboratory (EMBL) in the late 1990s (Rigaut, Shevchenko et al. 1999; Puig, Caspary 
et al. 2001) it is used as a tool for proteome exploration and has facilitated the 
characterisation of several protein complexes (Caspary, Shevchenko et al. 1999; 
Rigaut, Shevchenko et al. 1999; Bouveret, Rigaut et al. 2000; Puig, Caspary et al. 
2001). The first large-scale application of this technique was in 2002, where it was 
used to develop a visual map of the interaction of more than 230 multi-protein 
complexes in a yeast cell by systematically tagging the TAP tag to each proteiniv. 
Using this technique, identified targets were then validated and investigated as 
described below.  
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CHAPTER 2: Materials and Methods 
MATERIALS 
Reagents 
Low melting point agarose (15517022), Kanamycin (11815-024), Bromophenol blue, 
newborn Bovine serum (16010-159), PCR primers, foetal bovine serum (FBS), 
Trypsin (25300054), D-MEM (41966029) and Opti-MEM (11058021) were from 
Invitrogen (Paisley, UK). Complete, EDTA-free Protease inhibitors were obtained 
from Roche (Welwyn Garden City, UK). Skimmed Milk powder was from Tesco. LB 
agar, Triton-X100, Polybrene hexadimethrine bromide, Coomassie Brilliant blue, 
Phalloidin (P1951), Hoechst stain solution (H6024-10ML), PEI 1mg/ml, 
Paraformaldehyde (PFA), Glycine and Flag beads were obtained from Sigma Aldrich 
(Haverhill, UK). Amersham Hybond Polyvinylidene difluoride (PVDF) membranes, 
autoradiography Fuji Film, Glutathione sepharose 4FF beads (17-5132-02), Protein A 
Sepharose 4 fast flow beads (17-5280-01), Protein G Sepharose 4 Fast flow beads 
(17-0618-01) and Streptavidin Sepharose high performance beads (17-5113-01) was 
purchased from GE Healthcare (Buckinghamshire, UK). The LumiGlo/LumiGlo 
reserve chemiluminescence detection reagents were purchased from Insight 
Biotechnology Limited (Middlesex, UK). PfuUltra™ high-fidelity DNA polymerase and 
10× PfuUltra™ HF reaction buffer from Stratagene (CA, USA). Image clone, p8.91, 
pMDG and shRNA were ordered from Open Biosystems (MA, USA). Human fetal 
brain Poly A+ RNA and Human placental pLIB cDNA library (PT3230.1) were from 
Clontech (St-Germain-en-Laye, France). Methanol and coverslips (diameter: 13mm 
for 24 wells, Cat.-No. 631-0149) were from VWR (Leicestershire, UK). Mounting 
solution (S3023) from Dako Cytomation Ltd (Cambridgeshire, UK). MG-132 from 
Calbiochem (Nottingham, UK). Magnesium and Calcium free PBS tablets (BR014G) 
were from Fisher Scientific (Loughborough, UK). FACS tubes (2053-001, 
polypropylene, 5.4ml) were from Elkay. 
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Primary antibodies against AF6 (H-106), BRAF (F7), HA (F-7), HA (Y-11), PP1c (E9), 
RGL2 (F-30.1), RGL2 (H-120), Trim32 (H-204), Ubiquitin-HRP (P4D1), were from 
Santa Cruz Biotechnology (Heidelberg, Germany). AF6 (35/AF6), RAP1 (clone 3), 
RAP2 (12/RAP2) antibodies were from BD Transduction Laboratories (Oxford, UK). 
Antibody against FLAG (M2) was obtained from Sigma-Aldrich (Steinhelm, 
Germany). MINK (A302-191A), NIK/MAP4K4 (A301-502A) and TNIK (A302-695A) 
antibodies were from Bethyl Laboratories (Cambridge, UK). TRIM32 (10326-1-AP) 
from Protein Technology (Manchester, UK). TRIM32 (ab50555) from Abcam 
(Cambridge, UK). 
Anti-mouse IgG, peroxidase-linked species-specific whole antibody, from sheep (NA 
931) and Anti-rabbit IgG, peroxidase-linked species-specific whole antibody, from 
donkey (NA 934) from Amersham. Goat Anti-Mouse-HRP, Light Chain Specific (115-
035-174), Mouse mAb Anti-Rabbit-HRP, Light Chain Specific (211-032-171), Goat 
Anti-Rabbit-HRP, Fc Fragment Specific (111-035-046), Rabbit Anti-Mouse-HRP, Fc 
Fragment Specific (315-035-046) from Stratech Scientific. 
Buffers and solutions 
Reagent Recipe 
  
General Buffers and solutions  
  
0.5M EDTA pH 8.0 
(Ethylenediaminetetra-acetic acid) 
146.13g EDTA in total of 1L ddH2O adjusted 
to pH 8.0 with NaOH 
  
1 x PBS 137mM NaCl, 2.7mM KCl, 10.1mM 
Na2HPO4*H2O, 1.76mM KH2PO4, 1mM CaCl2, 
0.5mM MgCl2, pH 7.4 with HCl 
  
PBS-T buffer 10 x PBS, 0.1% Tween20 
  
PBS-E lysis buffer 1 x PBS, 1% Triton-X100, 1mM EDTA (1mM 
DTT, protease and Phosphatase inhibitor 
cocktail added for lysis) 
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PBS-M lysis buffer 1 x PBS, 1% Triton-X100, 5mM MgCl2 (1mM 
DTT, protease and Phosphatase inhibitor 
cocktail added for lysis) 
  
1M Tris pH8 121.1g Tris in total of 1l ddH2O 
  
  
Western Blotting  
  
1° Antibody buffer 3% BSA, PBS-T, 0.02% NaN3 
  
2° Antibody buffer/Blocking 
solution 
5% Milk/PBS-T 
  
NuPAGE MOPS Running buffer 209.2g MOPS (free acid); 121.2g Tris, pH 8.8; 
0.2% SDS; 6g EDTA 
  
NaN3 (Sodium Azide) 10% (w/v) NaN3, 500x stock solution 
  
20x Transfer buffer 
(add 10% MeOH when making 1x) 
80.16g Bicine; 104.6g Bis-Tris (free acid); 6g 
EDTA 
  
Phosphatase inhibitor cocktail 10mM Sodium Fluoride; 2mM Sodium 
Orthovanadate; 2mM Sodium 
Pyrophosphate, decahydrate; 2mM beta-
glycerophosphate 
  
  
FACS  
  
Staining Buffer 50g/ml PI, 100g/ml RNAse (DNAse free), 
PBS + 0.05 % Triton-X100 
Table 4: List of buffers and reagents 
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Kits used 
Kit Company 
  
PrimeScript One Step RT-PCR kit Ver.2 TaKaRa 
  
SuperScript One-Step RT-PCR for long 
templates 
Invitrogen 
  
QIAquick gel extraction kit QIAGEN 
  
QAIquick PCR purification kit QIAGEN 
  
GATEWAY Cloning technology Life Technologies 
  
QIAprep Spin Miniprep kit QIAGEN 
  
PureLink HiPure Plasmid Midiprep kit Invitrogen 
  
Table 5: Kits used 
 
Mammalian cell culture 
All media are stored at 4°C and used within 1 month. 
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Cell type Tissue of origin Media Additives 
    
C2C12 Mouse myoblast DMEM 
(Dulbecco’s 
Modified Eagles 
Media) 
Growth medium: 
20% FBS 
Fusion medium: 
2% HS 
    
HEK293T Human Embryonic 
Kidney 
DMEM 10% FBS 
    
HMLE Immortalised 
human mammary 
epithelial cells 
DMEM F12 5% HS, 20ng/ml 
EGF, 0.5μg/ml 
hydrocortisone, 
100ng/ml cholera 
toxin, 10μg/ml 
insulin, 2mM L-
glutamine 
    
U2OS Osteosarcoma DMEM 10% FBS 
    
Table 6: Mammalian cell culture 
 
METHODS 
Generation of constructs 
Polymerase chain reaction 
Human placental cDNA and image clones were used as a template for PCR of 
various genes, using Pfu Ultra High-Fidelity DNA polymerase enzyme. Samples were 
then run on 1.5% gel: TAE/agarose gel using 1 x sample loading buffer, with a 1kb 
ladder to allow the estimation of their size. This was compared to their literature 
values in order to ascertain whether the correct size fragment had been obtained. 
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For those samples that did not work on PCR from a cDNA library, RT-PCR was done 
on human foetal brain Poly A+ RNA (from Clonetech). The “Invitrogen SuperScript 
One-Step RT-PCR for long templates” and TAKARA “PrimeScript One Step RT-PCR kit 
Ver.2” kit were used.  
Extraction 
PCR products were purified following the QIAquick PCR purification kit as per 
manufacturer’s instructions. Then samples were digested with restriction enzymes, 
and then run on a wide combed, 1.5% agarose/TAE gel stained with GelSTAR. These 
were then cut using a scalpel, and placed in individual mircocentrifuge tubes. Using 
the QIAquick gel extraction kit, these were then gel purified as per the 
manufacturer’s instructions.  
Ligation 
Digested inserts were ligated into pENTR vector (cut with corresponding restriction 
enzymes) using T4 DNA ligase, overnight at 4°C. 
Transformation 
2.5μl of the ligation mix was then added to 25μl DH5α sub-cloning efficiency 
competent cells from Invitrogen. These were then left on ice for 30 mins in order to 
allow the ligation mix to bind to the outside of the cells. Cells were permeablised by 
heat shock at 42°C for 45 sec, allowing the vectors to enter, and placed on ice for a 
further 2 min in order to reduce permeability of the cells. 300μl of room 
temperature LB broth was then added to each sample, and incubated for 1h at 
37°C, in order to allow the cells to recover from the shock and for the antibody 
resistance, coded for by the vector, to be expressed by the cells. The samples were 
then plated on Kanamycin LB plates, and incubated overnight at 37°C. 
Colonies were picked, plasmid DNA was extracted using Qiagen spin Miniprep kits, 
and constructs were sequenced to confirm insertion of the correct gene. Miniprep 
DNA was combined with the required destination vector (e.g. DNA3-FLAG, myc, 
DEST-27 (GST), pLEX-, etc.) and clonase II mix was added to perform recombination 
reaction. Reaction was transformed and plated onto Ampicilin LB plates, from which 
colonies were picked and DNA was isolated. 
81 
 
Cell Culture 
For experimental purposes all cell lines were used at the lowest possible passage 
number. The cell lines used are adherent cells, cultured in a humidified atmosphere 
at 37°C and 5% CO2. Cells were grown to approximately 90% confluence before 
passaging. The media was aspirated and the cells were washed with PBS solution 
and incubated with 0.05% Trypsin/EDTA (1ml/10cm or 2ml/15cm dish) at room 
temperature for 2-3 minutes to detach. Pre-warmed cell culture media was added 
to inactivate the trypsin and cell clumps were disrupted through gentle pipetting. 
The suspension was then diluted and cells re-plated as required. C2C12 cells were 
differentiated by growing to ~80% confluence and replacing 20% FBS growth 
medium with 2% HS fusion medium. 
DNA Transfection 
Cells were transfected on the same day as seeding. For a single transfection assay, 
1.3x106 cells/well (6wp) or 10x106 cells/10cm plate were transfected with 2µg or 
8µg of plasmid DNA respectively in 200 µL Opti-MEM (Gibco) with 8µg or 32µg 
polyethylenimine (PEI, stock solution 1mg/ml). After 30 min incubation at RT, the 
transfection solution was then added to the cells and then the media was changed 
after 4-6h. Next day, 2mL of media was added to each well for boosting cells and 
cells were harvested the following day. 
For co-transfection assays, equal amounts of indicated plasmids were used, 
excluding ubiquitination assays for which HA-tagged ubiquitin was transfected at a 
higher ratio of 2:1:1 (w:w). 
Lentivirus generation 
In order to generate lentivirus, 3x106 HEK-293T cells were seeded on 6cm dishes in 
3ml media. After allowing the cells to settle for 3h, they were transfected with the 
lentiviral plasmid, using p8.91 (0.98μg/μl), pMDG (0.5μg/μl), lentiviral construct 
(0.5μg/μl) and PEI 1mg/ml. Medium was replaced 4-6h later and again 24h later. 
48h after transfection, supernatant containing virus was aliquoted into Polybrene to 
a final concentration of 10μg/ml and snap frozen (and stored at -80°C). Media was 
replaced and supernatant collected after a further 24 and 48h. 
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Lentiviral Infection 
Cells were seeded into 6wp and allowed to grow overnight to 50% confluence. Next 
day, frozen virus stocks in 1ml aliquots including 5 μg/ml Polybrene were thawed at 
37°C and then spun for 1 min at 16000 rpm at 4°C in order to pellet residual cells in 
the supernatant. Then cell medium was replaced by 1ml of the virus/polybrene 
solution. After 4h of virus supernatant incubation, the virus supernatant was 
removed and replaced with 2ml of growth medium for 24h before adding the 
appropriate selective agent. 
Protein extraction 
Proteins were isolated using 350µl/6wp or 1ml/10cm PBS-M lysis buffer or PBS-E 
lysis buffer for interaction and ubiquitination assays, respectively. Lysates were 
cleared of insoluble debris by centrifugation at 16,000 x g for 10 mins at 4°C. 
Immunoprecipitation/pull-down 
Proteins were purified using the corresponding beads: GST-glutathione beads 
(Amersham), Flag-Flag beads (Sigma). Lysates were rotated with the beads for 2h at 
4°C. These were washed x 3 with lysis buffer without protease or phosphatase 
inhibitors and drained with a needle. Samples were resuspended in 20µl (6wp) or 
30µl (10cm) LDS.  
SDS-polyacrylamide gel electrophoresis 
Samples were heated at 70°C for 10min to denature the proteins and an aliquot of 
the cell lysate (2µl) or immunoprecipitate 10µl (6wp) or 15µl (10cm) were loaded as 
specified onto the gel alongside a Precision Plus Protein Prestained Standards 
(BioRad). Proteins were separated using a 4-12% Bis/Tris gradient gel (Invitrogen). 
Gels were run using MOPS running buffer at 150V until the dye reached the bottom 
of the gel. The proteins were transferred to a methanol-activated polyvinylidene 
fluoride membrane (PVDF) membrane using Transfer buffer supplemented with 
10% methanol (v/v)) at 90 V for 90 min at 4°C using an BioRad Transfer system.  
Western Blot 
Membranes were stained with Coomassie (0.2% (w/v) Brilliant Blue Reagent 
(Sigma), 10% acetic acid (BDH), 50% methanol (BDH)) and blocked in PBS-T 
containing 5% skimmed milk prior to incubation with antibodies. Primary antibodies 
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were diluted in 3% BSA/PBS-T supplemented with 0.02% NaN3 at4 °C overnight. 
Membranes were washed three times with PBS-T and incubated for 1h at room 
temperature with secondary antibody, followed by washing three times with PBS-T. 
Binding of each antibody was detected using Lumiglow and Lumiglow reserve. The 
emitted fluorescence was detected using Photography film (Fujifilm) on SRX-101A x-
ray developer.  
Tandem Affinity Purification (TAP) 
TAP was performed from 10x15cm dishes of various cell lines (as specified) 
transiently transfected with TAP6-tagged constructs, as shown. The TAP6-tag 
contains streptactin-histidine-SBP and Flag tags. All steps were performed at 4⁰C. 
Cells were lysed with PBS-E lysis buffer: 1 x PBS, 1mM EDTA, 1% w/v Triton-X100, 
1mM DTT, Protease inhibitor cocktail (Roche) and Phosphatase Inhibitor solution 
(Sigma). Clarified pooled lysates were incubated with Streptavadine Sepharose High 
Performance beads (GE Healthcare) and washed extensively with PBS containing 
0.1% TX-100. Bound proteins were eluted with PBS / 0.1% TX-100 / 2mM Biotin and 
the eluate incubated with TALON Metal Affinity Resin (Clontech). After washing, 
bound proteins were eluted with 200mM Imidazole, concentrated by TCA 
precipitation, separated on 4-12% NuPAGE gels (Invitrogen) and stained with Simply 
Blue SafeStain (Invitrogen). Samples were then sent off to collaborators in San 
Francisco for Reversed-phase liquid chromatography-electrospray tandem mass 
spectrometry (LC-MS/MS) analysis. 
Cell Cycle Analysis 
Two days after retroviral infection with YFP-tagged protein, cells were spun at 
400xg for 4min and supernatant was removed and pellet was washed once with 
PBS. After removing the supernatant once again, the pellet was re-suspended in 
remaining PBS and fixed in cold 70% EtOH. Samples were then stored at 4°C 
overnight to fix. Samples were spun at 800xg for 4min and re-suspended in 750μl of 
staining buffer (50µg/ml PI (Sigma), 100µg/ml RNAse (DNAse free, Sigma), 0.05 % 
Triton X-100). Cells were treated with Ribonuclease to ensure that only DNA was 
stained. Cells were then incubated in the dark for 30min at RT, prior to FACS 
analysis using a CyAn ADP (Becton Coulter). Debris and cell doublets were excluded 
and the PI staining intensity was recorded as a measure of DNA content. For each 
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sample at least 10,000 events were acquired and data analysis was performed using 
Summit software. The cell cycle of YFP-positive cells is shown, no changes were 
seen in the YFP-negative population of cells. 
Colony Formation Assay 
Cells infected with lentivirus overexpressed proteins were counted and seeded in 
10cm plates at the same density. Cells were allowed to grow until the control 
reached ~90% confluence and then stained with crystal violet dye (Sigma; prepared 
as 0.5% solution in a 10% methanol/water mix). 
Proliferation assay 
Cells infected with lentivirus overexpressed proteins were counted manually and 
seeded in 24 well plates at various densities, depending on the cell line and rate of 
proliferation. They were then placed in the IncuCyte (Essen Instruments) and well 
density was measured every 2h until dense. Medium was changed regularly (every 
48h) between readings. Readings were analysed using Excel. 
Wound healing assay 
Cells were seeded in quadruplicate in 24 well plates (Imagelock plates distributed by 
Essen Instruments), grown to a confluent cell monolayer and wounded by a 
woundmaker (Essen Instruments) using 10 µL sterile tips. The cells were then 
washed with PBS twice and 500 μL media containing 10% FBS added. Plates were 
placed in the Essen Instruments IncuCyte and the wound area was monitored over 
time. Pictures were automatically taken every 2h for up to 2 days. Wound healing 
data was analysed by tracking the confluency (cell repopulation of the wound in %) 
over a period of time and plotting a graph over time by IncuCyte software version 
2010A. 
Localisation 
Cells were seeded on coverslips and allowed to attach. Cell monolayers were 
washed once with PBS and fixed with 4% PFA for 15 min at RT (250μL per well). PFA 
was aspirated and cells were washed 3 x 3 min with PBS before permeabilising with 
0.1% Triton-X100 for 10 min at room temperature. The Triton-X100 was aspirated 
and coverslips washed (3 x 3 min with PBS) and transferred to a wet chamber. Cells 
were stained with Hoechst (1:10000) and Phalloidin (1:2000) diluted in 2% BSA/PBS 
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for 10 min at RT to visualise the nucleus and actin cytoskeleton, respectively, where 
indicated. After 3 x 5 min wash with PBS, salts were removed by dipping each 
coverslip into H2O. Coverslips were dried and gently dropped onto the mounting 
solution (Dako Fluorescent mounting medium, S3023, Lot 10022881) that had been 
placed on slides. 
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Chapter 3: Validation of the TAP 
interaction 
TAP Identified Novel Targets of RAP2 
Tandem affinity purification (TAP) is an unbiased approach that allows high 
throughput identification of protein interactions. In order to identify novel 
interacting proteins of RAP2 that may shed light on its function, Dr Rodriguez-
Viciana had performed three independent TAP purifications using the TAP-tagged 
constitutively active V12 mutant of RAP2. Initially, TAP-RAP2 V12 was stably 
expressed by retroviral infection in A549 and HEK-293 cells. After purification and 
elution only 2 and 3 proteins respectively were identified by mass spectrometry as 
co-purifying specifically with RAP2 but not other control baits (Table 7). The E3 
ubiquitin ligase TRIM32 was the only protein that was identified in both 
purifications. RAP1GDS/SmgGDS is known to interact in a GTP-independent manner 
with multiple RAS family GTPases (Riess, Epplen et al. 1993). RADIL is a RA-domain 
containing protein that was subsequently shown to interact with RAP proteins 
(Smolen, Schott et al. 2007; Ahmed, Daulat et al. 2010). TBC1D10B functions as a 
GAP for several members of the Rab family (Ishibashi, Kanno et al. 2009).  
A third TAP purification was performed at a later time by transiently transfecting 
TAP-RAP2 V12 in HEK-293T cells. The higher levels of expression achieved by this 
approach coupled with the higher sensitivity of the mass spectrometry facilities 
used by our collaborators to analyse these samples, led to the identification of 
many more co-purifying proteins including several additional RAP2-specific 
interactors (Table 7). TRIM32 was again specifically co-purified with RAP2 for the 
third time. Other known RAP2 effectors such as AF6, RGL2, MINK, TNIK and NIK, 
were also identified, confirming the higher sensitivity of this approach. In addition 
to TRIM32, this TAP also identified the VPS29 and VPS35, which are known to form 
a complex (Nothwehr, Ha et al. 2000; Collins, Norwood et al. 2008; Swarbrick, Shaw 
et al. 2011) as RAP2 co-purifying proteins. 
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ID Unique peptides % Coverage 
RAP2A 11 57.9 
TRIM32 66 75.7 
RADIL 30 32.3 
TBCD10B 3 6.8 
A) TAP-RAP2A in 293 
 
ID Unique peptides % Coverage 
RAP2A 13 44.3 
TRIM32 36 50.4 
RAP1GDS 9 18.5 
B) TAP-RAP2A in A549 
 
ID Unique peptides % Coverage 
RAP2A 35 90.2 
MLLT4/AFADIN 71 44.8 
TNIK 67 47.9 
MAP4K4 27 19.6 
MINK1 23 13.6 
VPS35 14 21.2 
VPS29 3 17 
OBSL1 4 2.8 
RGL2 3 10.7 
RAP1GDS1 2 4.3 
TRIM32 1 1.7 
C) TAP-RAP2A in 293T 
 
 
Table 7: Novel and known RAP2 interactions identified by TAP screen. A-C) Three 
independent TAP experiments conducted in HEK-293, A549 and HEK-293T cell lines identified 
several potential interactors of RAP2. Due to a difference in the sensitivity of the mass 
spectrometer used, more targets were picked up on the final set of TAP data. D) Data 
summarised showing identified potential novel interactors of RAP2, including TRIM32 
(highlighted in red) which was pursued for further study. The successful detection of known 
RAP2 interactors serves as an internal positive control for this technique. 
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Antibody characterisation 
Various commercially available antibodies against TRIM32, MINK1, RAP1 and RAP2 
proteins were ordered for use in subsequent experiments. These were 
characterised, and their specificity tested, and the ability of the antibodies to 
specifically immunoprecipitate was determined, following the protocol described in 
the Methods section. 
MINK1, RAP2 and p85 were specifically detected by western blot with their 
respective antibodies in the lanes in which MINK1, RAP2 and p85 were 
immunoprecipitated (Figure 18). 
While the TRIM32 antibodies were able to detect overexpressed and endogenous 
TRIM32 by Western blotting, they are not able to specifically immunoprecipitate 
endogenous TRIM32 (Figure 18), therefore limiting the possibility of working with 
the endogenous protein by immunoprecipitation. 
 
Figure 18: RAP2, MINK1 and p85b antibodies are 
able to immunoprecipitate endogenous proteins, 
TRIM32 is not. HEK-293T lysates were incubated 
with Protein A or G beads and the indicated 
antibody for up to 4h. Lysates were then washed 
and run on an SDS-PAGE gel. The level of protein 
pulled-down was detected using western blot. 
Negative controls of closely related antibodies 
(Rabbit and Mouse SQSTM1 antibody) were used 
for both R- and M-, and did not show any bands. 
This reinforces the fact that the bands that were 
detected are likely to be specific. RAP2, MINK1 and 
p85b antibodies were able to immunoprecipitate 
the resepective proteins whereas the other 
antibodies tested (TRIM32, RAP1) were not. 
 
Generation of constructs 
To further explore protein-protein interactions, overexpression of a battery of 
tagged constructs (Table 8) was generated as described in the Methods section. 
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Each of these genes were ligated to ENTR Gateway vector (Gateway®, Invitrogen) 
and mutagenesis performed where appropriate and verified by sequencing. 
Gateway technology was then used to transfer the inserts into different Gateway-
compatible Tagged-destination vectors for expression in mammalian cells. The 
resulting tagged proteins (Flag-, GST-, Myc-, TAP6 tags) were used in subsequent 
experiments.  
Mutations at residues G12 and Q63 render RAP proteins insensitive to regulation by 
GAP resulting in a constitutively active GTP bound state. Therefore, G12V and Q63L 
mutations were generated to simulate constitutively active RAP1 and RAP2 
proteins. 
The RAP V12A38 and L63A38 mutants were generated because mutations at A38 in 
the effector domain prevent binding to downstream effectors, even when the 
protein is GTP-bound. These constructs were therefore used to demonstrate 
whether or not an interacting protein behaves as an effector of RAP. 
The T35S substitution in the effector domain of HRAS has previously been shown to 
differentially disrupt its ability to interact with some effectors (e.g. RalGDS, PI3K) 
but not others (RAF1). The equivalent mutant was generated in RAP2 to test 
whether it could differentially disrupt the interaction with TRIM32 or other RAP2 
effectors. 
As mentioned previously, there are five main TRIM32 mutants that have been 
identified; TRIM32 P130S (found in Bardet-Biedl syndrome) and TRIM32 R394H, 
D487N, 1559delC and ∆599 (identified in patients with LGMD2H). These, with the 
exception of 1559delC, were generated by PCR-site direction mutagenesis and were 
used to study whether they affected the interaction of TRIM32 with other proteins. 
Additionally, ∆RING deletes the RING domain while C23A disrupts the ability of the 
RING domain to function as an E3 ligase. These mutants were later used in order to 
determine whether the ubiquitin ligase function of TRIM32 is required for the RAP2-
TRIM32 interaction to take place. Finally, truncation products named TRIM32-C, -N 
and -C2 were generated in order to map the regions of TRIM32 mediating 
interactions. 
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Gene Mutations status Properties 
   
RAP1 Wt Wt 
 V12 Constitutively active mutant 
 V12 A38 Effector domain mutant 
   
RAP2 Wt Wt 
 V12 Constitutively active mutant 
 V12 A38 Effector domain mutant 
 V12 T35S Effector domain mutant 
 N17 Dominant negative 
 L63 Active mutant 
 L63 A38 Effector domain mutant 
   
TRIM32 Wt wild type 
 P130S BBS mutant 
 R394H LGMD2H mutant 
 D487N LGMD2H mutant 
 ∆588 LGMD2H mutant 
 ∆RING Deletion of RING domain (aa 20-63) 
 C23A Inactivating mutation in RING domain 
 N N-terminal half (aa 1-308) 
 C C-terminal half (aa 308-end) 
 C2 C-terminal fragment (aa 440 to end 
   
MINK Wt wild type 
TNIK Wt Wt 
mNIK wt  wt mouse isoform (kind gift from D.Barber) 
   
RIN1 Wt Wt 
RIN2a Wt Wt 
RIN3 Wt Wt 
   
TBC10D Wt Wt 
   
VPS25 Wt Wt 
VPS39 Wt Wt 
   
MRAS Wt Wt 
 L63 Constitutively active mutant 
 L63A38 Effector domain mutant 
NRAS Wt Wt 
 V12 Constitutively active mutant 
 V12A38 Effector domain mutant 
KRAS Wt Wt 
 V12 Constitutively active mutant 
 V12A38 Effector domain mutant 
 DUTR Deleted untranslated region 
 V12 DUTR Constitutively active mutant, deleted untranslated region 
 V12A38 DUTR Effector domain mutant, deleted untranslated region 
   
Ub 8x Ub kind gift from P. Meier and H. Plun-Favreau 
   
Table 8: List of Constructs generated. Shown above, the different constructs generated for 
subsequent use.  
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All generated constructs were sequenced in order to confirm correct protein 
sequence and correct insertion of mutations. In order to assess protein expression, 
each of these constructs was transfected into HEK-293T cells, and protein 
expression was assessed by immunoprecipitating samples with the associated tag 
(e.g. Flag-, GST-) as indicated and Western blotting on SDS-PAGE gels. Blots were 
stained by coomassie (A-C, Figure 19) or probed using specific tag antibodies (e.g. 
Flag-, GST-, Myc-, TAP6; D-F, Figure 19). All the transfected constructs encoded for 
proteins at the predicted size, taking into account the additional size of the tag. 
A) B)  
  
Figure 19: Example of 
Coomassie and Western 
blot data demonstrating 
expression levels of 
proteins. HEK-293T cells 
transfected with the 
indicated constructs 
were lysed after 48h, 
immunoprecipitated 
with the correlating tag 
and separated on SDS 
PAGE gels. In the 
Western blots shown 
above, construct 
expression is indicated 
with a red star. Protein 
expression is seen at the 
predicted size for each of 
the protein + tag above. 
A-C). Protein expression 
is detectable by 
Coomassie-Coomassie 
staining in all but 
TRIM32-N (figure B, lane 
9). This is, however, 
detectable by wb using 
the Flag antibody (D-F). 
D-F) GST- or Flag- 
antibody was used in 
order to detect protein 
expression. All proteins 
were detected at the 
predicted size. 
C) D) 
  
E) F) 
  
 
Expression levels of immunoprecipitated GST- and Flag-RAP2 constructs can be 
clearly detected by Coomassie staining of the blot (Figure 19A), with slightly lower 
expression of the GST-RAP2 N17 (dominant negative) construct (lane 6). 
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TRIM32 GST- and Flag-tagged constructs demonstrate lower expression levels that 
are barely detectable by Coomassie staining (Figure 19B), and in fact no detectable 
band is seen for Flag-TRIM32-N (lane 9). These constructs were re-run using more of 
the sample and in some cases the band was now detectable by Coomassie (Figure 
19C) and in others, the proteins were detected using the corresponding antibody, 
GST- or Flag as indicated (Figure 19D-E).  
Interestingly, the GST-TRIM32 constructs show laddering on the wt and the P130S 
mutant seen in BBS (lane 1-2) but not on the remaining LGMD2H mutants (lanes 3-
5, Figure 19E). Similarly, when using the Flag-TRIM32 construct, a double band can 
be seen with wt and P130S but not TRIM32 R394H, D487N or Δ588 LGMD2H 
mutants (Figure 19D). When detected with an anti- ubiquitin antibody, these extra 
bands/laddering were shown to be ubiquitinated TRIM32 proteins (see later). 
Validation of RAP2 interactions identified by TAP 
In order to validate and characterise the interactions detected by TAP (Table 7), 
Flag-tagged versions of either wild type (lane 4), constitutively active (V12, lane 5) 
and effector domain mutants (V12-A38, lane 6) of RAP2 were transiently 
transfected into HEK-293T cells. As controls for the specificity of the interactions, 
equivalent sets of wt and mutant versions of the closely related NRAS (lane 1-3) and 
MRAS (lane 7-9) members of the RAS family were also expressed in parallel. After 
immunoprecipitation of the tagged GTPase with FLAG-beads, associated 
endogenous proteins were detected by western blotting with the appropriate 
antibodies (Figure 20). 
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Figure 20: Endogenous TRIM32 immunoprecipitates with Flag-RAP2 wt and 
RAP2 V12. HEK-293T cells were transfected with Flag-RFG. Lysates were taken 
on day 3 and immunoprecipitated using Flag-beads. Proteins were separated 
using SDS-PAGE and Co-purifying proteins were detected by WB using 
endogenous antibodies. TRIM32 was shown to interact specifically with RAP2, 
and not NRAS or MRAS, with slightly stronger binding to the active RAP2 V12 
mutant and a slight disruption in the interaction with the defective RAP2 A38 
mutant. MINK and TNIK were also shown to bind specifically to RAP2, which is 
disrupted in the presence of the RAP2 A38 mutation. VPS35 was also shown to 
interact specifically with RAP2, although the interaction is not disrupted by the 
effector domain mutant RAP2 A38. 
 
Endogenous TRIM32 was found to co-immunoprecitiate specifically with RAP2 but 
not NRAS nor MRAS (Figure 20). The interaction was slightly stronger with the V12 
mutant (lane 5) and partially disrupted by the A38 mutation (lane 6), consistent 
with the activation- and effector domain-dependent interaction of an effector 
protein (see also later). 
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The MINK and TNIK family of GCK kinases was also shown to co-immunoprecitipate 
specifically with RAP2 but not any other RAS family GTPase tested. The interaction 
in both cases was strongly disrupted by the A38 substitution in the RAP2 effector 
domain (lane 6), consistent with their published role as RAP2 effectors (Taira, 
Umikawa et al. 2004; Nonaka, Takei et al. 2008). However, surprisingly, it was 
reproducibly observed that the wild type (lane 4) protein interacts more strongly 
than the V12 mutant (lane 5). This behaviour was also seen with NIK in other 
experiments (see Figure 21). Our data is consistent with binding in an effector 
domain-dependent manner, however, with a preference for the wt protein over the 
V12 mutant. We do not know the reason for this discrepancy. 
VPS35, which has not been previously reported to interact with RAP2 but was 
identified by TAP, can also be seen to co-immunoprecitpitate specifically with RAP2 
(lane 4-6) but not other RAS family members (Figure 20). In this case however, the 
interaction was not disrupted by the A38 substitution (lane 6). This suggests that 
VPS35 is a novel RAP2 interacting protein that may not function as a RAP2 effector, 
but could be involved in an upstream regulatory role, for example in mediating 
RAP2 transport (see discussion). 
RGL2 is a member of the RALGEF family that is known to interact with RAP2 and 
NRAS in an effector domain dependent manner, more strongly with the V12 (lanes 
2 and 5) than the wt (lane 1 and 4), with no binding to the A38 mutant (lane 3 and 
6) as seen above (Figure 20). 
AF6, that co-purified with TAP-RAP2 and is a known RAS family effector, can be 
shown to strongly co-immunoprecitipate with RAP2 as well as NRAS and MRAS in a 
manner that is strongly disrupted by the A38 effector domain mutations (Figure 20). 
This shows that AF6 is a promiscuous RAS family effector. In the case of NRAS and 
MRAS, the interaction takes place preferentially with the activating V12 or L63 
mutants (lane 2, lane 8 respectively). In contrast however, no difference can be 
seen between the wild type and V12 mutant (lane 4, lane 5 respectively) of RAP2 in 
its ability to interact with AF6. This could reflect the possibility, that unlike other 
RAS family GTPases, the wild type RAP2 protein may already be predominantly GTP-
bound in the cell in some contexts. 
95 
 
The BRAF and CRAF/RAF1 kinases interact in an effector domain dependent manner 
with NRAS and MRAS, binding more strongly to the activating mutants (lane 2 and 
8), than the wt (lane 1 and 7) with no binding seen with the A38 (lane 3 and 9). 
However, no binding is observed to RAP2.  
SHOC2 and PP1C behave as specific MRAS effectors, with demonstrably stronger 
MRAS L63 (lane 8) binding than wt (lane 7), and disrupted A38 binding (lane 9), and 
no interaction with any of the other RFGs. 
Assessing interaction with further RAP2 mutants 
To further characterise the specificity of these interactions, the interaction of RAP2 
with TRIM32 as well as other effectors was also tested in co-transfection assays. 
GST-tagged RAP2, MRAS and NRAS wild type, activating and effector domain 
mutants were co-transfected in HEK-293T cells together with Flag-tagged versions 
of TRIM32 or the indicated proteins (Figure 21).  
The A38 mutation in the effector domain of H/K/NRAS oncoproteins leads to full 
loss-of-function and is known to disrupt the interaction of RAS proteins with all 
known effectors. However, other substitutions within the RAS effector domain are 
known to create partial loss-of-function mutants by differentially disrupting the 
ability to interact with some effectors but not others. HRAS T35S for example can 
no longer interact with RALGDS or PI3K, while still being able to interact with RAF 
kinases and activate the RAF-ERK pathway (although with decreased 
efficiency)(White, Nicolette et al. 1995; Rodriguez-Viciana, Warne et al. 1997). 
These partial loss-of-function mutants have provided useful experimental tools to 
assess the contribution of the different RAS effector pathways to the known 
biological effects regulated by RAS. To test whether the equivalent T35S 
substitution in RAP2 could differentially disrupt the interaction with TRIM32 and/or 
other effectors, this mutation was also generated and tested. 
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Figure 21: The RAP2-V12T35S mutant partially disrupts the interactions with TRIM32 and RIN1, 
abrogates interactions with MINK, TNIK, NIK, RIN2α, and RGL2 and appears to have no effect 
on interactions with RGL and RALGDS. HEK-293T cells were transiently co-transfected with GST-
tagged RFG constructs and Flag-tagged interactors, and immunoblotted using the Flag antibody. 
Flag-tagged construct expression levels were analysed by western blotting the lysates with the 
Flag antibody. TRIM32 interacts specifically with RAP2 in an effector domain dependent manner. 
This interaction is also partially disrupted in the presence of the RAP2 T35S mutation. The 
specific MINK, TNIK and NIK interaction with RAP2 is abrogated in the presence of the RAP2 A38 
effector domain mutation, and almost entirely disrupted in the presence of the RAP2 T35S 
mutation. RIN1 and RIN2 interact with NRAS and MRAS in an activation- and effector-domain 
dependent manner. RIN1 appears to bind more strongly to RAP2 wt than RAP2 V12, with 
complete and partial disruption on A38 and T35S mutations respectively. RIN2 again interacts in 
an activation- and effector-domain dependent manner with RAP2, and this interaction is 
abolished with the RAP2 T35S mutation. 
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In co-transfection assays TRIM32 was again shown to interact specifically with RAP2 
but not NRAS, MRAS (Figure 21) or any other RAS family GTPase tested, including 
RAP1, KRAS, DIRAS1, DIRAS2 or DIRAS3 (data not shown). This shows, that even 
under conditions of overexpression, TRIM32 is a very specific RAP2 effector. RAP2 
V12 interacted more strongly than the wild type whereas the A38 mutation severely 
disrupts the interaction. The T35S mutation also strongly disrupts the interaction 
with TRIM32 although not as strongly as D38A. 
MINK, TNIK and NIK also interact specifically with RAP2 but not any other RAS family 
GTPases. However, contrary to what has been reported in the literature (Taira, 
Umikawa et al. 2004; Nonaka, Takei et al. 2008); we consistently see preferential 
binding to RAP2 wt than RAP2 V12 (Figure 21). 
As seen for TRIM32, D38A mutation severely disrupts the interaction with MINK 
whereas T35S has a partial effect. In this type of co-transfection assay, TNIK and NIK 
could be detected binding to wild type (but not V12 as the signal was likely too 
weak) RAP2. Because the A38 and T35S mutants were only generated within the 
background of the V12 mutation, the effect of only the A38 mutant on the 
interaction with TNIK and NIK could not be determined. 
RIN1 and RIN2 show strong activation- and effector domain-dependent interactions 
with NRAS (lane 1-3) and MRAS (lane 8-10) and both also interact with RAP2 and 
mutations in the effector domain also strongly disrupt this interaction, with RAP2 
A38 completely abrogating the interaction (lane 6) and T35S still displaying some 
residual binding to RIN1 (lane 7). Intriguingly, RAP2 V12 (lane 5) interacts more 
strongly than RAP2 wt (lane 4) with RIN2 whereas the opposite pattern was seen 
with RIN1 (Figure 21). 
The RALGEF family (RGL, RGFL2 and RalGDS) also interact with RAP2 and other RAS 
family members although with different efficiencies. For example, RalGDS showed 
the strongest interaction with RAP2 followed by MRAS with clearly weaker binding 
to NRAS. The A38 mutation blocked interaction with all three RALGEF family 
members. Interestingly however, whereas the S35 mutation in RAP2 strongly 
disrupts the interaction with RGL2, it only has a marginal effect on the interaction 
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with RGL and RalGDS (Figure 21). The results of the RAP2 interactions are 
summarised in Table 9. 
 
 MRAS RAP2 NRAS 
 wt L63 L63A38 wt V12 V12A38 V12 T35S wt V12 V12A38 
TRIM32       ++ +++   +       
MINK       ++ +           
TNIK       ++             
NIK       +             
RIN1   ++++   +++ +++   + +++ ++++   
RIN2   ++++   +       ++ +++++   
RGL   +++   + ++   + +++ ++++   
RGL2   +++   + ++       ++++   
RALGDS       ++++ ++++   ++++   ++   
 
Table 9: Summary of RAP2 interactions. Our data so far demonstrates that Trim32, MINK, TNIK and 
NIK specifically interact with RAP2. RIN1 and RIN2 interact with MRAS, RAP2 and NRAS. 
In the case of some RAS and RHO/RAC family GTPases, the ‘L61’ activating mutant 
was shown to interact more strongly with effectors than the V12 activating mutant. 
In order to test the possibility that a similar scenario may be taking place with RAP2, 
the equivalent L63 mutation was generated in RAP2. As the L63 contruct we 
generated did not express at the correct size, the RAP2 V12L63 mutant was used in 
subsequent studies (Figure 21). 
 
Figure 22: The RAP2 V12L63 mutant 
does not effect the TRIM32 interaction. 
GST-tagged RAP2 mutants were over-
expressed with Flag-tagged TRIM32. 
Cells were lysed after 48hours and GST-
tagged proteins were pulled down. 
Subsequently, samples were run on 
SDS-PAGE gel and interacting Flag-
tagged proteins were assessed using the 
Flag antibody. GST-RAP2 V12 and GST-
RAP2 V12L63 expression levels are 
comparable and no effect is seen on 
their affinity for TRIM32. 
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In co-transfection assays, no difference in the ability of the V12 or V12L63 RAP2 to 
associate with Flag-TRIM32 was detected (Figure 22). Therefore, RAP2 V12 was 
used in all subsequent studies. 
Summary 
Having identified several potential novel RAP2 interacting proteins via the unbiased 
approach of TAP, we then proceeded to validate them first using overexpressed 
RAP2 and endogenous proteins and then co-transfecting both RAP2 and the targets. 
TRIM32 binds very specifically to RAP2 but not other RAS family GTPases in an 
activation- and effector domain-dependent interaction. It binds preferentially to the 
V12 activating mutant over the wt RAP2 and the interaction is disrupted by the A38 
mutation in the effector domain. Therefore, TRIM32 behaves as a novel RAP2 
effector. 
VPS35 was found to interact specifically with RAP2, stronger with RAP2 V12 than 
wt. However, this interaction was not disrupted using a construct carrying the A38 
mutation suggesting that VPS35 may not function as an effector of RAP2, but it 
could be involved upstream of the pathway. 
Further interactions were also confirmed between MINK, TNIK and NIK (previously 
published), in an effector domain dependent manner, consistent with their 
published role as RAP2 effectors (Taira, Umikawa et al. 2004; Nonaka, Takei et al. 
2008). However, contrary to what has been reported in the literature, we 
consistently see preferential binding to RAP2 wt than RAP2 V12. This could be due 
to preferential binding to the GDP bound conformation of RAP2 when compared to 
the GTP-bound. Alternatively, the V12 mutation may affect the interaction in a 
guanine nucleotide independent manner. 
The T35S substitution in the effector domain of HRAS has previously been shown to 
differentially disrupt its ability to interact with some effectors (e.g. PI3K) but not 
others (RAF1). The equivalent mutant was generated in RAP2 to test whether it 
could differentially disrupt the interaction with TRIM32 or other RAP2 effectors. The 
T35S substitution in RAP2 only partially disrupts the interaction with TRIM32. RAP2 
V12 T35S binds weakly with RIN1, and not with Rin2. Additionally, RGL and RalGDS 
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interact with RAP2 V12 T35S, whereas RGL2 does not interact with RAP2 V12 T35S. 
This demonstrates that similar to the HRAS T35S substitution, the RAP2 V12 T35S 
residue selectively disrupts interactions both between different protein families as 
well as within them. 
Due to the robust nature of the experiments, the interesting links in the literature, 
and the availability of the reagents, subsequent experiments were conducted 
focusing mainly on understanding the RAP2-TRIM32 interaction.  
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Chapter 4: Assessing the Effect of 
TRIM32 mutants 
TRIM32 was identified as a novel RAP2 binding protein by TAP, and validated to 
interact in a GTP bound, effector domain-dependent manner. In order to better 
understand how RAP2 may regulate TRIM32 function, the dynamics of the 
interaction were investigated below. 
TAP experiments identify a network of protein interactions 
containing TRIM32 and RAP2 effectors 
In independent TAP purifications performed by Dr Rodriguez-Viciana TRIM32 was 
found to specifically co-purify with other TAP baits (Table 10). Mass spectrometry 
identified TRIM32 as one the most prominent bands co-purifying with TAP-MINK 
from HEK293T cells that were also co-expressing RAP2 V12, suggesting that MINK, 
TRIM32 and RAP2 may form a complex in vivo. TRIM32 and MAP4K4/NIK were also 
identified among other proteins co-purifying specifically in TAP purification of the 
p85β regulatory subunit of PI3K. Both results suggest that TRIM32 and members of 
the MINK/NIK/TNIK family of kinases may form a complex in vivo. TAP of the Ras 
family effector RIN2 identified TNIK as a co-purifying protein. 
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MINK (+RAP2) p85  RIN2 
TRIM32 NISCH CSNK2A1 
CDC37 MAP4K4 CSNK2B 
RAP2a TBC1D15 RRAS2 
14-3-3s 14-3-3s TNIK 
LONP1 TRIM32 RIN3 
CRBN CBL SH3GL1 
CDC123 IRS2 CAMK2D 
 IRS1 CAMK2G 
 INSRR CAMK2B 
 PIK3CB  
 PIK3R1  
 EGFR  
 ERBB2  
 
Table 10: TAP-MINK, p85β and RIN2. TAP-MINK and TAP-p85β identified 
TRIM32 (red) and as a potential target. TAP-p85β and TAP-RIN2 both 
detect members of the Ste20 kinases (green) as potential targets. 
This data is derived from three separate TAP-purifications using TAP -
MINK, -p85β and -RIN2 as indicated (top row) and the proteins listed 
below are those identified by TAP as potential interactors with the bait. 
 
A schematic was generated displaying interactions published in literature as well as 
those newly identified potential interactions in order to represent the possible 
signalling network we wished to investigate and help identify areas of 
overlap/interest for further study (Figure 23). 
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Figure 23: Schematic of interactions linking RAP2 to known and novel interactions. Grey lines 
indicate interactions that have previously been published in the literature, whereas red lines 
indicate those identified by TAP. 
 
It is apparent from the schematic that RAP2 and TRIM32 may be part of a network 
of protein interactions with the MINK/TNIK/NIK members of the Ste20 kinase 
family. There are several potentially novel pathways that can be inferred from a 
combination of what has been published in the literature and what has been 
identified from the various TAP experiments. Therefore, these genes were cloned 
by PCR and expression constructs generated for use in subsequent experiments in 
order to map the interaction site or assess whether RAP2 can modulate these 
interactions as well as TRIM32. 
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RAP2 interacts with TRIM32 C-terminus and requires the RING 
domain 
 
 
Figure 24: TRIM32 mutants. Truncation mutants are indicated above (N-terminal, aa 1-308) 
and below (C-terminus, aa 304-end). ∆RING is indicated by the cross on the RING domain. 
 
In order to map the region of TRIM32 that interacts with RAP2, the N- and C-
terminal halves of TRIM32 as well as a deletion mutant lacking the RING domain 
were expressed as GST-fusion proteins in HEK-293T cells together with Flag-RAP2 or 
Flag-MINK. After 48h, the cells were lysed and pulled-down using the GST-tag, and 
the interactions assessed using the Flag-antibody. 
 
Figure 25: RAP2 interacts with 
TRIM32-C-terminus. RAP2 binds to 
TRIM32 C-teminus and not N-
terminus with reduced interaction 
upon deletion of the RING domain. 
Conversely, MINK binds to the N-
terminus and not the C-terminus 
and is not affected by the RING 
domain deletion. This is surprising as 
the RING domain is located in the N-
terminal region, suggesting that it 
could be the activity (ubiquitination) 
of the RING domain that is enhances 
the RAP2-TRIM32 interaction. 
GST-TRIM32 wt, ∆RING, N-terminus or C-terminus (as indicated) were over-expressed with either 
Flag-RAP2 or Flag-MINK. Lysates were incubated with glutathione beads and interactions were 
detected using the Flag-antibody. 
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Flag-RAP2 binds to C- (lane 5), but not the N-terminal halve (lane 4) of TRIM32, 
although not as efficiently as the wild type protein (note difference in bait levels). In 
clear contrast, MINK binds to the N- but not C-terminus of TRIM32. This confirms 
the MINK-TAP result and validates MINK as a TRIM32 interacting protein. It also 
indicates that TRIM32 uses different domains to interact with both RAP2 and MINK 
and could thus bring them into the same complex in vivo (Figure 25). 
The RING domain is required for the E3-ligase activity of TRIM32, it works with E2 
enzymes to monoubiquitinate or polyubiquitinate substrates, most likely by acting 
as a scaffold, bridging the E2~Ub and its substrate. This was therefore mutated in 
order to determine whether RAP2 and MINK are still able to interact with TRIM32 
with a disrupted RING domain as this could indicate a link to TRIM32s E3 ligase 
activity. 
A) B) 
  
C)  
 
Figure 26: The level of RAP2, MINK and Myc 
pulled down by TRIM32 is slightly reduced, 
not affected and abrogated, respectively. 
More RAP2 V12 is pulled-down with TRIM32 
wt than ΔRING and Flag-Myc pull-down by 
TRIM32 wt was abrogated in the presence of 
the ΔRING mutation, suggesting that either 
the RING domain or the RING domain 
function (ubiquitination) is required to 
enhance this interaction. No effect is seen on 
MINK pull-down with TRIM32 wt compared to 
ΔRING suggesting that this is a pathway 
specific effect. 
GST-TRIM32 wt or ∆RING (as indicated) were over-expressed with either Flag-RAP2, Flag-MINK or 
Flag-Myc. Lysates were incubated with glutathione beads and interactions were detected using the 
Flag-antibody. SHOC2 construct was used as an unrelated control. 
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MINK interaction does not require the RING domain (lane 3, Figure 26). Note that 
although the interaction with wt TRIM32 appears weaker, the baits in lane 2 
indicate that this is likely a reflection of the lower expression levels achieved with 
the wild type protein. Conversely, disruption of the TRIM32-RING domain abrogates 
the Myc-TRIM32 interaction, seen on Figure 26C despite the stronger TRIM32 bait. 
Surprisingly, even though RAP2 can interact with the C-terminal half of TRIM32, 
deletion of the RING domain, which is located in the N-terminal half (Figure 24) also 
partially disrupts the interaction with RAP2.  
TRIM32 disease mutants disrupt the RAP2 V12 interaction but 
not MINK 
As mentioned previously, there are five main TRIM32 mutants that have been 
identified in disease; TRIM32 P130S (found in Bardet-Biedl syndrome) and TRIM32 
R394H, D487N and ∆599 (identified in patients with LGMD2H).  
In order to test whether these mutations had any effect on the interactions with 
RAP2 or MINK, and investigate whether these interactions are involved in either 
disease aetiology, the mutants were overexpressed in HEK-293T cells with either 
RAP2 or MINK by transient transfection.  
 
 
 
 
 
 
 
 
107 
 
 
A)  
 
B) Figure 27: TRIM32 R394H 
and D487N mutants 
disrupt RAP2 interaction. 
A) TRIM32 structure with 
disease mutants indicated 
by arrows. B-C) Flag-RAP2 
V12 and GST-TRIM32 wt 
and mutants were 
overexpressed in HEK-
293T cells as described 
previously. Lysates were 
then pulled down by the 
GST-tag, and interaction 
was assessed using the 
Flag-antibody. 
Membranes were also 
probed with endogenous 
Ub antibody to assess Ub 
levels for the different 
mutants. D) Flag-TRIM32 
wt and mutants and GST-
RAP2 V12 were 
overexpressed in HEK 
293T cells as described 
previously. A PKA-R2α 
construct was used as an 
unrelated control. 
 
C) 
 
D) 
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When GST-TRIM32 is used to pull-down RAP2, the P130S substitution in the B-box 
within the N-terminus of the protein that is found in BBS has no effect on the 
interaction with RAP2. In contrast R394H and D487N within the C-terminal NHL 
repeats strongly inhibit the interaction with RAP2 whereas Δ588 showed greatly 
diminished but still detectable interaction. None of the mutations had any effect on 
the interaction with MINK (Figure 27A). 
Laddering can be seen on the baits for GST-TRIM32 wt and P130S but not for 
TRIM32 R394H, D487N or Δ588. Using an antibody against endogenous ubiquitin, 
the laddering has been shown to correlate with ubiquitination, implicating the E3 
ligase activity of TRIM32 in the RAP2 interaction (Figure 27A). 
Similar results are seen when the experiment is done with immobilised GST-RAP2 
pulling down Flag-TRIM32 (Figure 27A), with R394H and D487N completely 
disrupting the interaction, Δ588 having a partial effect, whereas P130S behaved as 
the wild type. Flag-TRIM32 shows a double band which would correlate in size to 
mono- or di-ubiquitination of TRIM32. 
Modulation of TRIM32 interactions by RAP2 
As RAP2 is upstream of TRIM32, demonstrated by the effector-type properties of 
the interaction, it is likely that RAP2 regulates the function or activity of TRIM32. 
Therefore, we investigated several other TRIM32 interactions which we or others 
had identified and assessed whether RAP2 played a role in modulating these 
interactions. 
The ability of RAP2 to effect TRIM32 interactions was assessed by co-transfection of 
GST-TRIM32, Flag-tagged PIAS4/RIN2/MINK (as indicated) with or without Flag-
RAP2 V12 (as indicated). GST-TRIM32 was pulled down using Glutathione beads and 
interacting Flag-tagged proteins were detected using an anti-Flag antibody. 
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A) B) 
  
C) D) 
  
E) F) 
  
G)  
 
Figure 28: Effect of RAP2 expression on TRIM32 
interactions GST-TRIM32, Flag-tagged A) PIAS4, 
B) RIN2, C) MINK1, D) mNIK, E) Ago, F) MYC, G) 
Vps29 + Vps35 with or without Flag-RAP2 V12 (as 
indicated), were transiently transfected in HEK-
293T cells. GST-TRIM32 pulled-down, and 
interactions with the Flag-tagged constructs were 
assessed using the Flag antibody. A-C) PIAS4, 
RIN2 and MINK are specifically pulled-down by 
TRIM32, but the addition of RAP2 V12 does not 
affect the level of protein pulled-down. 
D) mNIK is pulled-down by TRIM32 and co-transfection with RAP2 V12 (even with poor expression of 
the RAP2 V12 construct) results in less mNIK being pulled-down by TRIM32. E) Ago is pulled-down by 
TRIM32 and addition of RAP2 V12 does not appear to affect this. However, despite RAP2 V12 being 
detected on pull down by TRIM32, such low levels are expressed in this experiment that it is not seen 
in the baits. F) MYC is pulled down by TRIM32 and co-expression of RAP2 results in an increase in the 
levels of MYC detected. G) VPS29 + VPS35 co-expression with TRIM32 enables detectable amounts of 
VPS35 to be pulled down by TRIM32, and this is abrogated on co-transfection with RAP2 V12. 
GST-CIP2A construct was used as an unrelated control. 
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TRIM32 is able to specifically pull down PIAS4, RIN2 and MINK and the co-
expression of RAP2 V12 (with RAP1 V12 as a control) does not appear to affect the 
strength of the interaction, suggesting that RAP2 V12 does not modulate TRIM32s 
ability to interact with these proteins (Figure 28A-C). 
In the case of mNIK, however, (Figure 28D) the mNIK-TRIM32 interaction is 
disrupted in the presence of RAP2 and this effect is seen more strongly with RAP2 
wt (lane 2) than RAP2 V12 (lane 3), which correlates with previously demonstrated 
interaction data showing a stronger interaction between mNIK and RAP2 wt than 
RAP2 V12 (Figure 21). It is possible that disruption in the MINK-TRIM32 interaction 
may be detected in the presence of RAP2 wt as it also binds more strongly to RAP2 
wt. 
Overexpressed Ago is pulled down by TRIM32 with no effect seen upon addition of 
RAP2 V12 (Figure 28E). However, despite RAP2 V12 being detected on pull down by 
TRIM32, such low levels are expressed in this experiment that it is not seen in the 
baits, with stronger RAP2 V12 expression, it is possible that an effect may be seen, 
however we were not able to obtain this data. 
MYC is pulled down by TRIM32 and co-expression of RAP2 results in an increase in 
the levels of MYC detected (Figure 28F), whereas VPS29 + VPS35 co-expression with 
TRIM32 enables detectable amounts of VPS35 to be pulled down by TRIM32, and 
this is abrogated on co-transfection with RAP2 V12 (Figure 28G). VPS29 functions as 
a scaffold protein that facilitates the linking of two subcomplexes for the assembly 
of the heteropentamer in endosomal protein sorting (Swarbrick, Shaw et al. 2011), 
which is a possible reason why it has not been detected on pull-down with TRIM32 
whereas VPS35 has. 
This series of experiments suggests that RAP2 modulates the TRIM32 interaction 
with downstream effectors in an effector-dependent manner. 
Summary 
In this section we have demonstrated that RAP2 interacts with TRIM32 C-terminus 
and LGMD2H disease mutants specifically disrupt this interaction. This disruption of 
the RAP2-TRIM32 interaction in the presence of the LGMD2H disease mutants and 
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not with the mutations found in BBS, establish a link between this interaction and 
muscular dystrophy. Interestingly, these LGMD2H mutations are all located in the 
NHL domain, a motif involved in protein-protein interactions (Edwards, Wilkinson et 
al. 2003) and previously shown in TRIM32 to associate with and enhance the activity 
of Argonautes (AGO), a miRNA (Schwamborn, Berezikov et al. 2009; Kudryashova, 
Struyk et al. 2011). Surprisingly, even though RAP2 can interact with the C-terminal 
half of TRIM32, deletion of the RING domain, which is located in the N-terminal half 
(Figure 24) also partially disrupts the interaction with RAP2. This suggests that in the 
context of the full length protein, RAP2 may make multiple contacts with the 
TRIM32 proteins, both at the C-terminus and with the RING domain. Alternatively, 
the activity of the RING domain for E3 ligase activity may be important for the 
interaction with RAP2. In clear contrast, MINK binds to the N- terminus of TRIM32 
and is not affected by mutations to the NHL or RING domain. This indicates that 
TRIM32 uses different domains to interact with both RAP2 and MINK and could thus 
bring them into the same complex in vivo. 
It has been shown using yeast two-hybrid that TRIM32 proteins form homodimers 
and that LGMD2H mutations (but not the BBS P130S mutation) disrupted 
homodimer formation (Saccone, Palmieri et al. 2008). With the Δ588 mutation, 
there was a partial effect with TRIM32 dimers still occuring, but slower growth seen 
in yeast two-hybrid analysis (Saccone, Palmieri et al. 2008). Therefore there is an 
interesting correlation between the ability of LGMD2H mutations to affect the 
ability of TRIM32 to interact with RAP2 (Figure 27) and to form homodimers 
(Saccone, Palmieri et al. 2008). 
Laddering can be seen on the baits for GST-TRIM32 wt and P130S but not for 
TRIM32 R394H, D487N or Δ588. Using an antibody against endogenous ubiquitin, 
the laddering has been shown to correlate with ubiquitination, implicating the E3 
ligase activity of TRIM32 in the RAP2 interaction (Figure 27). This is consistent with 
the previous result on Figure 26, where deletion of the RING domain decreased the 
interaction with RAP2 in the context of the ΔRING protein and further suggests that 
the RING domain may make contacts with the C-terminus NHL domains, and that 
this contacts may lead to ubiquitination of TRIM32. 
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This ability to selectively modulate TRIM32 interactions suggests a regulatory role 
for the RAP2-TRIM32 interactions. However, it has been stated in literature that 
there is a poor correlation between ubiquitin ligase activity and ability to bind E2 
substrates, or other downstream substrates, with high affinity (Lorick, Jensen et al. 
1999). Therefore, we proceeded to investigate the impact of RAP2 on TRIM32 
mediated ubiquitination. 
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Chapter 5: TRIM32 TAP Identifies 
further Potential Interactions 
TRIM32-TAP 
In order to identify additional interacting proteins of TRIM32 in a non-biased 
proteomic approach, we performed TAP purifications of TRIM32 in several cell 
types. Initially, TAP-tagged TRIM32 was stably expressed in the malignant 
meningioma cell line IOMM-Lee in parallel with unrelated proteins which served as 
specificity control. 
Levels of TRIM32 bait that were purified in this system were relatively low. 
Therefore, before sending the samples for analysis an additional TAP purification 
was performed in 293T cells. Transient transfection of these cells generally leads to 
higher expression levels and therefore higher sensitivity in TAP experiments. 
Furthermore, in an attempt to identify TRIM32-interacting proteins that may be 
regulated by RAP2, cells were co-transfected with either RAP2 V12 or a Control. This 
TAP purification was carried out using multiple alternative baits that served as 
specificity controls. After affinity purification, protein complexes were analysed by 
mass spectrometry by our collaborators Juan Oses and Alma Burlingame at the 
UCSF mass spectrometry facility. 
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Table 11: Peptides identified in TAP-TRIM32 purified from IOMM-LEE cells. IOMM-LEE cells were 
infected with lentivirus expressing TAP-tagged TRIM32 and Control1. Protein complexes were 
purified as described in material and methods and mass spectrometry performed by our 
collaborators (Juan Oses and Alma Burlingame) at the UCSF mass spectrometry facility. 
 
 
Table 12: Peptides identified in TAP-TRIM32 purified from 293T cells. 293T cells were transiently 
contransfected with TAP-TRIM32 and either Control wt or RAP2 V12. Protein complexes were 
purified as described in material and methods and mass spectrometry performed by our 
collaborators (Juan Oses and Alma Burlingame) at the UCSF mass spectrometry facility. 
 
The results of the TRIM32 co-purification TAP experiment are shown in Table 11 and 
Table 12 for IOMM-Lee and 293T cells respectively. Very few TRIM32-interacting 
proteins were identified and, in most cases, the numbers of peptides found was 
low. This suggests the need for extra caution until further validation. Some of the 
appear of particular interest as highlighted below, however, due to the delay in 
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receiving the data, there was insufficient time to conduct further experiments, 
therefore precluding validation and further analysis. 
14-3-3 proteins were identified in both purifications as TRIM32 interacting proteins. 
14-3-3 proteins are dimers that function as scaffold proteins. They bind in a 
phosphorylation dependent manner to a variety of proteins, and have been 
implicated in many key cellular processes such as metabolism, protein trafficking, 
signal transduction, apoptosis and cell-cycle regulation (Morrison 2009). 
Interestingly, in HEK-293T cells, 14-3-3 were preferentially associated with TRIM32 
when RAP2 was co-expressed suggesting that RAP2 may modulate TRIM32 function 
and/or activity by stimulating its association with 14-3-3. Recent studies by Ichimura 
et al confimed 14-3-3 as a binding part of TRIM32, showing that each of the 14-3-3 
isoforms interact with PKA phosphorylated TRIM32 in HEK293 cells (Ichiumura 
2014). Interestingly, it was shown that 14-3-3 binding prevented TRIM32 auto-
ubiquination as well as TRIM32 transubiquitination as well as the ability of TRIM32 
to form cytoplasmic bodies. These findings suggest that 14-3-3 isoforms play a role 
in the modulation of TRIM32 activity as well as in maintaining the proper level of 
soluble TRIM32 proteins (Song et al, 2005; Diaz-Griffero et al., 2006). 
In IOMM-Lee, but not HEK-293T cells, lamin A/C was found to strongly co-purify 
with TRIM32. Lamins are important for the incorporation and spacing of nuclear 
pores, regulation of nuclear size and the shape and mechanical properties of the 
nucleus. They also play an important role in physically connecting the nucleus to the 
cytoskeleton, most likely through their interaction with SUN proteins (Sad1p, UNC-
84) and nesprins. The protein complex formed by nesprins and SUN proteins is 
essential for intracellular force transmission, cell migration and cell polarization. 
Interestingly mutations in lamin A/C have been implicated in a variety of diseases 
including Emery–Dreifuss muscular dystrophy (EDMD), and limb-girdle muscular 
dystrophy type 1B (Ho and Lammerding 2012). Although the TRIM32-Lamin A/C 
interaction needs to be validated, considering that TRIM32 is also mutated in limb-
girdle muscular dystrophy (LGMD2H), it is tempting to speculate that the TRIM32-
lamin A/C interaction may be of special importance to muscle physiology and 
muscular dystrophy, as implied by the findings by LaBeau-DiMenna et al, and 
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Kudryashova et al highlighted below (LaBeau-DiMenna, Clark, et al. 2012; 
Kudryashova, Kudryashov et al. 2005). 
In HEK-293T cells one peptide was identified for Myomesin-1. This protein is also of 
particular relevance because of its role in muscle physiology. Myomesin is a 
structural component of the M-band of the sarcomere (see Figure 29). Muscle cells 
are composed of tubular myofibrils which are composed of repeating sections of 
sarcomeres, which are composed of long, fibrous proteins that slide past each other 
when the muscles contract and relax. Members of the MYOM protein family act to 
maintain the overall structural organisation of the M-band (Pinotsis, 
Chatziefthimiou et al. 2012) and mutations in myomesin are associated with 
cardiomyopathy (Siegert, Perrot et al. 2011), symptoms often seen in muscular 
dystrophies. Interestingly, findings by LaBeau-DiMenna demonstrated that the 
TRIM32 orthologue Thin is localised to the Z-disc in muscle and is essential for 
myofibril stability in Drosophila (LaBeau-DiMenna, Clark, et al. 2012). Findings by 
Kudryashova et al have already indicated that TRIM32 can bind to the thick filament 
protein myosin and ubiquitinates actin (Kudryashova, Kudryashov et al. 2005) and 
that TRIM32 localises to Z-line proteins in mice (Kudryashova, Wu et al. 2009). Due 
to high conservation of these structures in animals, it is likely that TRIM32 plays a 
similar role in mammalian muscle cells.  
A) Figure 29: Sarcomere cytoskeleton 
and M-band protein components. 
A) Scheme of the sarcomere 
depicting the main components of 
the sarcomeric cytoskeleton (M-
band, Z-disk and titin). B) Myomesin 
(white), M-protein (gray) and 
myomesin-3 (dark gray) are 
composed of immunoglobulin-like 
domains (ellipses) and fibronectin 
type 3 domains (rectangles). From 
ref: (Schoenauer, Emmert et al. 
2011). 
 
B) 
 
 
Cullin-2 is a member of the cullin family of hydrophobic proteins that function as 
scaffolds for E3 ubiquitin ligases. They combine with RING proteins to form Cullin-
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RING ubiquitin ligases (CRLs) and play an essential role in targeting proteins for 
ubiquitin-mediated modification. Because TRIM32 contains a RING domain, and has 
ubiquitin ligase activity, its co-purification with TRIM32 in HEK-293T cells is 
consistent with TRIM32 being a cullin-2 assosciated E3 ligase. Interestingly, no 
Cullin-2 peptides were detected when RAP2 was co-expressed suggesting that RAP2 
may modulate TRIM32 association with Cullin-2.  
Future work would involve validating these interactions and assessing their 
modulation by RAP2, as well as investigating whether they are substrates for 
TRIM32 ubiquitination. Also, exploring the possibility of a biological effect on the 
cells, such as a role on proliferation, migration, differentiation or TRIM32 
localisation, would be further down the line. 
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Chapter 6: Results – The Effect of 
TRIM32 Dependent Ubiquitination 
We have shown that the RAP2-TRIM32 interaction is partially interrupted upon 
mutation of the TRIM32 RING domain, the site responsible for E3 ligase activity of 
TRIM32. Additionally, laddering seen on TRIM32 wt and P130S baits by coommassie 
and western blot is indicative of ubiquitination, and is absent in TRIM32 R394H, 
D487N and ∆588 mutants – the mutations that disrupt the interaction with RAP2 as 
shown previously. From this we can infer that the ubiquitin ligase activity is 
disrupted in these mutants and that the ubiquitination function of TRIM32 is 
somehow linked to the RAP2-TRIM32 association. 
Combined with the information that RAP2 can selectively modulate TRIM32 
interactions with other proteins, the key point explored below is: can we detect a 
RAP2 mediated effect on TRIM32 Ub activity on other interactions? 
RAP2 is a substrate of TRIM32 Ubiquitination and mutations in 
RAP2 Regulate RAP2-Ubiquitination 
Prior to our investigations, it was necessary to set up and optimise the experimental 
system. Proteasome inhibitors are drugs that are often used in ubiquitination 
studies in order to reduce the degradation of ubiquitin-conjugated proteins in 
mammalian cells. MG-132 is a cell-permeable proteasome inhibitor and its effect 
was tested on HEK-293T cells by overexpressing HA-tagged Ub, RAP2 wt or RAP2 
mutants, TRIM32 wt or empty control as specified on the figure (Figure 30). These 
cells were then either treated with control or MG-132 for 3h prior to cell lysis and 
incubation with glutathione beads. RAP2 proteins were pulled down by the GST tag 
and the effect on the signal obtained by Western blot was assessed using the HA 
antibody. 
 
119 
 
A) B) 
 
 
 
 
Untreated Treated 
Figure 30: RAP2 is a substrate of TRIM32 ubiquitination. HEK-293T cells were co-transfected with 
HA-Ub (black), Flag-TRIM32 (blue), GST-RAP2 wt and mutants (green). A) Untreated cells, or B) 
treated with MG-132 for 3h were pulled-down using Glutathione beads. Proteins were separated 
using SDS-PAGE gel and transferred to PVDF membrane. Associated ubiquitin were detected using 
HA-antibody. Lower levels of ubiquitin were pulled down for samples that were pre-treated with 
MG-132 when compared to untreated samples with comparable bait levels. 
 
Comparing the ubiquitination levels both with and without MG-132, there was little 
difference and therefore subsequent experiments were conducted in the absence 
of MG-132.  
TRIM32 enhances the ubiquitination of RAP2 (Figure 30). The RAP2 V12 and V12L63 
mutants show little difference in ubiquitination levels both with and without 
TRIM32 (Figure 30A, lanes 7 and 13), with little detectable difference between the 
other mutations. Thus we looked at whether the different TRIM32 mutants would 
have an effect on the level of ubiquitination. 
TRIM32 mutants immunoprecipitate Ubiquitin to varying 
degrees 
To explore the effects of the disease mutants studied previously, TRIM32 wt and 
mutant proteins were transiently overexpressed in HEK-293T cells. Cell lysates were 
immunoprecipitated and levels of auto-ubiquitination were compared with 
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controls. TRIM2 is from the same sub-family (VII) as TRIM32, was therefore used as 
a closely related control while the C23A mutation is located within the RING domain 
of TRIM32 and should destroys its E3 ligase activity. 
 
A) B) 
  
 
Figure 31: Effect of TRIM32 mutants on ubiquitination. Results show variation in the 
levels of ubiquitination detected. Although more ubiquitin can be detected with the 
TRIM32 D487N mutant, bait expression is higher than the other TRIM32 constructs. The 
∆RING and C23A constructs do not show ubiquitination, likely due to the role of the 
RING domain in ubiquitination. 
HEK-293T cells were co-transfected with HA-Ub, Flag-TRIM32 wt or mutants as 
indicated. Lysates were taken on day 3 and samples were immunoprecipitated using 
Flag- beads. Proteins were separated using SDS-PAGE gel and transferred to PVDF 
membrane. Protein levels were detected using HA- antibody. Unrelated controls were 
A) Trim2 and Shoc2 B) CIP2A. 
  
As predicted, deleting the RING domain (Figure 31A, lane 4) or mutating the C23A 
residue (Figure 31A, lane 5) within the RING domain prevents TRIM32 auto-
ubiquitination, as this is the site of E3 ligase activity (Figure 31A). Also, no 
background ubiquitination was seen in the unrelated control (Figure 31A, lane 2) or 
in TRIM2 (Figure 31A, lane 1), reinforcing that the ubiquitination levels detected on 
TRIM32 wt were due to auto-ubiquitination. 
When comparing the effect of the disease mutants mentioned previously on the 
ubiquitin levels of TRIM32, different patterns of ubiquitination can be seen (Figure 
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31B). TRIM32 wt and P130S (Figure 31B, lanes 2-3) show a single band at the lower 
molecular weight that is not present in R394H, D487N or ∆588 (Figure 31B, lanes 4-
6). This band correlates to the second band seen on the baits and is also indicative 
of mono- ubiquitination as the band shift correlates to ~8.5kDa. This suggests that 
the wildtype (wt) and BBS mutant mono-ubiquitinate TRIM32, whereas mutations 
from LGMD2H abrogate the mono-(auto)-ubiquitination of TRIM32. We then 
proceeded to explore whether RAP2 could modulate this effect, and whether this 
modulation was also mutation dependent.  
RAP2 V12 variably effects auto-ubiquitination of TRIM32 
mutants 
In order to determine whether the RAP2-TRIM32 interaction plays a role in the 
modulation of TRIM32-dependent ubiquitination, HEK-293T cells were transiently 
transfected with TRIM32 wt or mutants either with or without RAP2 V12. GST-
TRIM32 was purified with glutathione beads and associated HA-ubiquitin measured 
with by Western blotting using an anti-HA- antibody. 
 
 
Figure 32: Effect of RAP2 V12 on TRIM32 mutant auto-ubiquitination: Results 
demonstrate variation in the ubiquitination levels. The TRIM32 R394H and D487N 
mutants show longer ubiquitin bands, indicating more ubiquitin molecules associated 
with the proteins, however, the bands are less intense than the TRIM32 wt and P130S 
mutants. Once again, TRIM32 ∆RING and C23A mutants do not show ubiquitination. 
HEK-293T cells were co-transfected with HA-Ub, GST-TRIM32 wt or mutants, with or 
without Flag-RAP2 V12 as specified. Lysates were taken on day 3 and samples were 
pulled-down using Glutathione-beads. Proteins were separated using SDS-PAGE gel and 
transferred to PVDF membrane. Protein levels were detected using HA- antibody. Shoc2 
constructs were used as an unrelated control. 
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Here again, we can see auto-ubiquitination of TRIM32 but no ubiquitination in the 
control lane (Figure 32, lanes 1 and 2) but only when the TRIM32 RING domain was 
intact, i.e. ubiquitination was impaired on ΔRING and C23A mutants (Figure 32, 
lanes 3-18). Looking at the remaining samples, we can again identify stronger bands 
in the wt and P130S mutants (lanes 3-4 and 5-6, respectively), and the weaker 
bands seen in R394H, D487N and Δ588 mutants (Figure 32; lanes 7-8, 9-10, and 11-
12, respectively). In all cases, the presence of RAP2 noticeably reduced the level of 
ubiquitin detected, even with the mutations where we have disrupted the TRIM32-
RAP2 interaction. For the R394H and D487N mutants (Figure 32, lanes 8 and 10, 
respectively), the TRIM32 auto-ubiquitination is almost completely reversed, while 
∆588 shows an intermediate effect (Figure 32, lane 11). This could somehow link 
back to the fact that the ∆588 mutant disrupts the TRIM32-RAP2 interaction only 
partially, and not as much as the other LGMD2H mutants (Figure 27). This suggests 
that the RAP2 effect on the auto-ubiquitination of TRIM32 is independent of the 
RAP2-TRIM32 interaction that was shown previously. 
Although we do not see the same pattern as Figure 31B, the GST-tag was used, 
adding 26kDa to the protein size. As a result, it is likely that the 8.5kDa shift from 
the mono-ubiquitination is no longer distinguishable from the ubiquitination smear. 
Effect of RAP2 on MINK, TNIK and NIK TRIM32-dependent 
Ubiquitination 
To test the possibility that RAP2 could modulate the ability of TRIM32 to 
ubiquitinate other RAP2 effectors within the same signalling complex, triple 
transfections were done in which the ability of TRIM32 to ubiquitinate other 
proteins was measured in the absence or presence of RAP2 (Figure 33). 
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A) B) 
 
 
 
 
C) Figure 33: RAP2 modulates the TRIM32 
dependent ubiquitination of mNIK, TNIK and 
MINK1. Overexpression of TRIM32 wt and RAP2 
wt, V12 (active) mutant and RAP2 V12A38 
(defective effector domain) mutant, with either 
A) mNIK, B) TNIK, C) MINK1 were used to assess 
the effect on TRIM32 dependent ubiquitination 
of mNIK, TNIK and MINK1 respectively. A) 
TRIM32 is required for ubiquitination to be 
detected and co-expression of RAP2 V12 reduces  
this effect. B) TRIM32 is required for ubiquitination to be detected. Co-expression of RAP2 wt 
slightly enhances the TRIM32-dependent TNIK ubiquitination, however, the expression of RAP2 V12 
and RAP2 V12A38 reduces the TRIM32 dependent ubiquitination of TNIK. C) TRIM32 enhances the 
ubiquitination of MINK above background ubiqutination is detected. 
2w = RAP2 wt, 2v = RAP2 V12, 2va = RAP2 V12A38 
 
TRIM32 stimulates and the constitutively active form of RAP2 () noticeably reduced 
the level of TRIM32-mediated ubiquitination of NIK (RAP2 V12, Figure 33A, lane 4, 
lane 3), although still above the levels seen in the absence of TRIM32 (lanes 1 and 
2). Apparently, NIK ubiquitination was also TRIM32 dependent (Figure 33A). 
While TNIK and MINK1 ubiquitination clearly increased in the presence of TRIM32 
(Figure 33B-C, lanes 5-8), the addition of RAP2 V12 reduced these ubiquitination 
levels (Figure 33B-C, lane 7). In clear contrast, the addition of RAP2 wt stimulates 
the TRIM32-mediated ubiquitination of TNIK and MINK (Figure 33B-C, lane 6), 
suggesting that the preferential binding of TNIK and MINK to RAP2 wt is relevant to 
their ubiquitination by TRIM32. 
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The TRIM32 dependent ubiquitination of RalGDS, RGL and 
RGL2 is modulated by RAP2 V12 
Subsequently, TRIM32 dependent ubiquitination of the RAP2 effectors RalGDS, RGL 
and RGL2 was assessed and the effect of RAP2 evaluated. 
A) B) 
  
C)  
 
Figure 34: RAP2 modulates the TRIM32 
dependent ubiquitination of RalGDS, RGL and 
RGL2. Overexpression of TRIM32 wt and RAP2 wt, 
V12 (active) mutant (+), with either A) RalGDS, B) 
RGL, C) RGL2 was used to assess the effect on 
TRIM32 dependent ubiquitination of these RAP2 
effectors. A-C) TRIM32 enhances ubiquitination, 
while RAP2 V12 overexpression altered the Ub 
distribution. B) RAP2 V12 co-expression increased 
the level of TRIM32-dependent RGL ubiquitination. 
 
The ubiquitination of RalGDS, RGL and RGL2 is stimulated in the presence of TRIM32 
(Figure 34A-C, lanes 3 and 4). Addition of RAP2 V12 decreased the level of TRIM32-
dependent ubiquitination of RalGDS but increased the TRIM32-dependent 
ubiquitination of RGL with no detectable effect on RGL2 (Figure 34, lanes 3 and 4).  
TRIM32 dependent ubiquitination of RIN1 and RIN2 
Having demonstrated RIN protein interaction with both RAP2 and TRIM32; the 
effect of these on RIN ubiquitination was then assessed by overexpressing RIN1 or 
RIN2, with or without TRIM32, plus or minus various RAP2 mutants, as indicated. 
These samples were transiently transfected and lysates taken after 48h, and 
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immunoprecipitated by the Flag-tagged RIN protein. Ubiquitination levels were 
detected using the HA-ab, for the HA-tag on the ubiquitin protein. 
A) B) 
  
C)  
 
Figure 35: RAP2 modulates the TRIM32 
dependent ubiquitination of RIN1, RIN2α and 
RIN2β in a substrate specific manner. 
Overexpression of TRIM32 wt and RAP2 wt, 
RAP2 V12 (active) mutant and RAP2 V12A38 
(defective effector domain) mutant, with 
either A) RIN1, B) RIN2α, and C) RIN2β were 
used to assess the effect on TRIM32 
dependent ubiquitination of these RAP2 
effectors. 
A-B) TRIM32 enhanced ubiquitination, while RAP2 wt and mutants effected the distribution of the 
Ub band, C) TRIM32 slightly increased the ubiquitination of RIN2β which was further enhanced by 
co-expression of RAP2 V12. 
2w = RAP2 wt, 2V = RAP2 V12, 2VA = RAP2 V12A38 
 
RIN1 showed some basal levels of ubiquitination in the absence of TRIM32 and 
RAP2 (Figure 35A, lane 1), which was abrogated by the addition of RAP2 V12 (Figure 
35A, lane 2). Addition of TRIM32 wt dramatically increased (Figure 35A, lanes 3 and 
4), whereas RAP2 V12 had little to no effect on the level of ubiquitination (Figure 
35A, lane 4). These findings show that the TRIM32-independent ubiquitination of 
RIN1 is decreased by RAP2 overexpression. RAP2 expression has no effect on the 
TRIM32-dependent ubiquitination (Figure 35A). 
RIN2α ubiquitination required TRIM32 wt (Figure 35B, lanes 5-8) and was increased 
in the presence of RAP2. Interestingly, despite RIN2α interaction with RAP2 being 
shown to occur in an activation- and effector domain dependent manner, RAP2 wt 
showed stronger ubiquitination of RIN2α than RAP2 V12 (Figure 35B, lane 6-7). 
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Similarly, RIN2β ubiquitination also increased in the presence of TRIM32 and RAP2 
V12 (Figure 35C).  
The TRIM32 Dependent Ubiquitination of PIAS2 and PIAS3 is 
altered by the presence of RAP2 and is disrupted by the TRIM32 
D487N mutant 
The effect of TRIM32 and RAP2 on the ubiquitination of PIAS2 and PIAS3, published 
effectors of RAP2, was then determined by overexpressing TRIM32 wt or D487N 
mutant and RAP2 V12 in HEK-293T cells. 
A) B) 
  
 
Figure 36: RAP2 alters the TRIM32 dependent ubiquitination of PIAS1 and PIAS2. 
Overexpression of TRIM32 wt and RAP2 wt, V12 (active) mutant and RAP2 V12A38 
(defective effector domain) mutant, with either A) PIAS2, B) PIAS3 were used to 
assess the effect on TRIM32 dependent ubiquitination of these RAP2 effectors. A-
B) TRIM32 is required for ubiquitination to be detected, while RAP2 V12 effects 
the distribution of the Ub band. A) Overexpression with the TRIM32 D487N 
mutant does not result in ubiquitination of PIAS2 (data not available for PIAS3). 
2w = RAP2 wt, 2v = RAP2 V12, 2va = RAP2 V12A38, DN = TRIM32 D487N mutant 
 
In PIAS2 and PIAS3 the presence of TRIM32 wt increases the level of ubiquitination 
of the respective proteins (Figure 36, lanes 3 and 4). In PIAS2 this effect is abrogated 
when TRIM32 D487N is used (Figure 36, lanes 5 and 6) (data not available for 
PIAS3). This suggests that TRIM32 D487N is unable to induce TRIM32-dependent 
ubiquitination of PIAS2. RAP2 V12 had little effect on the ubiquitination of PIAS2 or 
PIAS3 Figure 36A-B).  
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Inconclusive data on the effect of RAP2 and TRIM32 on protein 
ubiquitination 
Due to previous data (shown above) and information derived from the literature, 
several other interactions were also tested to assess the effect of RAP2 on their 
TRIM32 dependent ubiquitination. Unfortunately due to bait issues (Figure 37) and 
problems with reproduceability (Figure 38), we were unable to draw conclusions 
from this data, but these have been included below.  
A) B) 
 
 
 
C) Figure 37: Undetectable bait expression 
prevents an assessment of the effect of RAP2 
and TRIM32 on protein ubiquitination. 
Overexpression of TRIM32 wt and RAP2 V12 
(active) mutant with either A) PIAS1, B) PIAS4, 
and C) p85α were used to assess the effect on 
TRIM32 dependent ubiquitination of these RAP2 
effectors. However, due to the undetectable 
bait expression, it is not possible to determine 
whether the differences in ubiquitination levels 
are a biological effect or a result of loading 
differences. 
DN = TRIM32 D487N mutant  
 
Overexpression of TRIM32 wt and RAP2 V12 (active) mutant with either A) PIAS1, B) 
PIAS4, and C) p85α were used to assess the effect on TRIM32 dependent 
ubiquitination of these RAP2 effectors (Figure 37). However, due to the 
undetectable bait expression, it is not possible to determine whether the 
differences in ubiquitination levels are a biological effect or a result of loading 
differences. 
Furthermore, an assessment of the effect of TRIM32 on the ubiquitination of p85β, 
AGO and MYC also yielded inconclusive results due to the variability in the 
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ubiquitination detection patterns (Figure 38), suggesting that the ubiquitination of 
these proteins is very sensitive to variation. 
A) B) 
  
C)  
 
Figure 38: Quadruple transfections to assess the 
effect of RAP2 on the TRIM32-dependent and 
the TRIM32-independent ubiquitination of A) 
p85β, B) AGO and C) MYC. It was not possible to 
draw any conclusions from these experiments 
due to the variability in the levels of 
ubiquitination detected. 
 
Effect of TRIM32 mutations on RIN2α Ubiquitination 
Subsequently, the effect of different TRIM32 mutants on RIN2α ubiquitination 
levels was assessed. RAP2 V12 was also tested to ascertain whether it modulates 
the TRIM32 dependent ubiquitination of RIN2α and whether this modulation is 
affected by the TRIM32 mutants. 
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Figure 39: RAP2 modulates 
the TRIM32 mutant 
ubiquitination of RIN2α. 
Overexpression of TRIM32 
wt and mutants, with or 
without RAP2 V12, with 
RIN2α, was used to assess 
the effect of RAP2 V12 on 
TRIM32 mutant 
ubiquitination of RIN2α. 
+ = RAP2 V12, C23A = disrupts RING domain E3 ligase activity, P130S = mutation in BBS, D487N, 
∆588, R394H = LGMD2H mutations. 
 
Again, not surprisingly, we see that the disruption of the RING domain via a C23A 
mutation disrupted the TRIM32-dependent ubiquitination of RIN2α (Figure 39, 
lanes 1-2). The addition of TRIM32 increased RIN2α ubiquitination, with a greater 
effect seen with the wt than the disease mutants (Figure 39, lanes 3-12). This effect 
is further enhanced in the presence of RAP2 V12 (Figure 39, lanes 4, 6, 8, 10 and 
12), by varying degrees depending on the mutant, suggesting that the TRIM32-
dependent ubiquitination of RIN2α is enhanced by RAP2 V12. Notably, the RAP2 
V12-dependent increase in ubiquitination is abrogated when the TRIM32 D487N 
mutation is present and, to a lesser extent, is partially disrupted in the presence of 
the R394H and ∆588 mutations (Figure 39, lanes 7-12).  
Summary 
We demonstrated that TRIM32 enhances the level of RAP2 ubiquitination, 
indicating that as a result of its direct interaction with TRIM32 RAP2 activity could 
also be regulated by TRIM32. RAP2 ubiquitination by Nedd4-1 has been previously 
shown to control the function of RAP2A by perturbing interactions between GTP-
bound RAP2A and downstream targets (Kawabe, Neeb et al. 2010), this suggests 
that the TRIM32 ubiquitination of RAP2 may be regulating it’s downstream effects 
on the putative effectors we have identified above.  
Our data suggests that the TRIM32 disease mutantations affect the degree to which 
TRIM32-dependenent ubiquitination occurs, demonstrated by the varying degrees 
to which ubiquitin is immunoprecipitated by these overexpressed constructs. The 
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TRIM32 wt and BBS mutant show TRIM32 ubiquitination at a lower band by western 
blot, possibly mono-ubiquitination, this is not detected in the LGMD2H mutants. 
Additionally, GST-coomassie we detected laddering that correlated to 
ubiquitination. This could be mono-, di- and tri- ubiquitination or mono-
ubiquitination at multiple sites, although the nature of the ubiquitination was not 
investigated further. 
TNIK and MINK1 ubiquitination clearly increased in the presence of TRIM32 (Figure 
33), and the additional expression of the RAP2 V12 reduced these ubiquitination 
levels. However, the addition of RAP2 wt stimulates the ubiquitination of TNIK and 
MINK even further. TNIK and MINK binding to RAP2 wt is much stronger than to 
RAP2 V12, and RAP2 wt enhances the ubiquitination of TNIK and MINK. This 
suggests that the preferential binding of TNIK and MINK to RAP2 wt is relevant to 
their ubiquitination state and the inability or weak binding to RAP2 V12 reduces the 
ubiquitination of TNIK and MINK, possibly duw to RAP2 targetting the ubiquitination 
to another effector with a higher affinity to RAP2 V12. The ubiquitination of RalGDS, 
RGL and RGL2 all required the presence of TRIM32, while RAP2 V12 enhanced the 
ubiquitination of RGL (Figure 34). As RalGDS, RGL and RGL2 all interact more 
strongly with RAP2 V12 than wt, this supports the possibility that stronger 
interaction with RAP2 enhances the ubiquitination of protein.  
Having demonstrated RIN protein interaction with both RAP2 and TRIM32; the 
effect of these on RIN ubiquitination was then assessed. RIN1 showed some basal 
levels of ubiquitination in the absence of TRIM32 and RAP2 which were no longer 
detected on the overexpression of the RAP2 V12 construct. Addition of TRIM32 wt 
dramatically increased, whereas RAP2 V12 decreased the level of ubiquitination 
(Figure 35). 
RIN2α ubiquitination required TRIM32 wt and was increased in the presence of 
RAP2. RAP2 wt showed stronger ubiquitination of RIN2α than RAP2 V12, despite 
RIN2α interaction with RAP2 being shown to occur in an activation- and effector 
domain dependent manner. Similarly, RIN2β ubiquitination also increased in the 
presence of TRIM32 and RAP2 V12 (Figure 35). 
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The overexpression of TRIM32 was shown to increase RIN2α ubiquitination (Figure 
39), with a greater effect seen with the wt than the disease mutants (Figure 39). 
This effect was further enhanced in the presence of RAP2 V12 (Figure 39), by 
varying degrees depending on the mutant. This suggests that the TRIM32 and RAP2-
dependent increase in ubiquitination levels is affected and/or disrupted by the 
TRIM32 mutants. Notably, the RAP2 V12-dependent increase in ubiquitination is 
partially disrupted when the TRIM32 D487N mutant is used (Figure 39), which 
would be expected as we have previously shown that it no longer interacts with 
RAP2 V12 (Figure 39). 
In PIAS2 and PIAS3 the presence of TRIM32 wt increases the level of ubiquitination 
of the respective proteins. In PIAS2 this effect is abrogated when TRIM32 D487N is 
used (data not available for PIAS3). This suggests that TRIM32 D487N is unable to 
induce ubiquitination of PIAS2, possibly linked to its inability to interact with RAP2 
V12 (Figure 36). 
For some of the experiemental systems (e.g. Figure 38) there was a lot of variations 
in the expression levels seen and the effect of RAP2 on the TRIM32 modulated 
ubiquitination. This could be a result of many factors such as experimental 
sensitivity. In order to reduce the variation, upscaling the experiment to use more 
sample could reduce the margin for error and thus any variability that may have 
been introduced into the system.  
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Chapter 7: The Effect of TRIM32 
and RAP2 on Cellular Kinetics 
Localisation 
In the literature, RAP2 has been shown to localise primarily in the recycling 
endosomes, as well as the Golgi and plasma membrane (Uechi, Bayarjargal et al. 
2009; Gloerich, ten Klooster et al. 2012), whereas TRIM32 localisation has been 
demonstrated in cytoplasmic bodies, often around the nucleus (Locke, Tinsley et al. 
2009).  
RAS family GTPases are known to regulate the function of at least some of their 
effectors by recruiting them, upon activation, to specific membrane compartments 
and/or signalling complexes. For example, H/K/NRAS activate RAF kinases by 
recruiting them to the plasma membrane microdomains where other activating 
steps then take place (McKay and Morrison 2007). Similarly, MRAS recruits the 
SHOC2-PP1 complex to regulate the activity of RAF kinases at specialised signalling 
complexes (Rodriguez-Viciana, Oses-Prieto et al. 2006). We speculated that by 
analogy with other GTPases of the family, RAP2 may recruit TRIM32 to specific 
complexes at some membrane compartment upon activation. In order to test this, 
we first set out to investigate the localisation of both RAP2 and TRIM32 in several 
cell types to set the stage for potential co-localisation studies. 
RAP2 localisation in HMLE and U2OS cells 
By transducing the cells with overexpressed YFP-tagged proteins and fixing cells as 
described in the methods section, the localisation of RAP2 and TRIM32 was 
examined in various cell lines. Initial experiments were conducted in human 
mammary epithelial HMLE cells (Elenbaas, Spirio et al. 2001) (Figure 40). 
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A) HMLE   
 
Figure 40: RAP2 wt 
localisation in HMLE 
and U2OS cells. 
Cells were 
transduced with 
YFP-tagged RAP2 as 
described in the 
methods section 
and images were 
taken of live cells 
immediately after 
selection. In both 
HMLE and U2OS 
cells, RAP2 localises 
predominantly at 
the plasma 
membrane and 
appear enriched at 
areas of cell-cell 
contact. RAP2 = 
green. A) HMLE, B) 
U2OS. 
B) U2OS  
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YFP-RAP2 localises predominantly at the plasma membrane and appears enriched 
at areas of cell-cell contact in both HMLE cells and U2OS cells (Figure 40A-B). This 
appearance of a higher concentration of RAP2 may also be a result of seeing the 
more plasma membrane being visualised from above. This is in clear contrast to the 
results of Uechi et al showing predominant endosomal and Golgi localisation in 
COS-1 (monkey kidney tissue) cells (Uechi, Bayarjargal et al. 2009), suggesting the 
possibility of tissue dependent localisation. 
RAP2 wt and mutant localisation in U2OS osteosarcoma cells 
The localisation of YFP-RAP2 wt and mutant proteins was assessed in fixed U2OS 
osteosarcoma cell lines that were costained for actin (Phalloidin-red) and Hoechst 
nuclear staining (Figure 41). 
RAP2 wt RAP2 V12  
 
Figure 41: Localisation of 
RAP2 and TRIM32 in 
U2OS cells. U2OS cells 
were transduced with 
YFP-tagged 
overexpression constructs 
(green) and subsequently 
fixed and immunostained 
with Hoechst (blue) and 
Phalloidin (red). RAP2 
expression is highest at 
areas of cell-cell contact. 
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Looking at the U2OS RAP2 wt and V12 staining, we can see higher concentrations of 
RAP2 at areas of cell-cell contact, indicating localisation to the cell membrane. 
Contrary to the HMLEs, no perinuclear staining is seen (Figure 41). 
RAP2 localisation in mouse myoblast cells 
Due to the suggested involvement of the RAP2-TRIM32 interaction in LGMD2H, the 
localisation of RAP2 was investigated in the C2C12 mouse myoblast cell line.  
RAP2 
wt 
 
RAP2 
V12 
RAP2 
N17 
 
Figure 42: RAP2 localisation in mouse myoblast cell line. C2C12 cells were transduced with 
YFP-tagged protein using lentivirus and fixed after selection. RAP2 wt and V12 localises to 
areas of cell-cell contact as before, but higher levels are also expressed in the perinuclear 
region. RAP2 = green, Hoechst = Blue, Phalloidin = Red. 
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In the C2C12 cells, YFP-RAP2 wt and V12 localises to the plasma membrane in some 
cells as seen with U2OS and HMLE cells. However in this cell type much more 
prominent perinuclear staining consistent with Golgi/ER localisation is observed, 
although due to lack of time it was not possible to perform Golgi/ER counterstains 
to confirm this. Distinct dots and/or vesicles are seen in some cells which is 
consistent with the endosomal localisation reported by Uechi et al (Uechi, 
Bayarjargal et al. 2009; Gloerich, ten Klooster et al. 2012). 
TRIM32 localisation in osteosarcoma and myoblast cells 
In addition to RAP2 localisation, the localisation of TRIM32 wt cells was determined 
in osteosarcoma and myoblast cells. 
U2OS 
 
C2C12 
 
Figure 43: TRIM32 localisation in U2OS cells and C2C12 cells. U2OS and C2C12 cells, as 
indicated, were infected with YFP-tagged TRIM32 lentivirus, and cells were fixed after selection. 
TRIM32 staining is predominantly in the cytosol, around the nucleus. TRIM32 = Green, Hoechst = 
Blue, Phalloidin = Red. 
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In both U2OS and C2C12 cells, TRIM32 shows punctate staining in the cytosol, 
mainly clustering around the nucleus (Figure 43). This is consistent with the 
reported localisation of TRIM32 in cytoplasmic bodies, often around the nucleus 
(Locke, Tinsley et al. 2009). 
Proliferation, Motility and Differentiation 
The literature has stated that increased TRIM32 expression can lead to an increase 
in proliferation, transformation and cell motility via Abi in Hep2 cells (Kano, 
Miyajima et al. 2008) and that an increase in RAP2 expression can decrease cell 
spreading in HEK-293T cells (Uechi, Bayarjargal et al. 2009). Additionally, mutations 
in TRIM32 found in LGMD2H, a disease involving the degeneration of muscles, 
disrupt the TRIM32 interaction with RAP2. In order to better understand the role of 
this interaction on a cell type more relevant to muscle biology, we focused on the 
C2C12 mouse myoblast. C2C12 cells are a subclone (produced by Blau, Pavlath et al. 
1985) of the C2 mouse myoblast cell line established by D. Yaffe and O Saxel (Yaffe 
and Saxel 1977). C2 cells originate from 2-month-old normal mouse thigh muscle, 
70h after crush injury. The C2C12 cell line differentiates rapidly, forming contractile 
myotubes and producing characteristic muscle proteins. 
Effect of RAP2 and TRIM32 on proliferation of C2C12 cells  
Lentiviral transduction was used to stably overexpress constructs of interest in 
C2C12 cells (as described in the methods section) and cells were the manually 
counted and seeded in duplicate in 24 well plates. These were then placed into the 
IncuCyte FLR Live Cell Imaging System (Essen Bioscience) that can be used to follow 
kinetic cell proliferation, quantify cell migration and record changes in cell 
morphology. The IncuCyte system allows you to place a microscope inside your 
incubator, enabling around-the-clock kinetic imaging without the need to move and 
disturb cells from the controlled environment. It uses a proprietary imaging 
methodology to acquire phase-contrast images in multi-well plates and a 
confluence-based algorithm as a surrogate for cell number. Readings were taken 
measuring percentage confluence at regular intervals until plates reached 
confluence. 
138 
 
 
A) 
 
B) 
 
 
Figure 44: Effect of RAP2 and TRIM32 on proliferation of C2C12 cells. C2C12 cells were infected 
with the indicated lentiviral constructs and growth curves generated using the IncuCyte system, 
Pictures were taken every 2h with each data point being a composite of 4 different images. A and B 
show independent experiments. In both instances RAP2 N17 overexpression leads to increased cell 
proliferation. TRIM32, RAP2 wt and V12 did not show any consistent effect on the proliferation of 
C2C12 cells. 
 
Figure 44A and 1B show the data from independent experiments for C2C12 cells 
with control and TRIM32 wt, RAP2 wt, RAP2 V12 and RAP2 N17 overexpression. 
Looking at the initial slope of the curve, it appears as though there may be a slight 
increase on the rate of proliferation when RAP2 N17 is overexpressed, indicating 
that RAP2 plays a role in regulating proliferation. Although our preliminary 
experiments do not show an effect of TRIM32 on proliferation, Kano et al. have 
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demonstrated that overexpression of TRIM32 in NIH3T3 cells using retroviral 
transduction significantly increased cell growth as compared to mock transfected 
and mutant TRIM32 S651A (Kano, Miyajima et al. 2008). NIH3T3 cells naturally 
express TRIM32. It has been shown in the literature that TRIM32 S651A mutant is 
unable to bind 14-3-3, whereas it has been identified as a potential TRIM32 effector 
in our more recent TAP experiments (data above). The work of Ichimura et al., 
confirmed that its overexpression could not illicit the cell growth activity, suggesting 
that 14-3-3 binding is important for regulating the function of TRIM32 (Ichiumura 
2014). 
Overexpression of RAP2 has no effect on U2OS wound healing 
In order to assess the effect of overexpressed RAP2 on migration, we used stably 
infected cells, as described in the methods section. These cells were then grown to 
confluence and scratched using a wound-maker tool (Essen Biosciences) designed 
to generate consistent and precise wounds on multiwell plates (Figure 45). 
Looking at the effect of overexpressed RAP2 wt and RAP2 N17 on wound closure on 
the plotted data (Figure 45A) there does not appear to be a difference on the rate 
of migration. Similarly, comparing the wound mask from 30 h, a similar level of 
closure can be seen (Figure 45, middle row). This is visualised more clearly by the 
‘final mask’ (Figure 45B, bottom row). Unfortunately the data is not available for 
TRIM32. 
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Figure 45: Effects on migration. Confluent wells of U2OS cells infected with control, RAP2 wt or RAP2 N17 
were scratched and wound closure tracked using the Incucyte system. The Incucyte comes with a wound-
making tool to generate consistent and precise wounds on multiwell plates. By computing the initial 
wound mask and using a similar methodology as for kinetic growth assays, the Incucyte tracks and 
quantifies wound closure. No difference in migration was seen in the U2OS cell line. 
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Effect of RAP2 and TRIM32 wt overexpression on myogenic 
differentiation 
Skeletal muscle differentiation is a highly coordinated multistep process in which 
mononucleated myoblasts first withdraw from the cell cycle in response to 
extracelluar cues, differentiate into post-mitotic myocytes (early differentiation), 
and subsequently fuse into multinucleated myotubes (late differentiation) which 
finally bundle to form mature muscle fibres (terminal differentiation). This process 
is elaborately controlled by various regulatory factors. Given that the RAP2-TRIM32 
interaction is linked to LGMD2H, where muscle weakness and atrophy is caused by 
mutations of TRIM32, and that TRIM32 is involved in the regulation of 
differentiation and self-renewal in neural progenitor cells and that in the absence of 
TRIM32 myogenic differentiation is disrupted (Schwamborn, Berezikov et al. 2009; 
Nicklas, Otto et al. 2012), we wanted to assess whether an effect can be detected 
on the differentiation of muscle cells when overexpressing these proteins. 
To determine whether RAP2 and TRIM32 play a role in myogenic differentiation, we 
used lentiviral transduction of Trim32, RAP2 wt, RAP2 V12 (active) and RAP2 N17 
(dominant-negative) constructs and monitored morphological differences during 
cell differentiation (Figure 46). 
Upon the differentiation of C2C12 control cells, we can see that the cells have 
begun to fuse together to form thick, elongated tubules, distinct from the 
surrounding packed cells (Figure 46, row 1). On longer incubation with the fusion 
media, more of these can be seen. 
Little effect was seen upon overexpression of RAP2 wt and V12 (Figure 46, row 2 
and row 3), although there are occasional shorter, fatter cells that can be seen such 
as in the middle panel, which appear to be cells that are differentiating but unable 
to elongate. Strikingly RAP2 N17 overexpression results in a dramatic decrease in 
the number of myotubes observed. Cells appear flat and have lost their elongated 
shape (Figure 46, row 4).  
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Figure 46: RAP2 N17 inhibits differentiation of C2C12 cells. C2C12 myoblasts were 
transduced with control, RAP2 wt or TRIM32 wt. These were selected using puromycin 
selection and reseeded upon complete selection and changed to fusion media. Top row – 
C2C12 cells show formation of myotubes. Second and third row – RAP2 wt and V12 cells 
show normal myotube formation combined with the formation of shorter myotubes. Forth 
row – RAP2 N17 overexpression inhibits microtubule formation. Bottom row – TRIM32 wt 
overexpression may enhance microtubule formation. 
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Slightly enhanced muscle cell fusion was observed with exogenous TRIM32 (Figure 
46, row 5). Although it would be necessary to quantify this in order to be certain 
whether this difference is significant, this supports previous findings that TRIM32 
inhibition inhibits myogenic differentiation (Schwamborn, Berezikov et al. 2009; 
Nicklas, Otto et al. 2012). 
Summary 
RAP2 localisation varies in different cell lines. In HMLE and U2OS cells the 
localisation is predominantly in areas of cell-cell contact whereas in C2C12 cells 
localisation is both at the plasma membrane and perinuclear region, possibly the 
Golgi. Interestingly, disruption of RAP2 activation through the dominant-negative 
mutant (N17) results in stronger perinuclear/Golgi localisation suggesting that the 
localisation of RAP2 and its trafficking between Golgi and plasma membrane may be 
linked to its activation state.  
TRIM32 in U2OS and C2C12 gives a punctate staining consistent with vesicular 
localisation, concentrating to a region near the nucleus consistent with Golgi 
staining. From which it can be inferred that TRIM32 is either being transported or 
involved in transport, and is being processed in the Golgi. It is, of course possible 
that high levels of overexpression are resulting in the overexpressed protein being 
aggregated in vesicles. In order to overcome that it would be necessary to test 
different vector promoters in order to see whether there is a difference between 
high level and low level expression of TRIM32 or look at immunofluorescence with 
endogenous TRIM32. 
In C2C12 myoblast cells RAP2, in addition to the plasma membrane localisation seen 
with U2OS and HMLE cells, gave a very distinct Golgi and vesicular staining that was 
not observed in other cell types such as U2OS and HMLE cells. This suggests that 
RAP2 may localise to different membrane compartments in a cell-type (and likely 
context) dependent manner.  
Because of lack of time I was unable to successfully perform co-expression and co-
localisation studies and test for example the possibility that active RAP2 may 
translocate TRIM32 to the plasma membrane in HMLE or U2OS cells.  
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In C2C12 cells both RAP2 and TRIM32 localise to dots concentrated around the 
Golgi. Interestingly, this Golgi-like localisation is more prominent in the case of 
RAP2 N17 suggesting the activation cycle of RAP2 may be involved in its transport 
between the plasma membrane and other endomembrane compartments. 
Although because of lack of time I was unable to perform the experiments to see if 
RAP2 and TRIM32 co-localise in C2C12 cells, these cell-type specific observations 
are consistent with a specific role for the RAP2-TRIM32 interaction in muscle cell 
biology. 
RAP2 N17 consistently demonstrates an increase in proliferation and inhibits 
differentiation of C2C12 cells. This would suggest that RAP2 plays a role in reducing 
proliferation and that this effect is reversed on introduction of the RAP2 dominant-
negative construct, perhaps sequestering the GEFs of the endogenous RAP2 and 
thereby abrogating endogenous RAP2 activation. Use of si- or shRNA knockdown of 
RAP2 would confirm this. More recent studies by Cohen et al. also suggest that 
over-expression of TRIM32 induces or enhances muscle atrophy and that this is 
linked, in part, to the expression and interaction with Plakoglobin (Cohen, et al. 
2014). Further experiments to assess the implications of this protein in our cell line 
both individually and in combination with TRIM32 and/or RAP2 could provide a 
further understanding of the developmental and degredational implications of our 
interaction. 
Overexpressing TRIM32 also appears to decrease proliferation slightly, although this 
is contrary to the results of (Kano, Miyajima et al. 2008) in NIH3T3 cells, where they 
showed a marked increase in proliferation on TRIM32 overexpression. 
Nevertheless, it is possible for TRIM32 to show different effects in different cell 
lines, especially in cell lines of different origins. 
No effect was seen on migration with overexpression of RAP2, despite what is 
stated in the literature (Uechi, Bayarjargal et al. 2009). However, Uechi et al used 
COS-1 cells which are from monkey kidney tissue, and this discrepancy could be a 
result of cell-type specificity. Therefore, repeating this experiment within our 
muscle cell model could yield further interesting results. Similarly, the role of 
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TRIM32 in cell motility has also been published in the literature and would be worth 
investigating in our model (Kano, Miyajima et al. 2008). 
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Chapter 8: Discussion of the 
TRIM32-RAP2 Interaction Studies 
Validating and Characterising RAP2-TRIM32 interactions 
In this work we have identified several novel putative binding partners for the 
protein RAP2. Of these, TRIM32 was selected for further investigation and this 
putative interaction was confirmed by assessing the association of endogenous 
TRIM32 with overexpressed mutant and wt RAP2 proteins in HEK-293T cell lines. 
TRIM32 was shown to interact specifically in a RAP2 activation- and effector 
domain-dependent manner. The data presented in Figure 20, demonstrates this 
specificity by comparing the interaction with closely related RAS family members 
that did not interact with TRIM32. Several other interactions that were identified in 
the RAP2-TAP assay were also validated in a similar manner. Of these VPS35, a 
scaffold protein in the cargo complex, was found to interact specifically with RAP2 
in an activation but non-effector domain-dependent manner suggesting that VPS35 
is not an effector of RAP2 but could be involved upstream of the RAP2. Although 
this interaction was not pursued further, subsequent data indicate that it may play 
a role in the RAP2-TRIM32 interaction, discussed below. 
Previously published RAP2 interactions with NIK, TNIK and MINK were also validated 
as above. However, contrary to what has been published in the literature (Taira, 
Umikawa et al. 2004; Nonaka, Takei et al. 2008), we saw preferential binding of 
these factors to the wild-type RAP2 when compared to the active RAP2 V12 and 
RAP2 L63 mutants. These findings suggest that the interaction may not be 
activation-dependent although it is effector domain-dependent as the A38 mutant 
disrupts the interaction. This could be due to preferential binding to the GDP bound 
conformation of RAP2 when compared to the GTP-bound. Alternatively, the RAP2 
V12 mutation may affect the interaction in a Guanine nucleotide independent 
manner. Nonanka et al used glutathione-Sepharose resin carrying GTPγS-bound, 
GDP-bound, or nucleotide-free forms of GST-RAP2A for their assays, which could 
explain the difference between the interaction data obtained. Furthermore, when 
specific TRIM32 mutants, which have been previously implicated in LGMD2H, were 
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tested (Schoser, Frosk et al. 2005; Saccone, Palmieri et al. 2008; Borg, Stucka et al. 
2009; Cossee, Lagier-Tourenne et al. 2009) the RAP2-TRIM32 interaction was 
disrupted whereas the binding of these mutants to MINK was not. This strongly 
suggests that the RAP2-TRIM32 interaction is functionally involved in the pathology 
of this disease. Despite demonstrating that RAP2 interacts with C-terminus of 
TRIM32, we have also shown that mutations in the N-terminal RING domain that 
abrogate the E3 ligase activity of TRIM32 disrupt its interaction with RAP2 but not 
with MINK (Figure 26). Again, this is interesting as it implies that although RAP2 is 
binding to the C-terminus of TRIM32, the RING domain activity is necessary for the 
interaction between RAP2 and TRIM32. As the effector domain-dependent nature of 
the interaction suggests that RAP2 functions upstream of TRIM32, it is possible that 
RAP2 controls downstream effects of TRIM32, such as ubiquitination. It has also 
been shown that RING E3 activity can be controlled by binding partners, e.g. Cand1 
binds to Cullins and sequesters them in an inactive state (Liu, Furukawa et al. 2002; 
Zheng, Yang et al. 2002). 
RAP2 modulation of TRIM32 interactions 
The experimental data obtained in Chapter 4: Assessing the Effect of TRIM32 
mutants demonstrate that RAP2 and TRIM32 share a number of binding partners, a 
schematic of these putative interactions is shown in Figure 47. While RAP2 V12 does 
not appear to affect the TRIM32 interaction with PIAS4, RIN2 or MINK, the NIK-
TRIM32 interaction was slightly inhibited in the presence of RAP2 V12 while RAP2 
wt abrogated the binding of NIK to TRIM32. As MINK, TNIK and NIK interact more 
strongly to RAP2 wt than the V12 mutant, it is possible that a similar disruption 
occurs in MINK and TNIK. Therefore, to follow up on this finding, future 
investigations would need to look at whether MINK and TNIK interaction with 
TRIM32 can be modulated by RAP2 wt. 
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Figure 47: Schematic of RAP2 and TRIM32 interactions. Demonstrating a clear overlap in the binding 
partners of RAP2 and TRIM32. Green = shown experimentally, Red = shown by TAP, Grey = shown in 
literature. 
 
Ubiquitination 
LGMD2H mutations disrupt TRIM32-dependent Ubiquitination  
This ability to selectively modulate the binding of TRIM32 to other proteins suggests 
a regulatory role for the RAP2. We demonstrated that TRIM32 enhances the 
ubiquitination of RAP2, ubiquitinating RAP2 wt to a greater degree than the active 
mutants RAP2 V12 and V12L63. Additionally, blocking the RAP2 effector domain via 
the RAP2 V12A38 or RAP2 L63A38 mutations decrease the TRIM32-dependent 
ubiquitination of RAP2 when compared to the levels of ubiquitination seen with 
RAP2 wt (Figure 30). We suggest that the ubiquitination activity of TRIM32 is 
relevant to LGMD2H as the characteristic laddering pattern seen on the TRIM32 wt 
and P130S baits is indicative of endogenous ubiquitination, as determined by 
western blot, is absent in TRIM32 R394H, D487N and ∆588 mutants which are 
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associated with the disease. These LGMD2H disease mutatants also disrupt the 
TRIM32 interaction with RAP2. From this we can infer that the ubiquitin pathway is 
disrupted by these mutants and that the ubiquitination function of TRIM32 may be 
linked to in the RAP2-TRIM32 association which is linked to LGMD2H. Therefore, we 
proceeded to examine the impact of RAP2 on TRIM32 mediated ubiquitination. 
Auto-ubiquitination of TRIM32 
E3 ligases have the ability to auto-ubiquitinate through their intrinsic E3 ligase 
activity, which can lead to self- degradation via the proteasome (Bell, Malyukova et 
al. 2012; Xie, Avello et al. 2012). Similarly, we have shown exogenous auto-
ubiquitination of TRIM32, with those mutations associated with LGMD2H altering 
the degree of auto-ubiquitination. The TRIM32 wt and BBS mutants show a singe 
ubiquiting band below the ubiquitin smear, which correlates approximately to 
mono- or di-ubiquitination of TRIM32, whereas upon the introduction of the 
LGMD2H mutations, R394H, D487N and ∆588, this band is no longer detectable. 
When observing the effect of RAP2 on the auto-ubiquitination of TRIM32, it was 
observed that in all cases the presence of RAP2 noticeably reduced the level of 
ubiquitin detected, even with the mutations where we have disrupted the TRIM32-
RAP2 interaction. For the R394H and D487N mutants (Figure 32), the TRIM32 auto-
ubiquitination is almost completely reversed, while ∆588 shows an intermediate 
effect (Figure 32, lane 11). This could somehow link back to the fact that the ∆588 
mutant disrupts the TRIM32-RAP2 interaction only partially, and not as much as the 
other LGMD2H mutants (Figure 27). This suggests that the RAP2 effect on the auto-
ubiquitination of TRIM32 is independent of the RAP2-TRIM32 interaction that was 
shown previously. 
Ubiquitination of TNIK, NIK and MINK 
It has recently been shown that RAP2 forms a complex with TNIK and NEDD4-1 that 
leads to the ubiquitination of RAP2, thereby inhibiting it’s function and regulating 
neurite growth and arborisation in mammalian neurons (Kawabe, Neeb et al. 2010). 
While Kawabe et al did not see any ubiquitination of TNIK, we have shown that 
RAP2 can modulate the E3 ligase activity of TRIM32 towards MINK, TNIK and NIK. 
Although the ubiquitination of TNIK and MINK1 clearly increased in the presence of 
TRIM32 and upon the addition of RAP2 V12, the addition of RAP2 wt increases the 
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ubiquitination of TNIK and MINK even further. This suggests that the preferential 
binding of TNIK and MINK to RAP2 wt may influence their ubiquitination state.  
PIAS ubiquitination by TRIM32 
We started to investigate other pathways that may be aberrant in LGMD2H using 
the TRIM32 mutants by testing the ubiquitination status of other published binding 
partners of TRIM32. PIAS family members function as small ubiquitin-like modifier 
(SUMO) proteins and their interaction with RAP2 has been published (Hershko and 
Ciechanover 1998; Hay 2005). When looking at the ability of TRIM32 to ubiquitinate 
PIAS2 and PIAS3, we have shown that TRIM32 wt increases the ubiquitination of the 
respective proteins. In PIAS2 this effect is abrogated when TRIM32 D487N is used 
(data not available for PIAS3). This suggests that TRIM32 D487N is unable to induce 
ubiquitination of PIAS2, suggesting a link to LGMD2H, the muscular dystrophy 
within which this mutation is prevalent. 
RIN protein ubiquitination by TRIM32 
RIN proteins are close relatives of RAS and have been shown to play a role in 
mediating neuronal differentiation (Hoshino, Yoshimori et al. 2005). Having 
reproduced the RIN interaction with RAP2 and demonstrated a novel interaction 
with TRIM32 (Figure 21, Figure 28); the effect of these on RIN ubiquitination was 
then assessed. RIN1 showed some basal levels of ubiquitination in the absence of 
TRIM32 and RAP2 which were abrogated by the addition of RAP2 V12. TRIM32 wt 
dramatically increased the ubiquitination of RIN when compared to an empty 
control, whereas RAP2 V12 had no effect on level of TRIM32-dependent 
ubiquitination. 
RIN2 ubiquitination also increased on overexpression of TRIM32 wt in HEK-293T 
cells. Despite the RIN2 interaction with RAP2 occurring in an activation- and effector 
domain dependent manner, RAP2 wt showed greater TRIM32-dependent 
ubiquitination activity towards RIN2 when compared to RAP2 V12. Also, when 
TRIM32 LGMD2H disease mutants, D487N, R394H, ∆588 are overexpressed, RIN2 
ubiquitination is only slightly increased when compared to non-TRIM32 transfected 
control, and although RAP2 V12 still increases RIN2 ubiquitination in the presence 
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of the LGMD2H mutants, this effect is much more subtle then that which is seen 
with TRIM32 wt and the P130S BBS mutant. 
From all these findings, we suggest a model whereby RAP2 recruits TRIM32 and 
effectors (MINK in the example below) and brings them into proximity in order that 
TRIM32 can ubiquitinate both the RAP2 and the effector but this interaction is not 
responsible for the modulation of TRIM32 auto-ubiquitination (Figure 48). While we 
have provided experimental data to demonstrate these interactions and effects on 
ubiquitination, we have not shown conclusively that these interactions are direct, it 
is possible that other intermediate proteins are involved in enabling the recruitment 
of these proteins. 
 
Figure 48: RAP2 may modulate TRIM32 dependent ubiquitination of downstream targets. We 
propose a model that RAP2 enhances TRIM32 dependent ubiquitination of MINK by acting as a 
bridge to bring the two proteins to close proximity, resulting in MINK and RAP2 ubiquitination. 
 
In order to get a better understanding of the type of ubiquitination taking place, ie 
mono-, di- or poly- ubiqtuitination, it would be useful to take advantage of selective 
ubiquitin mutants that can only bind to specific residues, e.g. K48 or K63 (kind gift 
from P.Meier), that we may understand whether these proteins are being targeted 
for degradation or activation for downstream effects or any number of cellular 
processes. 
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Localisation 
RAS family GTPases are known to regulate the function of at least some of their 
effectors by recruiting them, upon activation, to specific membrane compartments 
and/or signalling complexes. For example, H/K/NRAS activate RAF kinases by 
recruiting them to the plasma membrane microdomains where other activating 
steps then take place (McKay and Morrison 2007). Similarly, MRAS recruits the 
SHOC2-PP1 complex to regulate the activity of RAF kinases at specialised signalling 
complexes (Rodriguez-Viciana, Oses-Prieto et al. 2006). We speculated that by 
analogy with other GTPases of the family, RAP2, upon activation, may recruit 
TRIM32 to specific complexes at some membrane compartment. In order to test 
this, we first set out to investigate the localisation of both RAP2 and TRIM32 in 
several cell types to set the stage for potential co-localisation studies. 
TRIM32 transduced in U2OS and C2C12 cells localises to punctate vesicles, 
accumulating to a region near the nucleus, possibly to the Golgi. From which it can 
be inferred that TRIM32 is either being transported or involved in transport from 
endosomes to the trans-Golgi network, and is being processed in the Golgi. It is, of 
course possible that overexpression of TRIM32 is resulting in the exogenous protein 
being aggregated in vesicles. In order to investigate this it would be necessary to 
test different vector promoters or inducible promoters in order to determine if the 
effect of increasing levels of TRIM32 alters localisation, or to use 
immunofluorescence to determine the localisation of endogenous TRIM32. 
Exogenous RAP2 localisation varies in different cell lines. In U2OS cells the protein is 
predominantly found in areas of cell-cell contact whereas in HMLEs and C2C12 cells 
localisation is both in regions of cell-cell contact and in the area surrounding the 
nucleus, possibly the Golgi. However, in the C2C12 cells, the dominant-negative 
RAP2 N17 mutant demonstrates a cytosolic and nuclear distribution and was not 
detected in areas of cell-cell contact. 
With putative Golgi localisation for TRIM32 and RAP2 seen in C2C12 cells, 
overexpressing RAP2 wt and mutant proteins, or use of si- or shRNA to abrogate 
RAP2 expression could disrupt the localisation of TRIM32, which would indicate that 
RAP2 is responsible for TRIM32 localisation. Conversely, looking at the TRIM32 
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disease mutants previously used, would allow us to determine whether it is TRIM32 
that is sequestering the RAP2 protein in order to determine its localisation. 
Additionally, testing the mutants in the RING domain that disrupt TRIM32s E3 ligase 
activity would allow us to establish whether this is a ubiquitination dependent 
effect. 
Using Golgi counter-stain to demonstrate whether TRIM32 and RAP2 are co-
localised to the Golgi, as well as looking at the localisation of some proteins known 
to be involved in retrograde transport of proteins from endosomes to the trans-
Golgi network in order to determine whether they have an effect on the localisation 
of TRIM32 or RAP2, e.g. VPS35 and VPS29. VPS35 is a component of the retromer 
complex and is involved in retrograde transport of proteins from endosomes to the 
trans-Golgi network, areas to which we have seen RAP2 and TRIM32 localisation. 
Therefore, by examining whether co-localisation of VPS35 with RAP2 or TRIM32 is 
occurring, or whether the knockdown of VPS35 disrupts the localisation of RAP2 or 
TRIM32 to the Golgi, than this would support the involvement of RAP2 or TRIM32 in 
transport, either as mediators or as being transported. 
Proliferation and Migration 
TRIM32 mediates the ubiquitination of Abi2, resulting in enchanced proliferation 
and cell motility in HEK-293T and NIH-3T3 cells (Kano, Miyajima et al. 2008). 
Although in our model, we did not see a significant effect of TRIM32 on 
proliferation or motility, through further investigation into the biological role of 
TRIM32 by inhibiting TRIM32 using sh- or siRNA, or by overexpressing the LGMD2H 
disease mutants, R394H, D487N and ∆588, or disrupting the E3 ligase activity of 
TRIM32 by mutating the RING domain, we may observe an effect on proliferation or 
motility. Nevertheless, the dominant-negative RAP2 N17 increased the proliferation 
of C2C12 cells, implying that endogenous RAP2 inhibits proliferation. Again, the use 
of si- or shRNA to knockdown RAP2 expression would corroborate this, and, as RAP2 
exists in three different isoforms, would enable us to discover if this is an isoform 
specific effect on proliferation. 
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Differentiation 
TRIM32 is expressed in both proliferating and differentiating satellite cell progeny 
and the absence of TRIM32 disrupts myogenic differentiation (Nicklas, Otto et al. 
2012). Additionally, TRIM32 has been shown to induce neuronal differentiation by 
ubiquitinating MYC and targeting it for degradation (Schwamborn, Berezikov et al. 
2009). Furthermore, c-MYC has been demonstrated to block the action of Myo-D 
and Myogenin-mediated skeletal muscle stem cell differentiation (Miner and Wold 
1991) and TRIM32 reverses the c-MYC-mediated block on differentiation by 
targeting c-MYC for degradation (Nicklas, Otto et al. 2012). 
TRIM32 appears to increase the differentiation of C2C12 cells used in our model. 
Additionally, the dominant-negative RAP2 N17 mutant consistently demonstrates 
an inhibition on the differentiation of C2C12 cells, indicating that abrogating RAP2 
activity inhibits myotube differentiation. Combined, this indicates that both TRIM32 
and RAP2 are required for the differentiation of skeletal muscle cells. As RAP2 N17 
is the dominant-negative mutant for RAP2, it would be interesting to look at 
whether inhibiting RAP2 by knocking down by sh- or siRNA, we can obtain a similar 
result. It is important to bear in mind that there are three different isoforms for 
RAP2. While it is possible that there may be an isoform specific effect of RAP2 on 
proliferation and differentiation, it would also be of interest to knockdown all three. 
In order to assess whether the subtle increase in differentiation identified for 
TRIM32 is in fact significant (Figure 46), it would be useful to repeat the experiment 
using fluorescent constructs which would then enable us to count the number of 
fluorescent-differentiated cells under each condition. Using myotube analysis, 
counting the myotube nuclei, by staining the nucleus, would also allow an 
assessment of the number of multinucleated cells. Alternatively, looking at the 
effect of TRIM32 knock down by sh- or siRNA to see whether differentiation is 
inhibited as in the paper (Schwamborn, Berezikov et al. 2009; Nicklas, Otto et al. 
2012). 
Interestingly, a recent paper in Molecular and Cellular Biology has demonstrated 
that NIK, a putative RAP2 and TRIM32 binding partner, attenuates the 
differentiation of C2C12 cells via its kinase activity in a Myf5 dependent manner, 
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silencing NIK expression using siRNA or expression of a NIK kinase-inactive mutant 
enhanced the differentiation of C2C12 myoblasts. NIK suppression results in 
elevated Myf5 expression and enhanced differentiation of C2C12 cells (Wang, 
Amano et al. 2012). A further study of some of the other RAP2 and TRIM32 binding 
partners that we have identified, and their effect on the differentiation of 
myoblasts by examining the expression of muscle differentiation markers such as 
Myf5, MyoD, myogenin and MRF4, would enable us to elucidate whether these 
novel interactions can also have an effect on the differentiation of C2C12 cells. 
Looking at transducing the cells with lentivirus at different stages of differentiation 
to identify at which stages RAP2 and TRIM32 may play a role.  
It would also be of additional interest to observe whether the TRIM32 mutants that 
we have previously demonstrated are unable to bind to RAP2 would have an effect 
on the differentiation of the cells similar to that seen when RAP2 activity is 
abrogated. A further look at the mutants that disrupt the E3 ligase activity of 
TRIM32, such as ΔRING and C23A, and a study of the effect of 14-3-3 would also 
inform us as to whether the TRIM32 ubiquitin activity plays a role. 
Summary 
Having demonstrated a novel interaction between RAP2 and TRIM32 that is linked 
to the disease LGMD2H, we then investigated the biological implications of this 
interaction. We propose that these proteins are involved in the proliferation and 
differentiation of myoblasts and that the E3 ligase activity may play a role. As 
suggested by current literature, the modulation of this activity is likely to be linked 
to several of the targets identified in our final TAP experiments, e.g. 14-3-3 as 
demonstrated by Ichimura et al. (Ichimura 2014). Through further investigation we 
hope to achieve a better understanding of the pathology of the LGMD2H disease as 
well as a deeper understanding of other possible implications of TRIM32 on 
neurodevelopmental phenotypes as suggested by the work of Lionel et al (Lionel, et 
al. 2014). 
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Chapter 9: Validation of the TAP-
NOEY2 data 
Identification of potential NOEY2 interactions 
Tandem affinity purification (TAP) is an unbiased approach that allows identification 
of protein interactions.  
In order to identify novel interacting proteins of NOEY2 that may shed light on its 
function, we had performed independent TAP purifications using TAP-tagged 
NOEY2. We identified PKA regulatory 1A (-R1α/PRKAR1A) and catalytic (-
cat/PRKACA) subunits that co-purified specifically with NOEY2 but not other baits, 
including other RAS family members (Table 13). 
 
ID Unique Peptides % Coverage Table 13: Novel NOEY2 
interactions identified by TAP 
screen in HEK-293T cells. 
NOEY2 was identified to 
interact with PRKAR1A and 
catalytic subunits. 
DIRAS3/NOEY2 26 46.3 
PRKAR1A 2 7.9 
PRKACA 1 2.6 
 
NOEY2 has tumour suppressor properties and PRKAR1A can also function as a 
tumour suppressor, however, the mechanism by which they act is not known. 
Therefore, the potential regulation of PRKAR1A by NOEY2 could provide a possible 
molecular mechanism for the tumour suppressor properties of NOEY2. This was 
considered an exciting preliminary finding that was selected for subsequent 
validation and characterization experiments. 
Antibody Characterisation 
Various commercially available antibodies against NOEY2, PRKAR1A, PRKAR2A and 
PRKACA proteins were ordered for use in subsequent experiments, and these were 
characterised, and their specificity tested prior to any further experiments being 
conducted. The ability of the antibodies to specifically immunoprecipitate was 
determined following the protocol described in the Methods section. Initially, 
PRKAR1A and PRKAR2A antibodies were tested for their ability to 
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immunoprecipitate PRKACA, where two different PRKACA antibodies were 
compared (Figure 49). 
 
 
 
Figure 49: PRKAR2A and PRKAR1A antibodies are able to immunoprecipitate 
endogenous PRKACA. HEK-293T lysates were incubated with Protein A or G 
beads and the indicated antibody for up to 4h. Lysates were then washed and 
run on an SDS-PAGE gel. The level of protein was detected by western blot. 
Rabbit and Mouse SHOC2 antibodies were used as unrelated control antibodies 
for immunoprecipiatation. 
 
Testing the ability of the PRKAR2A and PRKAR1A antibodies to immunoprecipitate 
endogenous PRKACA, we can see that both immunoprecipitate PRKACA. More 
PRKACA is found associated with PRKAR2A than PRKAR1A although from this 
experiment we cannot say whether that is only a reflection of the relative levels of 
expression of PRKAR2A vs PRKAR1A in this cell line resulting in more capacity to pull 
down the PRKACA protein. Also from this experiment it was apparent that the 
PRKACA sc-903 antibody had higher sensitivity in western blot. In summary; R2A 
and R1A antibodies IP endogenous protein (Figure 49). 
In order to compare the ability of a panel of commercially available antibodies to 
immunoprecipitate and detect by western blot NOEY2 an experiment was set up 
where Flag-tagged NOEY2 was overexpressed in 293T cells and FLAG beads used as 
a positive control (Error! Reference source not found.).  
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Figure 50: NOEY2 antibody is able to immunoprecipitate overexpressed Flag-NOEY2. 
HEK-293T lysates with overexpressed Flag-NOEY2, NRAS-V12 or Di-Ras1 as indicated, 
were split and incubated with Protein A or G beads and the indicated antibody for up to 
4h. Lysates were then washed and run on an SDS-PAGE gel. The level of protein pulled-
down was detected using western blot. NRAS V12 and DIRAS1 were used as unrelated 
and closely related controls respectively and the level of NOEY2 expression is shown on 
the righthand lanes. 
 
HEK-293T cells were transfected with Flag-NOEY2, Flag-NRAS V12 or Di-Ras1 as 
construct of interest, unrelated and closely related background controls 
respectively. Each lysate was then divided into 4 tubes and these were then 
immunoprecipitated using either Flag- beads, PT-NOEY2 antibody, CA-NOEY2 
antibody or Di-Ras1 antibody as indicated above (Error! Reference source not 
found.). Samples were then run on western blot, and interactions detected using 
CA- or PT-NOEY2 antibodies as indicated. Flag-bead immunoprecipitated NOEY2 can 
be detected with both NOEY2 antibodies, (CA more sensitive than PT). Additionally, 
on immunoprecipitation with the PT antibody, we can then detect a band using the 
CA antibody, suggesting that the PT antibody is able to immunoprecipitate NOEY2. 
Immunoprecipitation by the CA-NOEY2 antibody yielded a lot of background (Error! 
Reference source not found.). Di-Ras1 immunoprecipitation was used as a negative 
control and no interaction was detected in these lanes. In brief, both antibodies can 
detect NOEY2 and the PT/R antibody can immunoprecipitate although with very 
poor efficiency as compared to the Flag-antibody positive control. Furthermore, the 
PT/R antibody can only immunoprecipitate the overexpressed protein (Flag-NOEY2 
transfected lanes) but not the endogenous NOEY2 (data not shown). After 
validating that the antibodies can specifically recognise NOEY2 (but not other 
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related GTPases) the CA antibody was used to measure NOEY2 expression levels in a 
panel of cell lines derived from multiple tissue and tumour types. 
Lysates were taken from cell lines derived from different tissues and tumour types 
(as indicated, Figure 51) in order to assess the endogenous NOEY2 expression levels. 
Based on reported observations that loss of NOEY2 expression is linked to tumour 
progression in some tumours, we were hoping to find cell lines that had lost 
expression (Yu, Xu et al. 1999; Hisatomi, Nagao et al. 2002). Cells were grown to 
90% confluence and lysed using PBS-M lysis buffer. Samples were prepared and gels 
run and transferred as described in the methods section and the membrane was 
probed with the NOEY2 antibody.  
 
 
Figure 51: NOEY2 is expressed in a panel of cell lines. Lysates were taken of various cell lines, as 
specified, and run on SDS-PAGE gels. Expression levels were assessed using NOEY2 antibody with 
PRKAR2A used as a loading control. NOEY2 expression can be detected in all cell lines except 
mesenchymal stem cells (MSC). 
 
PRKAR2A is an ubiquituously expressed protein and was used as our loading control. 
However we detected NOEY2 expression everywhere except mesenchymal stem 
cells (MSC), in other lanes where there is no NOEY2 the PRKAR2A loading control 
has no band, so it is likely a loading effect. Interestingly K562 and Sup T1, both 
haematopoietic suspension cells, show stronger bands. K562 was shown to express 
DIRAS3 according to microarray data on “gnf atlas”. 
Generation of constructs 
To further explore protein-protein interactions, overexpression of a battery of 
tagged constructs (Table 14) was generated as described in the Methods section. 
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These genes were ligated to ENTR Gateway vector (Gateway®, Invitrogen) and 
mutagenesis was performed and verified by sequencing where appropriate. 
Gateway technology was then used to transfer the inserts into different Gateway-
compatible tagged- destination vectors for expression in mammalian cells. The 
resulting tagged proteins (Flag-, GST-, Myc-, TAP6 tags) were used in subsequent 
experiments.  
Gene Mutations status Properties 
   
NOEY2 wt Wild-type (wt) 
 ∆N N-terminal extension deleted 
 T69S Effector domain 
 E71G Effector domain 
 N72D, T73S Effector domain 
 Y74C Effector domain 
 C227S CAAX box 
 A45V46 GTP-binding/Possibly activating 
 K93A, G95Q GTP-binding/Possibly activating 
   
NOEY3 wt Wt 
NOEY4 wt Wt 
   
PRKAR1A wt Wt 
 N N-terminal truncation (aa 1-135 ) 
 C C-terminal truncation (aa 136-382 ) 
PRKAR1B wt Wt 
PRKAR2A wt Wt 
PRKAR2B wt Wt 
PRKACA wt Wt 
   
 
Table 14: List of Constructs generated. Shown above, the different 
constructs generated. For each protein, various mutations were 
generated using the primers listed.  
 
The N-terminal extension in NOEY2 (Figure 52) has been shown to confer some of 
its tumour suppressor properties (Luo, Fang et al. 2003). The mutants T69S, E71G, 
N72D, T73S, Y74C were selected as they align with the RAS effector domains. C227S 
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was selected due to its position in the CAAX domain, as previously discussed role of 
this region in tumourigenesis (Choy, Chiu et al. 1999), while K93AG95Q fall under a 
further GTP-binding domain and correlate to A59Q61 which are activating 
mutations in RAS. 
 
 
 
Figure 52: Comparison of the amino-acid sequences of NOEY2 (ARHI), RAP, and HRAS proteins. 
NOEY2 has a unique N-terminal extension and residue changes that correspond to the highly 
conserved residues in RAS and RAP. The alignment was carried out with the Clustal W program by 
(Luo, Fang et al. 2003). Numbers indicate residues. Hyphens represent gaps introduced for optimal 
alignment. Conserved GTP-binding domains (G1-5 in a and shadowed area in, the position of the 
conserved CAAX motif, the putative effector domain, and residues mutated in the dominant-
positive/negative RAS proteins are labelled as indicated in the figure. 
Figure from (Luo, Fang et al. 2003). 
 
All generated constructs were sequenced in order to confirm correct insertion of 
mutations. In order to assess protein expression, each of these constructs was 
transfected into HEK-293T cells, and protein expression was assessed by Western 
blotting on SDS-PAGE gels. Blots were then probed using specific tag antibodies (e.g. 
Flag-, GST-, Myc-, TAP6; data not shown). All the transfected constructs encoded for 
proteins at the predicted size, taking into account the additional size of the tag. 
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Figure 53: PRKAR1A structure. PRKAR1A consists of a dimerization/docking domain (orange), linking 
region (purple) and cAMP binding domain A and B (pink and green, respectively). Upon cAMP 
binding, the inactive holoenzyme dissociates into a dimer of regulatory subunits bound to four cAMP 
and two free monomeric catalytic subunits which can then proceed to activate downstream 
effectors. 
Figure from http://prkar1a.nichd.nih.gov/hmdb/prkar1a.html 
 
Validation of NOEY2 interactions 
In order to validate and characterise the interactions detected by TAP (Table 13), 
Flag-tagged NOEY2 (lane 10, Figure 54) and RFG controls were overexpressed in 
HEK-293T cells and subsequently immunoprecipitated with Flag-beads. Samples 
were run on SDS-PAGE and interacting endogenous proteins detected using specific 
antibodies. 
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Figure 54: Endogenous PRKAR1A and PRKACAT interact with FLAG-NOEY2. HEK-293T cells were 
transfected with Flag-RFG. Lysates were taken on day 3 and immunoprecipitated using Flag- beads. 
Proteins were separated using SDS-PAGE gel and probed with the indicated antibodies. 
 
Endogenous PRKAR1A and PRKACA were found to co-immunoprecipitate specifically 
with NOEY2 but not NOEY3, NOEY4 nor NRAS (Figure 54). The band seen on MRAS 
immunoprecipites does not appear to be activation or effector domain dependent, 
and appears most likely to be background binding. This demonstrates the potential 
for the antibody to bind unspecifically. As equivalent NOEY2 mutants that 
discriminate between activation/effector domain dependent binding vs unspecific 
binding were not known, a series of NOEY2 constructs were generated to attempt 
to find mutations to that effect, in order to disrupt the NOEY2 interaction with 
PRAKR1A and PRKACA and confirm specificity. 
AF6, a promiscuous RAS family effector, can be shown to strongly co-
immunoprecitipate with RAP2, NRAS and MRAS in a manner that is strongly 
disrupted by the A38 effector domain mutations (Figure 54). In the case of NRAS 
and MRAS, the interaction takes place preferentially with the activating V12 mutant 
(lane 2, lane 14-15 respectively). In contrast however, no difference can be seen 
between wild type and V12 versions (lane 4, lane 5) of RAP2 in its ability to interact 
with AF6. This could be a reflection of the possibility, that unlike other RAS family 
GTPases, the wild type RAP2 protein may already be predominantly GTP-bound in 
the cell in some contexts. 
SHOC2 behaves as specific MRAS effector, with demonstrably stronger MRAS L63 
(lane 8) binding than wt (lane 7), and disrupted A38 binding (lane 9), and no 
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interaction with any of the other RFGs. There does appear to be background binding 
to NOEY4 (lane 12). 
NOEY2 mutants 
To further characterize the specificity of the interaction of NOEY2 with PRKAR1A 
and PRKACA and demonstrate that the interaction could indeed be disrupted, and 
was not unspecific, a panel of NOEY2 mutants were generated based on sequence 
alignments and similarities with other RFG mutants that disrupt binding with their 
respective down-stream effectors. Other constructs were produced based on the 
literature identifying features of NOEY2, such as the N-terminal extension, that 
could be of interest. 
The A38 mutation in the effector domain of H/K/NRAS oncoproteins leads to full 
loss-of-function and is known to disrupt the interaction of RAS proteins with all 
known effectors. However, other substitutions within the RAS effector domain are 
known to create partial loss-of-function mutants by differentially disrupting the 
ability to interact with some effectors but not others. HRAS T35S for example can 
no longer interact with RALGDS or PI3K, while still being able to interact with RAF 
kinases and activate the RAF-ERK pathway (although with decreased 
efficiency)(White, Nicolette et al. 1995; Rodriguez-Viciana, Warne et al. 1997). 
These partial loss-of-function mutants have provided useful experimental tools to 
assess the contribution of the different RAS effector pathways to the known 
biological effects regulated by RAS. As similarly disruptive mutations were not 
known for NOEY2, mutations were generated in the GTP-binding domain and 
effector domains in order to test whether the equivalent substitutions in NOEY2 
could differentially disrupt the interaction with PRKAR1A and/or PRKACA. 
Additionally, the role of the NOEY2 N-terminal extension in tumourigenesis has 
been published in the literature (Luo, Fang et al. 2003), thus we included the N-
terminal deletion mutant in our panel. 
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Figure 55: Endogenous PRKACA and PRKAR1A show unspecific binding to NOEY2 and RFGs 
respectively. HEK-293T cells were transfected with Flag-NOEY2 mutants and RFGs controls. Lysates 
were taken on day 3 and immunoprecipitated samples were run on SDS PAGE gel and transferred to 
PVDF membrane. Protein levels were detected using endogenous antibody. All the NOEY2 mutants 
show binding to PRKACA and all the RFGs bind to PRKAR1A consistent with unspecific binding. 
 
 
Endogenous PRKACA and PRKAR1A were found to co-immunoprecipitate with all 
the NOEY2 mutants (Figure 55). Contrary to previous experiments, some PRKAR1A 
interaction could also be detected associating with the MRAS, NOEY3 and NOEY4 
controls. This suggests a level of background binding, rendering it difficult to assess 
whether the NOEY2 interaction is consistent and specific.  
Mapping N vs C 
We also attempted to map the interaction using a different approach, looking at 
where NOEY2 binds on PRKAR1A. For this, truncation mutants (N-terminal or C-
terminal) were generated as described previously with both Flag- and GST-tags. 
These were overexpressed in HEK-293T cells and immunoprecipitated or pulled-
down using Flag- or GST- beads respectively. Endogenous PRKACA and NOEY2 
interactions were then detected with previously used antibodies (Figure 56). 
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Figure 56: Overexpressing full length or 
truncated (N-terminal or C-terminal) PRKAR1A 
and probing for endogenous PRKACA and 
NOEY2 to map their interaction sites. PKACA 
interaction with PRKAR1A is only disrupted 
with the C-truncation, not the N, and does not 
appear to be affected by treatment with 8Br-
cAMP. This is seen with both the Flag- and GST- 
beads. The Noey2 interaction with PRKAR1A 
does not appear to be disrupted by any of the 
mutations when immunoprecipitated with the 
Flag- beads, however no interaction in seen 
with the GST- beads. It is possible that the Flag- 
bands are non-specific background 
interactions. 
 
Endogenous PRKACA interacts with the N-, but not the C-terminal domain of 
PRKAR1A when using either Flag or GST-constructs (Figure 56) consistent with 
PRKACA binding to the N-terminal region of PKAR1A. However when probing for 
NOEY2, it is detected with both the PRKAR1A-N and -C terminal truncation mutant. 
This seems highly unlikely and suggests (in combination with other experiments) 
that NOEY2 may just be very ‘sticky’ and bind non-specifically to some proteins. 
Drug conditions 
Prior to those later results questioning the specificity of the NOEY2 interactions and 
based on the original promising results experiments were performed to study how 
NOEY2 could regulate PKA activity. NOEY2 could be bind to PRKAR1A and thereby 
stimulate or inhibit PRKAR1A binding or dissociation to PRKACA subunit. This 
modulation could be either direct or indirect. In other words, NOEY2 could 
stimulate dissociation of PRKAR1A or it could inhibit dissociation induced by PKA 
activators. In order to test this we set out to optimize an experimental system 
measuring the dissociation of the regulatory subunits from PRKACA and stimulating 
the dissociation using drug treatments over time. By identifying the lowest dose of 
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drug that induces dissociation and looking at a time course of 
dissociation/reassociation, it would then be possible to assess whether NOEY2 
inhibits dissociation or does not completely block dissociation but only delays it. 
Because RFGs (including NOEY2) need Mg2+ to bind to the guanine nucleotide and 
be in an active state, different lysis conditions were also tested, comparing the use 
of PBS-M (in the presence of Mg2+) and PBS-E (in the presence of EDTA, i.e. no Mg2+) 
(Paduch, Jelen et al. 2001). 
 
HEK-293T cells were transfected with Flag-PRKACA and after 48h treated with either 
8-Br-cAMP (lanes 2-4 and lanes 9-11, Figure 57) or Forskolin (lanes 5-7 and 12-14, 
Figure 57) as indicated. Lysis was with either PBS-E (EDTA, lanes 1-7, Figure 57) or 
PBS-M (Mg2+, lanes 8-14, Figure 57) and samples were immunoprecipitated with 
Flag-antibody and probed for PRKAR1A or PRKAR2A as indicated (Figure 57).  
 
 
 
Figure 57: Optimising drug treatment conditions by comparing Br-cAMP to 
forskolin (Fsk) over time, lysing in the presence of EDTA or Mg2+. HEK-293T 
cells were transfected with Flag-PRKACA and after 48h treated with either 8-
Br-cAMP or Forskolin as indicated above. Lysis was with either PBS-E (EDTA) or 
PBS-M (Mg
2+
) and samples were immunoprecipitated with Flag-antibody and 
probed for PRKAR1A or PRKAR2A as indicated. PRKAR1A no longer associates 
with PRKACA when treated with 8-Br-cAMP and Forskolin under PBS-E lysis 
conditions, whereas it can be immunoprecipitated by PRKACA under PBS-M 
lysis and IP conditions. 
 
We found different behaviour of PRKAR1A and PRKAR2A immunoprecipitation with 
PRKACA when the lysis buffer had Mg2+ vs EDTA. PRKAR1A and PRKAR2A are not 
detected in PRKACA immunoprecipitates after 8-Br-cAMP or forskolin treatment at 
each time point tested under PBS-E lysis conditions. 
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Under PBS-M lysis and immunoprecipitation conditions, PRKAR1A is 
immunoprecipitated by PRKACA with both 8-Br-cAMP and forskolin treatment at 
each time point tested, except 90’ Forskolin treatment although this appears to be a 
bait issue. Under PBS-M lysis and immunoprecipitation conditions, PRKAR2A 
dissociation with Br-cAMP and forskolin at each time point tested except with 5’ 
Forskolin treatment where only partial dissociation is seen. This suggests that 
although 8-Br-cAMP and forskolin can potently stimulate dissociation of both 
PRKR1A and PRKR2A from PRKACA, PRKR1A may be able to reassociate with 
PRKACA after cell lysis when Mg2+ is present. 
Colony Formation 
As mentioned previously, it has been demonstrated in the literature that NOEY2 
expression is lost in breast and ovarian tumours, and that introduction of NOEY2 
can inhibit the growth of transformed cells that have lost expression of the 
endogenous gene (Yu, Xu et al. 1999). Therefore, we tested the proliferation effects 
of NOEY2 expression in a panel of cell lines. Cells were infected with lenti- or retro- 
virus and selection was introduced to ensure only successfully transduced cells 
remain. Once selected, cells were seeded at equal density in 6 well plates and 
grown until a control (GFP) well reaches confluence. The colony formation of each 
sample was then compared visually as below (Figure 58). An overview of the data 
obtained is shown in Table 15. 
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Figure 58: Colony formation assays showed no reproducible effect of Noey2 or PRKAR1A on cell 
proliferation. Multiple cell lines were infected with PRKAR1A, PRKAR2A, Noey2 and closely related 
Di-Ras family members Noe3 and Noe4 as negative controls. No consistent effect was seen on colony 
growth, even in cell lines such as SkBr3 which the literature had shown to be affected. 
 
 
No inhibitory effects of either NOEY2 or PRKAR1A were seen on the proliferation 
rate of multiple cell lines tested and therefore I could not reproduce any of the 
published observations of the inhibitory effects of NOEY1 and PRKAR1A on 
proliferation (Yu, Xu et al. 1999).  
 
  
Source Cell line 
Effect on 
proliferation 
Tested 
Human ovarian carcinoma 
Hey No effect 4 times 
Skov3 No effect 3 times 
A2780 No effect 2 times 
Human breast carcinoma 
SkBr3 No effect 4 times 
MCF7 No effect 1 time 
Thyroid carcinoma 8505 No effect 3 times 
Fibrosarcoma HT1080 No effect 2 times 
 
Table 15: Summary of data obtained through colony formation assays. Despite testing 
multiple times in multiple cell lines, including those used in the literature, no effect was 
seen upon the overexpression of NOEY2. 
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Chapter 10: Discussion – NOEY2 
Although the initial interaction data seem to confirm the TAP results and showed 
promise, the Noey2 interaction with PRKAR1A was not consistently reproducible, 
with the distinct possibility that it was an unspecific interaction as a result of NOEY2 
being sticky. Additionally, we had problems reproducing published data of the 
tumour suppressor properties of both NOEY2 and PKAR1A – I assessed the Noey2 
and PRKAR1A effect on proliferation/colony formation on a panel of cell lines 
selected both from amongst those shown to be affected in the literature as well as 
some other closely related cell lines but was unable to reproduce any inhibitory 
effect on proliferation despite multiple attempts. 
Several differences in approach exist between literature (Yu, Xu et al. 1999) and 
those shown above, namely the use of transfection as opposed to transduction, 
respectively. Yu, Xu et al used the transient transfection of the NOEY2 constructs 
and seeded the cells with selection medium after 48h. As a result, those cells 
seeded were newly transfected, however not selected, so that non-transfected cells 
were also included in the wells. It is therefore a possibility that the colony formation 
assays shown are indicative of the transfection efficiency of certain constructs 
rather than representative of the effect of each construct. 
Conversely, in the experimental data included above, cells were transduced using a 
viral vector and selected prior to seeding. This delayed the seeding of the cells, 
however all cells that were seeded consisted of the construct of interest. Although 
transfected cells had been assessed for expression levels, due to time constraints 
and issues with initial interaction data, this had not been carried out for the virally 
induced cells so the data cannot confirm expression of the intended construct. 
However, the visible fluorescence and antibiotic resistance (both in the construct, 
original transfected cell lines and confirmed in the transduced cells) does suggest a 
strong probability of the construct of interest being present. Furthermore, the 
assessment by (Yu, Xu et al. 1999) involved seeding the cells at very low density, 
allowing them to grow for two weeks and counting the number of colonies that had 
formed. In our experiments we seeded more cells per dish and observed the 
171 
 
confluence/coverage of the cells once the controls had reached confluence. It is 
possible that the inhibitory effect of our constructs would have been more apparent 
if the cells were left to grow for longer and had our initial interaction data proved 
more robust, further experiments would have then been conducted in order to 
attempt to reproduce the findings reported in the literature. 
Nevertheless, as a result of the difficulties in reproducing the initial interaction data, 
the NOEY2 project was abandoned and I went on to study the RAP2 interaction that 
constitutes the majority of this thesis. 
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